

16.2.6. Individual Efficacy Response Data

Number	Title
Listing 16.2.6.1	Derived Efficacy Data
Listing 16.2.6.2	Response Assessment: RECIST Criteria - Phase 2 Subjects
Listing 16.2.6.3	Target Lesions - Phase 2 Subjects
Listing 16.2.6.4	Non Target Lesions - Phase 2 Subjects
Listing 16.2.6.5	New Lesions - Phase 2 Subjects
Listing 16.2.6.6	Long Term Follow-Up

Listing 16.2.6.1
Derived Efficacy Data

Study Phase	Subject ID	Treatment Group	Overall Survival ^[1] (Months)	Overall Survival Status	Progression-Free Survival ^[2] (Months)	Progression-Free Survival Status	Best Tumor Response ^[3]	Duration of Response ^[4] (Months)	Duration of Response Status
Phase 2	0101-0002	ADIPemPlatinum	7.00	Deceased	4.01	Censored	SD		
	0101-0003	PlaceboPemPlatinum	4.47	Deceased	1.28	Censored	SD		
	0101-0004	ADIPemPlatinum	7.00	Deceased	5.85	Censored	SD		
	0101-0006	PlaceboPemPlatinum	17.68	Deceased	8.02	PD	PR	3.65	PD
	0101-0008	ADIPemPlatinum	36.99	Deceased	1.31	Censored	SD		
	0101-0009	ADIPemPlatinum	3.68	Deceased	1.64	Censored	SD		
	0101-0010	PlaceboPemPlatinum	36.37	Censored	3.02	Censored	SD		
	0101-0011	ADIPemPlatinum	8.67	Deceased	5.75	Censored	SD		
	0102-0001	ADIPemPlatinum	24.48	Deceased	3.98	Censored	SD		
	0102-0002	ADIPemPlatinum	55.69	Censored	10.84	Censored	PR	8.31	Censored
	0102-0003	PlaceboPemPlatinum	3.06	Deceased	1.22	PD	PD		
	0102-0004	PlaceboPemPlatinum	4.96	Deceased	2.60	PD	SD		
	0102-0005	PlaceboPemPlatinum	4.34	Deceased	2.60	Censored	SD		
	0102-0006	PlaceboPemPlatinum	13.44	Deceased	1.18	Censored	SD		
	0102-0007	ADIPemPlatinum	21.03	Deceased	1.18	Censored	SD		
	0102-0008	PlaceboPemPlatinum	2.53	Deceased	2.10	PD	SD		
	0102-0009	PlaceboPemPlatinum	7.69	Deceased	2.56	Censored	SD		
	0103-0001	ADIPemPlatinum	0.30	Deceased	0.30	Deceased	Missing or Not Evaluable		
	0103-0003	ADIPemPlatinum	10.51	Deceased	6.64	Censored	SD		
	0103-0005	ADIPemPlatinum	0.23	Deceased	0.23	Deceased	Missing or Not Evaluable		
	0103-0006	PlaceboPemPlatinum	11.96	Deceased	3.91	Censored	SD		
	0103-0009	ADIPemPlatinum	7.85	Deceased	1.45	PD	PD		

Abbreviations: CR = complete response; N/A = not applicable; PD = progressive disease; PFS = progression free survival; PR = partial response; SD = stable disease

Note: Disease assessments for Phase 2 subjects up until the end of Phase 2 interim analysis (May 2020) were determined by blinded independent central review. For Phase 2 subjects who were still on study treatment and progression free at the end of Phase 2 interim analysis (subjects 0107-0008, 0107-0010, 0201-0031, 0201-0034, 0201-0045, 0201-0053, 0201-0054, 0202-0004, 0203-0013, 0207-0004, 0208-0008, 0211-0003, and 0212-0006), subsequent disease assessments were determined by the investigator. All disease assessments for Phase 3 subjects were determined by the investigator.

^[1] Calculated as the time from randomization until death. In the event that no death is documented prior to study termination or analysis cutoff, OS was censored at the last known date the subject is known to be alive, either through completion of on-study visits or through survival follow-up contact.

^[2] Calculated as the time from randomization until date of tumor progression or death. In the event that no tumor progression or death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS was censored at the date of the last tumor assessment demonstrating no tumor progression.

^[3] The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requirement for confirmation.

^[4] Calculated for subjects who have a best tumor response of CR or PR as the time from date of initial response of CR or PR until date of tumor progression or death. Subjects without tumor progression or death at the end of treatment were censored using the date of the last tumor assessment demonstrating no tumor progression.

Listing 16.2.6.1
Derived Efficacy Data

Study Phase	Subject ID	Treatment Group	Overall Survival ^[1] (Months)	Overall Survival Status	Progression-Free Survival ^[2] (Months)	Progression-Free Survival Status	Best Tumor Response ^[3]	Duration of Response ^[4] (Months)	Duration of Response Status
Phase 2	0104-0001	PlaceboPemPlatinum	18.79	Deceased	2.27	PD	PD		
	0104-0003	PlaceboPemPlatinum	4.73	Deceased	0.03	Censored	Missing or Not Evaluable		
	0104-0004	ADIPemPlatinum	37.75	Censored	7.62	PD	SD		
	0104-0006	ADIPemPlatinum	5.91	Deceased	5.32	PD	SD		
	0107-0001	ADIPemPlatinum	21.88	Deceased	5.22	PD	SD		
	0107-0002	PlaceboPemPlatinum	33.68	Deceased	13.17	PD	CR	11.76	PD
	0107-0003	ADIPemPlatinum	1.77	Deceased	0.03	Censored	Missing or Not Evaluable		
	0107-0004	ADIPemPlatinum	12.52	Deceased	4.07	Censored	SD		
	0107-0005	ADIPemPlatinum	8.28	Censored	7.72	PD	SD		
	0107-0006	ADIPemPlatinum	5.13	Deceased	2.69	Censored	SD		
	0107-0007	ADIPemPlatinum	2.50	Deceased	1.31	Censored	SD		
	0107-0008	ADIPemPlatinum	10.74	Deceased	9.59	Censored	PR	5.55	Censored
	0107-0010	PlaceboPemPlatinum	16.33	Deceased	5.75	PD	SD		
	0108-0002	PlaceboPemPlatinum	1.64	Deceased	1.45	PD	PD		
	0108-0003	ADIPemPlatinum	1.91	Deceased	1.41	Censored	SD		
	0108-0004	PlaceboPemPlatinum	2.53	Deceased	1.25	PD	PD		
	0108-0006	PlaceboPemPlatinum	25.26	Deceased	1.41	PD	PD		
	0110-0001	ADIPemPlatinum	30.39	Deceased	2.83	PD	SD		
	0110-0002	ADIPemPlatinum	7.85	Deceased	2.76	Censored	SD		
	0112-0002	ADIPemPlatinum	1.54	Deceased	0.03	Censored	Missing or Not Evaluable		
	0112-0003	PlaceboPemPlatinum	10.38	Deceased	3.94	Censored	SD		
	0201-0001	PlaceboPemPlatinum	9.53	Deceased	3.98	Censored	PR	2.79	Censored

Abbreviations: CR = complete response; N/A = not applicable; PD = progressive disease; PFS = progression free survival; PR = partial response; SD = stable disease

Note: Disease assessments for Phase 2 subjects up until the end of Phase 2 interim analysis (May 2020) were determined by blinded independent central review. For Phase 2 subjects who were still on study treatment and progression free at the end of Phase 2 interim analysis (subjects 0107-0008, 0107-0010, 0201-0031, 0201-0034, 0201-0045, 0201-0053, 0201-0054, 0202-0004, 0203-0013, 0207-0004, 0208-0008, 0211-0003, and 0212-0006), subsequent disease assessments were determined by the investigator. All disease assessments for Phase 3 subjects were determined by the investigator.

^[1] Calculated as the time from randomization until death. In the event that no death is documented prior to study termination or analysis cutoff, OS was censored at the last known date the subject is known to be alive, either through completion of on-study visits or through survival follow-up contact.

^[2] Calculated as the time from randomization until date of tumor progression or death. In the event that no tumor progression or death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS was censored at the date of the last tumor assessment demonstrating no tumor progression.

^[3] The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requirement for confirmation.

^[4] Calculated for subjects who have a best tumor response of CR or PR as the time from date of initial response of CR or PR until date of tumor progression or death. Subjects without tumor progression or death at the end of treatment were censored using the date of the last tumor assessment demonstrating no tumor progression.

Listing 16.2.6.1
Derived Efficacy Data

Study Phase	Subject ID	Treatment Group	Overall Survival ^[1] (Months)	Overall Survival Status	Progression-Free Survival ^[2] (Months)	Progression-Free Survival Status	Best Tumor Response ^[3]	Duration of Response ^[4] (Months)	Duration of Response Status
Phase 2	0201-0002	PlaceboPemPlatinum	2.10	Deceased	2.10	Deceased	SD		
	0201-0004	PlaceboPemPlatinum	2.76	Deceased	1.41	Censored	SD		
	0201-0005	ADIPemPlatinum	14.92	Deceased	7.20	PD	SD		
	0201-0006	ADIPemPlatinum	5.85	Deceased	3.98	PD	SD		
	0201-0007	ADIPemPlatinum	19.32	Deceased	1.22	Censored	SD		
	0201-0008	ADIPemPlatinum	13.86	Deceased	9.49	Censored	SD		
	0201-0009	PlaceboPemPlatinum	23.56	Deceased	12.29	PD	PR	4.63	PD
	0201-0011	PlaceboPemPlatinum	21.78	Deceased	5.85	PD	SD		
	0201-0013	ADIPemPlatinum	6.54	Deceased	3.98	Censored	SD		
	0201-0014	PlaceboPemPlatinum	3.38	Deceased	2.46	PD	SD		
	0201-0015	ADIPemPlatinum	25.79	Deceased	5.85	PD	SD		
	0201-0016	PlaceboPemPlatinum	11.76	Deceased	11.76	Deceased	SD		
	0201-0017	PlaceboPemPlatinum	6.97	Deceased	3.52	Censored	SD		
	0201-0018	ADIPemPlatinum	18.30	Deceased	11.33	PD	SD		
	0201-0019	ADIPemPlatinum	14.19	Deceased	3.52	PD	SD		
	0201-0020	PlaceboPemPlatinum	10.38	Deceased	3.98	PD	SD		
	0201-0021	PlaceboPemPlatinum	6.14	Deceased	5.36	Censored	SD		
	0201-0022	PlaceboPemPlatinum	49.22	Censored	0.03	Censored	Missing or Not Evaluable		
	0201-0023	ADIPemPlatinum	15.67	Deceased	11.33	Censored	SD		
	0201-0024	ADIPemPlatinum	6.21	Deceased	5.26	Censored	SD		
	0201-0025	PlaceboPemPlatinum	23.43	Deceased	9.46	Censored	SD		
	0201-0026	PlaceboPemPlatinum	4.04	Deceased	1.22	PD	PD		

Abbreviations: CR = complete response; N/A = not applicable; PD = progressive disease; PFS = progression free survival; PR = partial response; SD = stable disease

Note: Disease assessments for Phase 2 subjects up until the end of Phase 2 interim analysis (May 2020) were determined by blinded independent central review. For Phase 2 subjects who were still on study treatment and progression free at the end of Phase 2 interim analysis (subjects 0107-0008, 0107-0010, 0201-0031, 0201-0034, 0201-0045, 0201-0053, 0201-0054, 0202-0004, 0203-0013, 0207-0004, 0208-0008, 0211-0003, and 0212-0006), subsequent disease assessments were determined by the investigator. All disease assessments for Phase 3 subjects were determined by the investigator.

^[1] Calculated as the time from randomization until death. In the event that no death is documented prior to study termination or analysis cutoff, OS was censored at the last known date the subject is known to be alive, either through completion of on-study visits or through survival follow-up contact.

^[2] Calculated as the time from randomization until date of tumor progression or death. In the event that no tumor progression or death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS was censored at the date of the last tumor assessment demonstrating no tumor progression.

^[3] The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requirement for confirmation.

^[4] Calculated for subjects who have a best tumor response of CR or PR as the time from date of initial response of CR or PR until date of tumor progression or death. Subjects without tumor progression or death at the end of treatment were censored using the date of the last tumor assessment demonstrating no tumor progression.

Listing 16.2.6.1
Derived Efficacy Data

Study Phase	Subject ID	Treatment Group	Overall Survival ^[1] (Months)	Overall Survival Status	Progression-Free Survival ^[2] (Months)	Progression-Free Survival Status	Best Tumor Response ^[3]	Duration of Response ^[4] (Months)	Duration of Response Status
Phase 2	0201-0027	PlaceboPemPlatinum	9.46	Deceased	2.33	PD	SD		
	0201-0028	PlaceboPemPlatinum	6.70	Deceased	2.20	Censored	SD		
	0201-0030	PlaceboPemPlatinum	4.90	Deceased	2.60	Censored	SD		
	0201-0031	ADIPemPlatinum	43.79	Censored	24.05	Censored	PR	18.27	Censored
	0201-0033	ADIPemPlatinum	12.91	Deceased	5.78	PD	SD		
	0201-0034	ADIPemPlatinum	43.99	Censored	23.10	Censored	PR	21.52	Censored
	0201-0035	PlaceboPemPlatinum	8.71	Deceased	5.78	PD	SD		
	0201-0036	ADIPemPlatinum	5.13	Deceased	1.61	Censored	SD		
	0201-0038	ADIPemPlatinum	13.86	Deceased	8.54	PD	SD		
	0201-0039	ADIPemPlatinum	19.81	Deceased	4.90	PD	SD		
	0201-0040	PlaceboPemPlatinum	13.50	Deceased	9.03	PD	PR	7.85	PD
	0201-0041	ADIPemPlatinum	19.06	Deceased	7.20	PD	PR	4.63	PD
	0201-0043	ADIPemPlatinum	38.93	Censored	5.82	PD	PR	4.63	PD
	0201-0044	PlaceboPemPlatinum	13.08	Deceased	10.64	Censored	PR	8.08	Censored
	0201-0045	PlaceboPemPlatinum	31.24	Deceased	15.93	PD	PR	11.99	PD
	0201-0046	ADIPemPlatinum	11.04	Deceased	3.98	PD	SD		
	0201-0047	PlaceboPemPlatinum	5.26	Deceased	3.98	Censored	SD		
	0201-0048	PlaceboPemPlatinum	6.05	Deceased	1.58	Censored	SD		
	0201-0049	ADIPemPlatinum	4.30	Deceased	1.51	Censored	SD		
	0201-0050	PlaceboPemPlatinum	12.42	Deceased	4.01	Censored	SD		
	0201-0051	PlaceboPemPlatinum	7.82	Deceased	5.36	PD	PR	2.79	PD
	0201-0052	PlaceboPemPlatinum	3.61	Deceased	1.22	Censored	SD		

Abbreviations: CR = complete response; N/A = not applicable; PD = progressive disease; PFS = progression free survival; PR = partial response; SD = stable disease

Note: Disease assessments for Phase 2 subjects up until the end of Phase 2 interim analysis (May 2020) were determined by blinded independent central review. For Phase 2 subjects who were still on study treatment and progression free at the end of Phase 2 interim analysis (subjects 0107-0008, 0107-0010, 0201-0031, 0201-0034, 0201-0045, 0201-0053, 0201-0054, 0202-0004, 0203-0013, 0207-0004, 0208-0008, 0211-0003, and 0212-0006), subsequent disease assessments were determined by the investigator. All disease assessments for Phase 3 subjects were determined by the investigator.

^[1] Calculated as the time from randomization until death. In the event that no death is documented prior to study termination or analysis cutoff, OS was censored at the last known date the subject is known to be alive, either through completion of on-study visits or through survival follow-up contact.

^[2] Calculated as the time from randomization until date of tumor progression or death. In the event that no tumor progression or death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS was censored at the date of the last tumor assessment demonstrating no tumor progression.

^[3] The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requirement for confirmation.

^[4] Calculated for subjects who have a best tumor response of CR or PR as the time from date of initial response of CR or PR until date of tumor progression or death. Subjects without tumor progression or death at the end of treatment were censored using the date of the last tumor assessment demonstrating no tumor progression.

Listing 16.2.6.1
Derived Efficacy Data

Study Phase	Subject ID	Treatment Group	Overall Survival ^[1] (Months)	Overall Survival Status	Progression-Free Survival ^[2] (Months)	Progression-Free Survival Status	Best Tumor Response ^[3]	Duration of Response ^[4] (Months)	Duration of Response Status
Phase 2	0201-0053	ADIPemPlatinum	23.56	Deceased	11.56	PD	SD		
	0201-0054	PlaceboPemPlatinum	13.31	Deceased	9.53	PD	SD		
	0201-0056	ADIPemPlatinum	3.75	Deceased	0.03	Censored	Missing or Not Evaluable		
	0202-0001	PlaceboPemPlatinum	9.66	Deceased	4.14	Censored	SD		
	0202-0002	ADIPemPlatinum	9.20	Deceased	4.17	Censored	PR	2.56	Censored
	0202-0003	ADIPemPlatinum	27.89	Deceased	6.05	PD	SD		
	0202-0004	ADIPemPlatinum	39.39	Censored	23.52	Censored	PR	22.34	Censored
	0202-0005	PlaceboPemPlatinum	7.62	Deceased	5.65	PD	SD		
	0203-0001	ADIPemPlatinum	5.42	Deceased	3.78	Censored	SD		
	0203-0002	PlaceboPemPlatinum	40.44	Deceased	2.83	Censored	SD		
	0203-0004	ADIPemPlatinum	2.53	Deceased	1.48	PD	PD		
	0203-0005	ADIPemPlatinum	13.57	Deceased	6.05	Censored	SD		
	0203-0006	PlaceboPemPlatinum	1.18	Deceased	1.18	Deceased	Missing or Not Evaluable		
	0203-0008	PlaceboPemPlatinum	13.14	Deceased	6.28	PD	PR	4.63	PD
	0203-0009	PlaceboPemPlatinum	5.88	Deceased	4.17	Censored	SD		
	0203-0010	ADIPemPlatinum	9.30	Deceased	0.03	Censored	Missing or Not Evaluable		
	0203-0013	ADIPemPlatinum	40.44	Censored	19.38	Censored	PR	16.39	Censored
	0203-0014	ADIPemPlatinum	11.79	Deceased	7.39	PD	PR	3.71	PD
	0203-0015	PlaceboPemPlatinum	10.32	Deceased	3.94	Censored	SD		
	0203-0016	PlaceboPemPlatinum	6.31	Deceased	6.31	Deceased	SD		
	0203-0018	PlaceboPemPlatinum	0.99	Deceased	0.99	Deceased	Missing or Not Evaluable		
	0204-0001	PlaceboPemPlatinum	9.26	Deceased	5.75	PD	PR	4.40	PD

Abbreviations: CR = complete response; N/A = not applicable; PD = progressive disease; PFS = progression free survival; PR = partial response; SD = stable disease

Note: Disease assessments for Phase 2 subjects up until the end of Phase 2 interim analysis (May 2020) were determined by blinded independent central review. For Phase 2 subjects who were still on study treatment and progression free at the end of Phase 2 interim analysis (subjects 0107-0008, 0107-0010, 0201-0031, 0201-0034, 0201-0045, 0201-0053, 0201-0054, 0202-0004, 0203-0013, 0207-0004, 0208-0008, 0211-0003, and 0212-0006), subsequent disease assessments were determined by the investigator. All disease assessments for Phase 3 subjects were determined by the investigator.

^[1] Calculated as the time from randomization until death. In the event that no death is documented prior to study termination or analysis cutoff, OS was censored at the last known date the subject is known to be alive, either through completion of on-study visits or through survival follow-up contact.

^[2] Calculated as the time from randomization until date of tumor progression or death. In the event that no tumor progression or death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS was censored at the date of the last tumor assessment demonstrating no tumor progression.

^[3] The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requirement for confirmation.

^[4] Calculated for subjects who have a best tumor response of CR or PR as the time from date of initial response of CR or PR until date of tumor progression or death. Subjects without tumor progression or death at the end of treatment were censored using the date of the last tumor assessment demonstrating no tumor progression.

Listing 16.2.6.1
Derived Efficacy Data

Study Phase	Subject ID	Treatment Group	Overall Survival ^[1] (Months)	Overall Survival Status	Progression-Free Survival ^[2] (Months)	Progression-Free Survival Status	Best Tumor Response ^[3]	Duration of Response ^[4] (Months)	Duration of Response Status
Phase 2	0204-0002	ADIPemPlatinum	5.62	Deceased	1.41	Censored	SD		
	0204-0003	PlaceboPemPlatinum	3.88	Deceased	1.15	PD	PD		
	0204-0004	PlaceboPemPlatinum	2.63	Deceased	2.63	Deceased	SD		
	0204-0005	ADIPemPlatinum	21.98	Deceased	9.30	PD	SD		
	0204-0006	ADIPemPlatinum	4.76	Deceased	2.56	Censored	SD		
	0204-0007	ADIPemPlatinum	7.52	Deceased	3.98	PD	SD		
	0204-0008	PlaceboPemPlatinum	14.88	Deceased	7.59	PD	PR	3.65	PD
	0204-0009	PlaceboPemPlatinum	15.57	Deceased	5.78	PD	SD		
	0204-0010	ADIPemPlatinum	5.06	Deceased	2.79	Censored	SD		
	0204-0011	ADIPemPlatinum	7.92	Deceased	4.11	PD	SD		
	0205-0001	ADIPemPlatinum	12.16	Deceased	7.85	PD	SD		
	0205-0002	PlaceboPemPlatinum	7.36	Deceased	4.11	PD	SD		
	0205-0005	PlaceboPemPlatinum	7.49	Deceased	2.66	PD	SD		
	0205-0006	PlaceboPemPlatinum	1.02	Deceased	0.03	Censored	Missing or Not Evaluable		
	0207-0001	ADIPemPlatinum	0.46	Deceased	0.46	Deceased	Missing or Not Evaluable		
	0207-0002	PlaceboPemPlatinum	5.88	Deceased	0.03	Censored	Missing or Not Evaluable		
	0207-0003	ADIPemPlatinum	3.19	Deceased	2.89	PD	SD		
	0207-0004	PlaceboPemPlatinum	5.72	Deceased	1.28	Censored	Missing or Not Evaluable		
	0208-0001	ADIPemPlatinum	8.34	Deceased	6.24	PD	SD		
	0208-0002	ADIPemPlatinum	5.72	Deceased	2.60	PD	SD		
	0208-0003	ADIPemPlatinum	1.77	Deceased	1.28	PD	PD		
	0208-0004	PlaceboPemPlatinum	4.27	Deceased	4.14	PD	SD		

Abbreviations: CR = complete response; N/A = not applicable; PD = progressive disease; PFS = progression free survival; PR = partial response; SD = stable disease

Note: Disease assessments for Phase 2 subjects up until the end of Phase 2 interim analysis (May 2020) were determined by blinded independent central review. For Phase 2 subjects who were still on study treatment and progression free at the end of Phase 2 interim analysis (subjects 0107-0008, 0107-0010, 0201-0031, 0201-0034, 0201-0045, 0201-0053, 0201-0054, 0202-0004, 0203-0013, 0207-0004, 0208-0008, 0211-0003, and 0212-0006), subsequent disease assessments were determined by the investigator. All disease assessments for Phase 3 subjects were determined by the investigator.

^[1] Calculated as the time from randomization until death. In the event that no death is documented prior to study termination or analysis cutoff, OS was censored at the last known date the subject is known to be alive, either through completion of on-study visits or through survival follow-up contact.

^[2] Calculated as the time from randomization until date of tumor progression or death. In the event that no tumor progression or death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS was censored at the date of the last tumor assessment demonstrating no tumor progression.

^[3] The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requirement for confirmation.

^[4] Calculated for subjects who have a best tumor response of CR or PR as the time from date of initial response of CR or PR until date of tumor progression or death. Subjects without tumor progression or death at the end of treatment were censored using the date of the last tumor assessment demonstrating no tumor progression.

Listing 16.2.6.1
Derived Efficacy Data

Study Phase	Subject ID	Treatment Group	Overall Survival ^[1] (Months)	Overall Survival Status	Progression-Free Survival ^[2] (Months)	Progression-Free Survival Status	Best Tumor Response ^[3]	Duration of Response ^[4] (Months)	Duration of Response Status
Phase 2	0208-0006	ADIPemPlatinum	17.05	Deceased	4.24	PD	SD		
	0208-0007	ADIPemPlatinum	2.17	Deceased	1.48	PD	PD		
	0208-0008	ADIPemPlatinum	18.00	Deceased	6.90	PD	SD		
	0209-0001	ADIPemPlatinum	18.73	Deceased	9.53	PD	SD		
	0209-0003	ADIPemPlatinum	6.08	Deceased	2.14	Censored	SD		
	0209-0004	ADIPemPlatinum	33.68	Censored	6.08	Censored	PR	3.32	Censored
	0209-0005	ADIPemPlatinum	5.26	Deceased	1.31	PD	PD		
	0211-0001	PlaceboPemPlatinum	12.06	Deceased	5.85	PD	SD		
	0211-0002	PlaceboPemPlatinum	7.10	Deceased	1.77	Censored	SD		
	0211-0003	ADIPemPlatinum	33.45	Censored	6.08	PD	SD		
	0211-0004	PlaceboPemPlatinum	5.72	Deceased	4.14	PD	SD		
	0211-0005	PlaceboPemPlatinum	4.86	Deceased	1.38	PD	PD		
	0212-0001	ADIPemPlatinum	10.94	Deceased	5.98	Censored	SD		
	0212-0002	ADIPemPlatinum	3.68	Deceased	3.68	Deceased	SD		
	0212-0003	ADIPemPlatinum	3.45	Deceased	1.22	Censored	SD		
	0212-0004	PlaceboPemPlatinum	13.27	Deceased	5.26	PD	SD		
	0212-0005	PlaceboPemPlatinum	3.71	Deceased	2.14	PD	SD		
	0212-0006	ADIPemPlatinum	36.34	Censored	24.15	Censored	SD		
	0212-0007	ADIPemPlatinum	5.32	Deceased	3.94	PD	SD		
	0212-0008	ADIPemPlatinum	2.50	Deceased	1.18	PD	PD		
	0301-0001	PlaceboPemPlatinum	3.09	Deceased	1.25	Censored	SD		
	0301-0002	PlaceboPemPlatinum	34.96	Deceased	7.43	PD	SD		

Abbreviations: CR = complete response; N/A = not applicable; PD = progressive disease; PFS = progression free survival; PR = partial response; SD = stable disease

Note: Disease assessments for Phase 2 subjects up until the end of Phase 2 interim analysis (May 2020) were determined by blinded independent central review. For Phase 2 subjects who were still on study treatment and progression free at the end of Phase 2 interim analysis (subjects 0107-0008, 0107-0010, 0201-0031, 0201-0034, 0201-0045, 0201-0053, 0201-0054, 0202-0004, 0203-0013, 0207-0004, 0208-0008, 0211-0003, and 0212-0006), subsequent disease assessments were determined by the investigator. All disease assessments for Phase 3 subjects were determined by the investigator.

^[1] Calculated as the time from randomization until death. In the event that no death is documented prior to study termination or analysis cutoff, OS was censored at the last known date the subject is known to be alive, either through completion of on-study visits or through survival follow-up contact.

^[2] Calculated as the time from randomization until date of tumor progression or death. In the event that no tumor progression or death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS was censored at the date of the last tumor assessment demonstrating no tumor progression.

^[3] The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requirement for confirmation.

^[4] Calculated for subjects who have a best tumor response of CR or PR as the time from date of initial response of CR or PR until date of tumor progression or death. Subjects without tumor progression or death at the end of treatment were censored using the date of the last tumor assessment demonstrating no tumor progression.

Listing 16.2.6.1
Derived Efficacy Data

Study Phase	Subject ID	Treatment Group	Overall Survival ^[1] (Months)	Overall Survival Status	Progression-Free Survival ^[2] (Months)	Progression-Free Survival Status	Best Tumor Response ^[3]	Duration of Response ^[4] (Months)	Duration of Response Status
Phase 2	0301-0003	PlaceboPemPlatinum	1.71	Deceased	1.22	PD	PD		
	0301-0004	PlaceboPemPlatinum	15.93	Deceased	2.60	Censored	SD		
	0301-0005	PlaceboPemPlatinum	12.39	Deceased	5.55	Censored	SD		
	0301-0006	PlaceboPemPlatinum	17.02	Deceased	7.20	Censored	SD		
	0301-0007	PlaceboPemPlatinum	7.59	Deceased	2.53	PD	SD		
	0304-0001	PlaceboPemPlatinum	1.28	Deceased	0.03	Censored	Missing or Not Evaluable		
	0305-0001	ADIPemPlatinum	20.40	Deceased	7.66	Censored	SD		
	0305-0002	PlaceboPemPlatinum	1.97	Deceased	1.22	PD	PD		
	0502-0001	ADIPemPlatinum	34.00	Censored	5.95	PD	SD		
	0502-0002	ADIPemPlatinum	8.64	Deceased	5.39	Censored	SD		
	0503-0001	PlaceboPemPlatinum	9.53	Deceased	1.81	Censored	SD		
	0503-0003	PlaceboPemPlatinum	0.69	Deceased	0.69	Deceased	Missing or Not Evaluable		
	0506-0001	ADIPemPlatinum	3.84	Deceased	3.84	Deceased	SD		
	0506-0002	PlaceboPemPlatinum	17.02	Deceased	7.92	Censored	PR	6.47	Censored
	0509-0002	PlaceboPemPlatinum	8.64	Deceased	2.92	PD	SD		
	0511-0001	ADIPemPlatinum	10.91	Deceased	7.49	PD	PR	6.11	PD
	0511-0002	PlaceboPemPlatinum	8.41	Deceased	2.66	Censored	SD		
	0511-0003	PlaceboPemPlatinum	6.97	Deceased	2.63	Censored	SD		
	1201-0001	PlaceboPemPlatinum	3.19	Deceased	3.19	Deceased	SD		
	1206-0001	PlaceboPemPlatinum	7.89	Deceased	5.06	PD	SD		
	1206-0002	PlaceboPemPlatinum	1.87	Deceased	0.03	Censored	Missing or Not Evaluable		
	1206-0003	PlaceboPemPlatinum	1.25	Deceased	0.03	Censored	Missing or Not Evaluable		

Abbreviations: CR = complete response; N/A = not applicable; PD = progressive disease; PFS = progression free survival; PR = partial response; SD = stable disease

Note: Disease assessments for Phase 2 subjects up until the end of Phase 2 interim analysis (May 2020) were determined by blinded independent central review. For Phase 2 subjects who were still on study treatment and progression free at the end of Phase 2 interim analysis (subjects 0107-0008, 0107-0010, 0201-0031, 0201-0034, 0201-0045, 0201-0053, 0201-0054, 0202-0004, 0203-0013, 0207-0004, 0208-0008, 0211-0003, and 0212-0006), subsequent disease assessments were determined by the investigator. All disease assessments for Phase 3 subjects were determined by the investigator.

^[1] Calculated as the time from randomization until death. In the event that no death is documented prior to study termination or analysis cutoff, OS was censored at the last known date the subject is known to be alive, either through completion of on-study visits or through survival follow-up contact.

^[2] Calculated as the time from randomization until date of tumor progression or death. In the event that no tumor progression or death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS was censored at the date of the last tumor assessment demonstrating no tumor progression.

^[3] The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requirement for confirmation.

^[4] Calculated for subjects who have a best tumor response of CR or PR as the time from date of initial response of CR or PR until date of tumor progression or death. Subjects without tumor progression or death at the end of treatment were censored using the date of the last tumor assessment demonstrating no tumor progression.

Listing 16.2.6.1
Derived Efficacy Data

Study Phase	Subject ID	Treatment Group	Overall Survival ^[1] (Months)	Overall Survival Status	Progression-Free Survival ^[2] (Months)	Progression-Free Survival Status	Best Tumor Response ^[3]	Duration of Response ^[4] (Months)	Duration of Response Status
Phase 3	0102-0010	ADIPemPlatinum	5.32	Deceased	3.98	PD	N/A		
	0102-0011	ADIPemPlatinum	3.75	Deceased	1.18	Censored	N/A		
	0102-0012	ADIPemPlatinum	17.94	Deceased	7.62	PD	N/A		
	0102-0013	PlaceboPemPlatinum	4.90	Deceased	2.56	PD	N/A		
	0102-0014	ADIPemPlatinum	9.82	Deceased	9.30	PD	N/A		
	0102-0015	ADIPemPlatinum	4.86	Deceased	2.23	Censored	N/A		
	0103-0010	PlaceboPemPlatinum	7.23	Deceased	5.98	Censored	N/A		
	0107-0011	PlaceboPemPlatinum	3.32	Deceased	2.43	PD	N/A		
	0108-0007	ADIPemPlatinum	30.19	Censored	11.76	PD	N/A		
	0108-0009	PlaceboPemPlatinum	13.17	Deceased	7.66	PD	N/A		
	0201-0057	PlaceboPemPlatinum	1.71	Deceased	0.62	Censored	N/A		
	0201-0058	ADIPemPlatinum	2.46	Deceased	1.41	Censored	N/A		
	0201-0060	PlaceboPemPlatinum	3.15	Deceased	2.20	PD	N/A		
	0201-0061	PlaceboPemPlatinum	2.79	Deceased	2.79	Deceased	N/A		
	0202-0007	PlaceboPemPlatinum	2.46	Deceased	1.18	PD	N/A		
	0203-0019	ADIPemPlatinum	2.10	Deceased	0.03	Censored	N/A		
	0210-0001	ADIPemPlatinum	14.78	Deceased	4.21	PD	N/A		
	0211-0006	PlaceboPemPlatinum	2.73	Deceased	2.73	Deceased	N/A		
	0211-0007	PlaceboPemPlatinum	2.20	Deceased	2.20	Deceased	N/A		
	0212-0010	ADIPemPlatinum	4.60	Deceased	0.82	Censored	N/A		
	0212-0011	ADIPemPlatinum	8.34	Deceased	1.48	Censored	N/A		
	0212-0012	PlaceboPemPlatinum	7.36	Deceased	4.83	Censored	N/A		

Abbreviations: CR = complete response; N/A = not applicable; PD = progressive disease; PFS = progression free survival; PR = partial response; SD = stable disease

Note: Disease assessments for Phase 2 subjects up until the end of Phase 2 interim analysis (May 2020) were determined by blinded independent central review. For Phase 2 subjects who were still on study treatment and progression free at the end of Phase 2 interim analysis (subjects 0107-0008, 0107-0010, 0201-0031, 0201-0034, 0201-0045, 0201-0053, 0201-0054, 0202-0004, 0203-0013, 0207-0004, 0208-0008, 0211-0003, and 0212-0006), subsequent disease assessments were determined by the investigator. All disease assessments for Phase 3 subjects were determined by the investigator.

^[1] Calculated as the time from randomization until death. In the event that no death is documented prior to study termination or analysis cutoff, OS was censored at the last known date the subject is known to be alive, either through completion of on-study visits or through survival follow-up contact.

^[2] Calculated as the time from randomization until date of tumor progression or death. In the event that no tumor progression or death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS was censored at the date of the last tumor assessment demonstrating no tumor progression.

^[3] The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requirement for confirmation.

^[4] Calculated for subjects who have a best tumor response of CR or PR as the time from date of initial response of CR or PR until date of tumor progression or death. Subjects without tumor progression or death at the end of treatment were censored using the date of the last tumor assessment demonstrating no tumor progression.

Listing 16.2.6.1
Derived Efficacy Data

Study Phase	Subject ID	Treatment Group	Overall Survival ^[1] (Months)	Overall Survival Status	Progression-Free Survival ^[2] (Months)	Progression-Free Survival Status	Best Tumor Response ^[3]	Duration of Response ^[4] (Months)	Duration of Response Status
Phase 3	0214-0002	ADIPemPlatinum	12.32	Deceased	0.03	Censored	N/A		
	0217-0001	ADIPemPlatinum	22.83	Deceased	19.61	PD	N/A		
	0217-0002	PlaceboPemPlatinum	14.78	Censored	6.87	PD	N/A		
	0218-0001	PlaceboPemPlatinum	8.80	Deceased	4.73	PD	N/A		
	0218-0002	ADIPemPlatinum	0.59	Deceased	0.59	Deceased	N/A		
	0218-0003	ADIPemPlatinum	13.93	Deceased	11.07	PD	N/A		
	0218-0005	ADIPemPlatinum	9.86	Deceased	4.14	PD	N/A		
	0218-0006	PlaceboPemPlatinum	9.26	Deceased	3.98	PD	N/A		
	0218-0007	PlaceboPemPlatinum	4.11	Deceased	2.76	Censored	N/A		
	0218-0008	PlaceboPemPlatinum	10.28	Deceased	7.62	PD	N/A		
	0218-0012	PlaceboPemPlatinum	2.66	Deceased	1.51	PD	N/A		
	0218-0013	ADIPemPlatinum	20.86	Censored	7.66	PD	N/A		
	0218-0014	ADIPemPlatinum	6.67	Deceased	6.11	PD	N/A		
	0218-0015	ADIPemPlatinum	1.35	Deceased	1.35	Deceased	N/A		
	0218-0016	ADIPemPlatinum	8.64	Deceased	7.43	PD	N/A		
	0218-0018	ADIPemPlatinum	3.22	Deceased	2.66	PD	N/A		
	0218-0019	PlaceboPemPlatinum	12.09	Deceased	6.05	PD	N/A		
	0219-0001	ADIPemPlatinum	4.14	Deceased	0.95	PD	N/A		
	0219-0002	ADIPemPlatinum	3.98	Deceased	1.48	PD	N/A		
	0219-0003	PlaceboPemPlatinum	10.78	Deceased	4.21	PD	N/A		
	0219-0004	PlaceboPemPlatinum	18.20	Deceased	3.98	PD	N/A		
	0219-0005	ADIPemPlatinum	12.71	Deceased	3.94	PD	N/A		

Abbreviations: CR = complete response; N/A = not applicable; PD = progressive disease; PFS = progression free survival; PR = partial response; SD = stable disease

Note: Disease assessments for Phase 2 subjects up until the end of Phase 2 interim analysis (May 2020) were determined by blinded independent central review. For Phase 2 subjects who were still on study treatment and progression free at the end of Phase 2 interim analysis (subjects 0107-0008, 0107-0010, 0201-0031, 0201-0034, 0201-0045, 0201-0053, 0201-0054, 0202-0004, 0203-0013, 0207-0004, 0208-0008, 0211-0003, and 0212-0006), subsequent disease assessments were determined by the investigator. All disease assessments for Phase 3 subjects were determined by the investigator.

^[1] Calculated as the time from randomization until death. In the event that no death is documented prior to study termination or analysis cutoff, OS was censored at the last known date the subject is known to be alive, either through completion of on-study visits or through survival follow-up contact.

^[2] Calculated as the time from randomization until date of tumor progression or death. In the event that no tumor progression or death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS was censored at the date of the last tumor assessment demonstrating no tumor progression.

^[3] The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requirement for confirmation.

^[4] Calculated for subjects who have a best tumor response of CR or PR as the time from date of initial response of CR or PR until date of tumor progression or death. Subjects without tumor progression or death at the end of treatment were censored using the date of the last tumor assessment demonstrating no tumor progression.

Listing 16.2.6.1
Derived Efficacy Data

Study Phase	Subject ID	Treatment Group	Overall Survival ^[1] (Months)	Overall Survival Status	Progression-Free Survival ^[2] (Months)	Progression-Free Survival Status	Best Tumor Response ^[3]	Duration of Response ^[4] (Months)	Duration of Response Status
Phase 3	0219-0006	ADIPemPlatinum	9.49	Deceased	6.97	PD	N/A		
	0302-0001	PlaceboPemPlatinum	25.10	Deceased	5.78	Censored	N/A		
	0303-0001	ADIPemPlatinum	8.61	Deceased	7.75	PD	N/A		
	0303-0002	ADIPemPlatinum	5.32	Deceased	1.15	Censored	N/A		
	0304-0002	ADIPemPlatinum	1.12	Deceased	1.12	Deceased	N/A		
	0304-0003	PlaceboPemPlatinum	15.67	Deceased	9.36	PD	N/A		
	0304-0004	PlaceboPemPlatinum	4.21	Deceased	2.79	PD	N/A		
	0305-0004	ADIPemPlatinum	15.24	Deceased	2.86	Censored	N/A		
	0305-0005	ADIPemPlatinum	12.45	Deceased	1.25	Censored	N/A		
	0502-0003	ADIPemPlatinum	9.82	Deceased	1.71	PD	N/A		
	0502-0004	ADIPemPlatinum	18.14	Censored	12.91	PD	N/A		
	0502-0005	ADIPemPlatinum	16.30	Censored	5.98	PD	N/A		
	0502-0006	PlaceboPemPlatinum	16.07	Censored	5.59	PD	N/A		
	0502-0008	ADIPemPlatinum	13.60	Deceased	5.75	PD	N/A		
	0502-0010	ADIPemPlatinum	8.77	Deceased	2.89	PD	N/A		
	0502-0011	PlaceboPemPlatinum	11.63	Censored	7.82	PD	N/A		
	0505-0001	PlaceboPemPlatinum	9.89	Deceased	1.81	PD	N/A		
	0505-0002	PlaceboPemPlatinum	10.94	Deceased	5.91	PD	N/A		
	0506-0004	PlaceboPemPlatinum	1.38	Deceased	1.38	Deceased	N/A		
	0506-0005	PlaceboPemPlatinum	10.02	Deceased	10.02	Deceased	N/A		
	0506-0006	ADIPemPlatinum	8.84	Deceased	6.24	PD	N/A		
	0506-0008	PlaceboPemPlatinum	16.39	Censored	6.01	PD	N/A		

Abbreviations: CR = complete response; N/A = not applicable; PD = progressive disease; PFS = progression free survival; PR = partial response; SD = stable disease

Note: Disease assessments for Phase 2 subjects up until the end of Phase 2 interim analysis (May 2020) were determined by blinded independent central review. For Phase 2 subjects who were still on study treatment and progression free at the end of Phase 2 interim analysis (subjects 0107-0008, 0107-0010, 0201-0031, 0201-0034, 0201-0045, 0201-0053, 0201-0054, 0202-0004, 0203-0013, 0207-0004, 0208-0008, 0211-0003, and 0212-0006), subsequent disease assessments were determined by the investigator. All disease assessments for Phase 3 subjects were determined by the investigator.

^[1] Calculated as the time from randomization until death. In the event that no death is documented prior to study termination or analysis cutoff, OS was censored at the last known date the subject is known to be alive, either through completion of on-study visits or through survival follow-up contact.

^[2] Calculated as the time from randomization until date of tumor progression or death. In the event that no tumor progression or death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS was censored at the date of the last tumor assessment demonstrating no tumor progression.

^[3] The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requirement for confirmation.

^[4] Calculated for subjects who have a best tumor response of CR or PR as the time from date of initial response of CR or PR until date of tumor progression or death. Subjects without tumor progression or death at the end of treatment were censored using the date of the last tumor assessment demonstrating no tumor progression.

Listing 16.2.6.1
Derived Efficacy Data

Study Phase	Subject ID	Treatment Group	Overall Survival ^[1] (Months)	Overall Survival Status	Progression-Free Survival ^[2] (Months)	Progression-Free Survival Status	Best Tumor Response ^[3]	Duration of Response ^[4] (Months)	Duration of Response Status
Phase 3	0506-0009	ADIPemPlatinum	6.54	Deceased	4.17	PD	N/A		
	0506-0010	ADIPemPlatinum	12.75	Censored	11.53	Censored	N/A		
	0508-0001	PlaceboPemPlatinum	3.15	Deceased	2.63	Censored	N/A		
	0510-0001	PlaceboPemPlatinum	30.19	Deceased	2.07	Censored	N/A		
	0511-0004	PlaceboPemPlatinum	20.50	Censored	4.70	Censored	N/A		
	0511-0005	PlaceboPemPlatinum	20.93	Censored	4.44	Censored	N/A		
	0511-0006	PlaceboPemPlatinum	4.93	Deceased	3.06	Censored	N/A		

Abbreviations: CR = complete response; N/A = not applicable; PD = progressive disease; PFS = progression free survival; PR = partial response; SD = stable disease

Note: Disease assessments for Phase 2 subjects up until the end of Phase 2 interim analysis (May 2020) were determined by blinded independent central review. For Phase 2 subjects who were still on study treatment and progression free at the end of Phase 2 interim analysis (subjects 0107-0008, 0107-0010, 0201-0031, 0201-0034, 0201-0045, 0201-0053, 0201-0054, 0202-0004, 0203-0013, 0207-0004, 0208-0008, 0211-0003, and 0212-0006), subsequent disease assessments were determined by the investigator. All disease assessments for Phase 3 subjects were determined by the investigator.

^[1] Calculated as the time from randomization until death. In the event that no death is documented prior to study termination or analysis cutoff, OS was censored at the last known date the subject is known to be alive, either through completion of on-study visits or through survival follow-up contact.

^[2] Calculated as the time from randomization until date of tumor progression or death. In the event that no tumor progression or death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS was censored at the date of the last tumor assessment demonstrating no tumor progression.

^[3] The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requirement for confirmation.

^[4] Calculated for subjects who have a best tumor response of CR or PR as the time from date of initial response of CR or PR until date of tumor progression or death. Subjects without tumor progression or death at the end of treatment were censored using the date of the last tumor assessment demonstrating no tumor progression.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0101-0002	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	06APR2018 (38)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	18MAY2018 (80)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	29JUN2018 (122)		mRECIST	SD		No	SD
0101-0003	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	04MAY2018 (38)		mRECIST	SD		No	SD
0101-0004	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	20JUN2018 (38)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	01AUG2018 (80)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 6, Day 15	Yes	14SEP2018 (124)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Week 26	Yes	07NOV2018 (178)		mRECIST	SD	Non-CR/Non-PD	No	SD
0101-0006	PlaceboPemPlatinum	PR	Cycle 2, Day 15	Yes	15MAY2019 (38)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	01JUL2019 (85)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	15AUG2019 (130)		mRECIST	PR		No	PR
			Unscheduled	Yes	08OCT2019 (184)		mRECIST	PR		No	PR
			Week 34	Yes	03DEC2019 (240)		mRECIST	PD		No	PD
0101-0008	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	18JUN2019 (37)		RECIST 1.1 and mRECIST	SD		No	SD
0101-0009	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	05AUG2019 (48)		mRECIST	SD		No	SD
0101-0010	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	09SEP2019 (43)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	18OCT2019 (82)		mRECIST	PR		No	PR
			Unscheduled	Yes	24OCT2019 (88)		mRECIST	PR		No	PR

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0101-0011	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	12OCT2019 (39)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	20NOV2019 (78)		mRECIST	PR	Non-CR/Non-PD	No	PR
			Cycle 6, Day 15	Yes	04JAN2020 (123)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Week 26	Yes	25FEB2020 (175)		mRECIST	SD	Non-CR/Non-PD	No	SD
0102-0001	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	11OCT2017 (36)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	22NOV2017 (78)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	04JAN2018 (121)		RECIST 1.1 and mRECIST	SD		No	SD
0102-0002	ADIPemPlatinum	PR	Cycle 2, Day 15	Yes	31JAN2018 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	14MAR2018 (78)		mRECIST	PR		No	PR
			Cycle 6, Day 15	No							
			Unscheduled	Yes	11APR2018 (106)		mRECIST	PR		No	PR
			Week 24	Yes	06JUN2018 (162)		mRECIST	PR		No	PR
			Week 32	Yes	01AUG2018 (218)		mRECIST	PR		No	PR
			Week 40	Yes	26SEP2018 (274)		mRECIST	PR		No	PR
			Week 48	Yes	21NOV2018 (330)		mRECIST	PR		No	PR
0102-0003	PlaceboPemPlatinum	PD	Cycle 2, Day 15	Yes	08MAR2018 (37)		mRECIST	PD	Non-CR/Non-PD	Yes	PD
0102-0004	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	21MAR2018 (37)		RECIST 1.1 and mRECIST	SD	Non-CR/Non-PD	No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0102-0004	PlaceboPemPlatinum	SD	Cycle 4, Day 15	Yes	02MAY2018 (79)		RECIST 1.1 and mRECIST	SD	PD	No	PD
0102-0005	PlaceboPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15	Yes Yes	23MAY2018 (36) 05JUL2018 (79)		mRECIST mRECIST	SD SD		No No	SD SD
0102-0006	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	13FEB2019 (36)		RECIST 1.1 and mRECIST	SD		No	SD
0102-0007	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	21AUG2019 (36)		RECIST 1.1 and mRECIST	SD		No	SD
0102-0008	PlaceboPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 1	Yes Yes	23OCT2019 (36) 20NOV2019 (64)		mRECIST mRECIST	PR PD		No Yes	PR PD
0102-0009	PlaceboPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15	Yes Yes	04NOV2019 (36) 16DEC2019 (78)		mRECIST mRECIST	SD SD		No No	SD SD
0103-0003	ADIPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15 Cycle 6, Day 15 Unscheduled Week 26	Yes Yes Yes Yes Yes	17APR2018 (42) 23MAY2018 (78) 05JUL2018 (121) 02AUG2018 (149) 25SEP2018 (203)		mRECIST mRECIST mRECIST mRECIST mRECIST	SD SD SD SD PR		No No No No No	SD SD SD SD PR
0103-0006	PlaceboPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15	Yes Yes	19JUL2018 (36) 30AUG2018 (78)		mRECIST mRECIST	SD SD		No No	SD SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0103-0006	PlaceboPemPlatinum	SD	Cycle 6, Day 15	Yes	10OCT2018 (119)		mRECIST	SD		No	SD
0103-0009	ADIPemPlatinum	PD	Cycle 2, Day 15 Cycle 4, Day 15	Yes Yes	26SEP2019 (44) 07NOV2019 (86)		mRECIST mRECIST	SD PR		Yes Yes	PD PD
0104-0001	PlaceboPemPlatinum	PD	Cycle 2, Day 15 Cycle 4, Day 15	Yes Yes	14MAY2018 (34) 18JUN2018 (69)		mRECIST mRECIST	SD PD		No No	SD PD
0104-0004	ADIPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15 Cycle 6, Day 15 Week 22 Week 26 Week 34	Yes Yes Yes Yes Yes Yes	22JUL2019 (36) 03SEP2019 (79) 14OCT2019 (120) 11NOV2019 (148) 09DEC2019 (176) 03FEB2020 (232)		mRECIST mRECIST mRECIST mRECIST mRECIST mRECIST	SD SD SD SD PR PD		No No No No No No	SD SD SD SD PR PD
0104-0006	ADIPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15 Cycle 6, Day 15 Week 24	Yes Yes Yes Yes	09DEC2019 (36) 20JAN2020 (78) 02MAR2020 (120) 13APR2020 (162)		mRECIST mRECIST mRECIST mRECIST	SD SD PR PD		No No No No	SD SD PR PD
0107-0001	ADIPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15 Cycle 6, Day 15 Unscheduled	Yes Yes Yes Yes	17MAY2018 (38) 02JUL2018 (84) 13AUG2018 (126) 11SEP2018 (155)		mRECIST mRECIST mRECIST mRECIST	SD SD SD PD		No No No No	SD SD SD PD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0107-0002	PlaceboPemPlatinum	CR	Cycle 2, Day 15	Yes	02OCT2018 (42)		RECIST 1.1 and mRECIST	PR		No	PR
			Cycle 4, Day 15	Yes	09NOV2018 (80)		RECIST 1.1 and mRECIST	PR		No	PR
			Cycle 6, Day 15	Yes	27DEC2018 (128)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 26	Yes	30JAN2019 (162)		RECIST 1.1 and mRECIST	CR		No	CR
			Week 34	Yes	08APR2019 (230)		RECIST 1.1 and mRECIST	CR		No	CR
			Week 42	Yes	06JUN2019 (289)		RECIST 1.1 and mRECIST	CR		No	CR
			Week 50	Yes	29JUL2019 (342)		RECIST 1.1 and mRECIST	CR		No	CR
			Week 58	Yes	24SEP2019 (399)		RECIST 1.1 and mRECIST	PD		No	PD
			Week 66	Yes	19NOV2019 (455)		RECIST 1.1 and mRECIST	PD		No	PD
0107-0004	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	25JAN2019 (39)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	08MAR2019 (81)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	19APR2019 (123)		mRECIST	SD		No	SD
0107-0005	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	04APR2019 (45)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	13MAY2019 (84)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	24JUN2019 (126)		mRECIST	SD		No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0107-0005	ADIPemPlatinum	SD	Week 26 Week 34	Yes Yes	12AUG2019 (175) 07OCT2019 (231)		mRECIST mRECIST	SD PD		No No	SD PD
0107-0006	ADIPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15	Yes Yes	19APR2019 (38) 31MAY2019 (80)		mRECIST mRECIST	SD SD		No No	SD SD
0107-0007	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	26NOV2019 (37)		mRECIST	SD		No	SD
0107-0008	ADIPemPlatinum	PR	Cycle 2, Day 15 Cycle 4, Day 15 Cycle 6, Day 15 Week 26	Yes Yes Yes Yes	06DEC2019 (39) 21JAN2020 (85) 25FEB2020 (120) 21APR2020 (176)		mRECIST mRECIST mRECIST mRECIST	SD SD PR PR		No No No No	SD SD PR PR
0107-0010	PlaceboPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15 Cycle 6, Day 15	Yes Yes Yes	05JAN2020 (42) 14FEB2020 (82) 24MAR2020 (121)		mRECIST mRECIST mRECIST	SD PR SD		No No No	SD PR SD
0108-0002	PlaceboPemPlatinum	PD	Cycle 2, Day 15	Yes	08MAR2019 (38)		mRECIST	PD		No	PD
0108-0003	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	23APR2019 (42)		RECIST 1.1 and mRECIST	SD		No	SD
0108-0004	PlaceboPemPlatinum	PD	Cycle 2, Day 15	Yes	06JUN2019 (37)		mRECIST	PD		No	PD
0108-0006	PlaceboPemPlatinum	PD	Cycle 2, Day 15	Yes	10DEC2019 (42)		mRECIST	PD		Yes	PD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0110-0001	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	11SEP2018 (43)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	23OCT2018 (85)		RECIST 1.1 and mRECIST	SD		Yes	PD
0110-0002	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	25MAR2019 (42)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	06MAY2019 (84)		mRECIST	SD	Non-CR/Non-PD	No	SD
0112-0003	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	29OCT2019 (36)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 4, Day 1	Yes	10DEC2019 (78)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	21JAN2020 (120)		RECIST 1.1 and mRECIST	SD		No	SD
0201-0001	PlaceboPemPlatinum	PR	Cycle 2, Day 15	Yes	06SEP2017 (36)		mRECIST	PR		No	PR
			Cycle 4, Day 15	Yes	18OCT2017 (78)		mRECIST	PR		No	PR
			Cycle 6, Day 15	Yes	29NOV2017 (120)		mRECIST	PR		No	PR
0201-0002	PlaceboPemPlatinum	NE	Cycle 2, Day 15	Yes	12SEP2017 (35)		mRECIST	SD		No	SD
0201-0004	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	18OCT2017 (43)		RECIST 1.1 and mRECIST	SD		No	SD
0201-0005	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	19OCT2017 (37)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	30NOV2017 (79)		mRECIST	SD		No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0201-0005	ADIPemPlatinum	SD	Cycle 6, Day 15	Yes	11JAN2018 (121)		mRECIST	SD		No	SD
			Week 24	Yes	21FEB2018 (162)		mRECIST	SD		No	SD
			Week 32	Yes	18APR2018 (218)		mRECIST	PD		No	PD
0201-0006	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	18OCT2017 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	29NOV2017 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	10JAN2018 (120)		mRECIST	PD		No	PD
0201-0007	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	15NOV2017 (36)		mRECIST	SD		No	SD
0201-0008	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	30AUG2018 (37)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	11OCT2018 (79)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	22NOV2018 (121)		mRECIST	SD		No	SD
			Week 26	Yes	17JAN2019 (177)		mRECIST	SD		No	SD
			Week 34	Yes	13MAR2019 (232)		mRECIST	SD		No	SD
			Week 40	Yes	08MAY2019 (288)		mRECIST	SD		No	SD
0201-0009	PlaceboPemPlatinum	PR	Cycle 2, Day 15	Yes	30NOV2017 (37)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	11JAN2018 (79)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	21FEB2018 (120)		mRECIST	SD		No	SD
			Week 24	Yes	12APR2018 (170)		mRECIST	SD		No	SD
			Week 34	Yes	13JUN2018 (232)		mRECIST	PR		No	PR
			Week 38	Yes	11JUL2018 (260)		mRECIST	PR		No	PR
			Week 46	Yes	05SEP2018 (316)		mRECIST	PR		No	PR
			Week 54	Yes	31OCT2018 (372)		mRECIST	PD		No	PD
			Week 62	Yes	24DEC2018 (426)		mRECIST	PD		No	PD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0201-0011	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	17JAN2018 (36)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	28FEB2018 (78)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 6, Day 15	Yes	04APR2018 (113)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Week 24	Yes	06JUN2018 (176)		mRECIST	PD	PD	No	PD
0201-0013	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	07MAR2018 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	18APR2018 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	30MAY2018 (120)		mRECIST	SD		No	SD
0201-0014	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	21MAR2018 (36)		RECIST 1.1 and mRECIST	SD		No	SD
			Unscheduled	Yes	27APR2018 (73)		RECIST 1.1 and mRECIST	PD		No	PD
0201-0015	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	18APR2018 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	29MAY2018 (77)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	13JUL2018 (122)		mRECIST	SD		No	SD
			Week 26	Yes	06SEP2018 (177)		mRECIST	PD		No	PD
0201-0016	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	08MAY2018 (35)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	19JUN2018 (77)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	31JUL2018 (119)		RECIST 1.1 and mRECIST	PR		No	PR

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0201-0016	PlaceboPemPlatinum	SD	Week 22	Yes	28AUG2018 (147)		RECIST 1.1 and mRECIST	SD		No	SD
			Week 30	Yes	23OCT2018 (203)		RECIST 1.1 and mRECIST	SD		No	SD
			Week 38	Yes	18DEC2018 (259)		RECIST 1.1 and mRECIST	SD		No	SD
			Unscheduled	Yes	16JAN2019 (288)		RECIST 1.1 and mRECIST	SD		No	SD
			Week 46	Yes	12FEB2019 (315)		RECIST 1.1 and mRECIST	SD		No	SD
0201-0017	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	29MAY2018 (35)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	10JUL2018 (77)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 6, Day 15	Yes	07AUG2018 (105)		mRECIST	PR	Non-CR/Non-PD	No	PR
0201-0018	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	05JUN2018 (36)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	17JUL2018 (78)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 6, Day 15	Yes	28AUG2018 (120)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Week 26	Yes	23OCT2018 (176)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Week 34	Yes	18DEC2018 (232)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Week 40	Yes	12FEB2019 (288)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Week 50	Yes	09APR2019 (344)		mRECIST	PD	Non-CR/Non-PD	No	PD
0201-0019	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	13JUN2018 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	25JUL2018 (78)		mRECIST	PR		No	PR
			Unscheduled	Yes	22AUG2018 (106)		mRECIST	PD		No	PD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0201-0019	ADIPemPlatinum	SD	Week 24	Yes	17OCT2018 (162)		mRECIST	PD		No	PD
0201-0020	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	11JUL2018 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	22AUG2018 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	03OCT2018 (120)		mRECIST	PD		No	PD
0201-0021	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	01AUG2018 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	12SEP2018 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	25OCT2018 (121)		mRECIST	SD		No	SD
			Week 24	Yes	05DEC2018 (162)		mRECIST	SD		No	SD
0201-0023	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	22AUG2018 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	03OCT2018 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	14NOV2018 (120)		mRECIST	SD		No	SD
			Week 26	Yes	09JAN2019 (176)		mRECIST	SD		No	SD
			Week 32	Yes	06MAR2019 (232)		mRECIST	SD		No	SD
			Week 40	Yes	01MAY2019 (288)		mRECIST	SD		No	SD
			Unscheduled	Yes	25JUN2019 (343)		mRECIST	SD		No	SD
0201-0024	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	05SEP2018 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	17OCT2018 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	28NOV2018 (120)		mRECIST	SD		No	SD
			Unscheduled	Yes	05JAN2019 (158)		mRECIST	SD		No	SD
0201-0025	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	19DEC2018 (36)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	30JAN2019 (78)		mRECIST	SD	Non-CR/Non-PD	No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0201-0025	PlaceboPemPlatinum	SD	Cycle 6, Day 15	Yes	13MAR2019 (120)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Week 26	Yes	07MAY2019 (175)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Week 34	Yes	02JUL2019 (231)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Week 42	Yes	27AUG2019 (287)		mRECIST	SD	Non-CR/Non-PD	No	SD
0201-0026	PlaceboPemPlatinum	PD	Cycle 2, Day 15	Yes	11OCT2018 (37)		RECIST 1.1 and mRECIST	SD		Yes	PD
0201-0027	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	06NOV2018 (36)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	No	11DEC2018 (71)		mRECIST	PD	Non-CR/Non-PD	No	PD
			Unscheduled	Yes	24DEC2018 (84)		mRECIST	PD	PD	No	PD
0201-0028	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	21NOV2018 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 1	Yes	21DEC2018 (66)		mRECIST	SD		No	SD
0201-0030	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	21NOV2018 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	02JAN2019 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	No							
0201-0031	ADIPemPlatinum	PR	Cycle 2, Day 15	Yes	05DEC2018 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	16JAN2019 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	27FEB2019 (120)		mRECIST	SD		No	SD
			Week 26	Yes	24APR2019 (176)		mRECIST	PR		No	PR
			Week 30	Yes	22MAY2019 (204)		mRECIST	PR		No	PR
			Week 38	Yes	17JUL2019 (260)		mRECIST	PR		No	PR
			Week 46	Yes	17SEP2019 (322)		mRECIST	PR		No	PR

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0201-0031	ADIPemPlatinum	PR	Week 54	Yes	12NOV2019 (378)		mRECIST	PR		No	PR
			Week 62	Yes	07JAN2020 (434)		mRECIST	PR		No	PR
			Week 72	Yes	03MAR2020 (490)		mRECIST	PR		No	PR
			Week 82	Yes	26MAY2020 (574)		mRECIST	PR		No	PR
0201-0033	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	20FEB2019 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	03APR2019 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	15MAY2019 (120)		mRECIST	SD		No	SD
			Week 26	Yes	10JUL2019 (176)		mRECIST	SD		Yes	PD
0201-0034	ADIPemPlatinum	PR	Cycle 2, Day 15	Yes	21JAN2019 (48)		RECIST 1.1 and mRECIST	PR		No	PR
			Cycle 4, Day 15	Yes	20FEB2019 (78)		RECIST 1.1 and mRECIST	PR		No	PR
			Cycle 6, Day 15	No	25APR2019 (142)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 24	Yes	23MAY2019 (170)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 34	Yes	18JUL2019 (226)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 42	Yes	25SEP2019 (295)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 50	Yes	19NOV2019 (350)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 58	Yes	21JAN2020 (413)		RECIST 1.1 and mRECIST	PR		No	PR

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0201-0034	ADIPemPlatinum	PR	Week 66	Yes	17MAR2020 (469)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 74	Yes	19MAY2020 (532)		RECIST 1.1 and mRECIST	PR		No	PR
0201-0035	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	16JAN2019 (43)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	21FEB2019 (79)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	03APR2019 (120)		mRECIST	SD		No	SD
			Week 26	Yes	29MAY2019 (176)		mRECIST	SD		Yes	PD
0201-0036	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	22JAN2019 (49)		mRECIST	SD		No	SD
0201-0038	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	20FEB2019 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	03APR2019 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 1	Yes	01MAY2019 (106)		mRECIST	SD		No	SD
			Week 24	Yes	25JUN2019 (161)		mRECIST	SD		No	SD
			Week 30	Yes	06AUG2019 (203)		mRECIST	SD		No	SD
			Week 38	Yes	01OCT2019 (259)		mRECIST	PD		No	PD
0201-0039	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	07MAR2019 (37)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	18APR2019 (79)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 6, Day 15	Yes	30MAY2019 (121)		mRECIST	PR	Non-CR/Non-PD	No	PR
			Week 22	Yes	26JUN2019 (148)		mRECIST	PD	Non-CR/Non-PD	No	PD
			Week 30	Yes	20AUG2019 (203)		mRECIST	PD	Non-CR/Non-PD	No	PD
0201-0040	PlaceboPemPlatinum	PR	Cycle 2, Day 15	Yes	19MAR2019 (36)		mRECIST	PR		No	PR

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0201-0040	PlaceboPemPlatinum	PR	Cycle 4, Day 15	Yes	30APR2019 (78)		mRECIST	PR		No	PR
			Cycle 6, Day 15	Yes	28MAY2019 (106)		mRECIST	PR		No	PR
			Week 24	Yes	23JUL2019 (162)		mRECIST	PR		No	PR
			Week 34	Yes	17SEP2019 (218)		mRECIST	SD		No	SD
			Week 40	Yes	12NOV2019 (274)		mRECIST	PD		No	PD
			Week 48	Yes	06JAN2020 (329)		mRECIST	PD		No	PD
			Week 56	Yes	03MAR2020 (386)		mRECIST	PD		No	PD
0201-0041	ADIPemPlatinum	PR	Cycle 2, Day 15	Yes	09MAY2019 (37)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	19JUN2019 (78)		mRECIST	PR		No	PR
			Cycle 6, Day 1	Yes	17JUL2019 (106)		mRECIST	PR		No	PR
			Week 24	Yes	11SEP2019 (162)		mRECIST	PR		No	PR
			Week 32	Yes	06NOV2019 (218)		mRECIST	PD		No	PD
0201-0043	ADIPemPlatinum	PR	Cycle 2, Day 15	Yes	12JUN2019 (36)		mRECIST	PR		No	PR
			Cycle 4, Day 15	Yes	30JUL2019 (84)		mRECIST	PR		No	PR
			Week 22	Yes	21SEP2019 (137)		mRECIST	PR		No	PR
			Week 26	Yes	30OCT2019 (176)		mRECIST	PD		Yes	PD
0201-0044	PlaceboPemPlatinum	PR	Cycle 2, Day 15	Yes	19JUN2019 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	31JUL2019 (78)		mRECIST	PR		No	PR
			Cycle 6, Day 15	Yes	11SEP2019 (120)		mRECIST	PR		No	PR
			Week 26	Yes	06NOV2019 (176)		mRECIST	PR		No	PR
			Unscheduled	Yes	11DEC2019 (211)		mRECIST	PR		No	PR
			Week 38	Yes	05FEB2020 (267)		mRECIST	PR		No	PR
			Week 48	Yes	01APR2020 (323)		mRECIST	PR		No	PR

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0201-0045	PlaceboPemPlatinum	PR	Cycle 2, Day 15	Yes	29MAY2019 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	10JUL2019 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	21AUG2019 (120)		mRECIST	PR		No	PR
			Week 22	Yes	18SEP2019 (148)		mRECIST	PR		No	PR
			Week 30	Yes	13NOV2019 (204)		mRECIST	PD		No	SD
			Week 38	Yes	08JAN2020 (260)		mRECIST	SD		No	SD
			Week 46	Yes	04MAR2020 (316)		mRECIST	PR		No	PR
			Week 54	Yes	29APR2020 (372)		mRECIST	PR		No	PR
0201-0046	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	19JUN2019 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	31JUL2019 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	11SEP2019 (120)		mRECIST	PD		No	PD
0201-0047	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	19JUN2019 (36)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	31JUL2019 (78)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	11SEP2019 (120)		RECIST 1.1 and mRECIST	SD		No	SD
0201-0048	PlaceboPemPlatinum	SD	Unscheduled	Yes	20JUL2019 (47)		mRECIST	SD		No	SD
0201-0049	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	08AUG2019 (45)		mRECIST	SD		No	SD
0201-0050	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	29AUG2019 (38)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	10OCT2019 (80)		mRECIST	PR	Non-CR/Non-PD	No	PR

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0201-0050	PlaceboPemPlatinum	SD	Cycle 6, Day 15	Yes	20NOV2019 (121)		mRECIST	SD	Non-CR/Non-PD	No	SD
0201-0051	PlaceboPemPlatinum	PR	Cycle 2, Day 15	Yes	06AUG2019 (36)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	17SEP2019 (78)		RECIST 1.1 and mRECIST	PR		No	PR
			Cycle 6, Day 1	Yes	25OCT2019 (116)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 24	Yes	10DEC2019 (162)		RECIST 1.1 and mRECIST	PR		Yes	PD
0201-0052	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	21AUG2019 (36)		RECIST 1.1 and mRECIST	SD		No	SD
0201-0053	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	21AUG2019 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	No	01OCT2019 (77)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	12NOV2019 (119)		mRECIST	SD		No	SD
			Week 26	Yes	15JAN2020 (183)		mRECIST	SD		No	SD
			Week 34	Yes	11MAR2020 (239)		mRECIST	PR		No	PR
			Week 42	Yes	06MAY2020 (295)		mRECIST	SD		No	SD
0201-0054	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	25SEP2019 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	06NOV2019 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	18DEC2019 (120)		mRECIST	SD		No	SD
			Week 26	Yes	12FEB2020 (176)		mRECIST	SD		No	SD
			Week 34	Yes	08APR2020 (232)		mRECIST	SD		No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0202-0001	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	16MAY2018 (43)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	25JUN2018 (83)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	06AUG2018 (125)		RECIST 1.1 and mRECIST	SD		No	SD
0202-0002	ADIPemPlatinum	PR	Cycle 2, Day 15	Yes	31OCT2018 (50)		mRECIST	PR	Non-CR/Non-PD	No	PR
			Cycle 4, Day 15	Yes	03DEC2018 (83)		mRECIST	PR	Non-CR/Non-PD	No	PR
			Cycle 6, Day 15	Yes	16JAN2019 (127)		mRECIST	PR	Non-CR/Non-PD	No	PR
0202-0003	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	01JUL2019 (42)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	13AUG2019 (85)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	28SEP2019 (131)		mRECIST	SD		No	SD
			Week 26	Yes	19NOV2019 (183)		mRECIST	PD		No	PD
0202-0004	ADIPemPlatinum	PR	Cycle 2, Day 15	Yes	12JUN2019 (36)		RECIST 1.1 and mRECIST	PR		No	PR
			Cycle 4, Day 15	Yes	24JUL2019 (78)		RECIST 1.1 and mRECIST	PR		No	PR
			Cycle 6, Day 15	Yes	28AUG2019 (113)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 24	Yes	23OCT2019 (169)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 30	Yes	04DEC2019 (211)		RECIST 1.1 and mRECIST	PR		No	PR

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0202-0004	ADIPemPlatinum	PR	Week 38	Yes	15JAN2020 (253)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 42	Yes	26FEB2020 (295)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 50	Yes	08APR2020 (337)		RECIST 1.1 and mRECIST	PR		No	PR
			Week 54	Yes	20MAY2020 (379)		RECIST 1.1 and mRECIST	PR		No	PR
0202-0005	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	30DEC2019 (48)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	12FEB2020 (92)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	18MAR2020 (127)		RECIST 1.1 and mRECIST	SD		No	SD
			Week 24	Yes	30APR2020 (170)		RECIST 1.1 and mRECIST	PD		No	PD
0203-0001	ADIPemPlatinum	SD	Cycle 2, Day 15	No	18JAN2018 (45)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	28FEB2018 (86)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	28MAR2018 (114)		mRECIST	SD		No	SD
0203-0002	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	14FEB2018 (44)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	28MAR2018 (86)		mRECIST	SD		No	SD
			Cycle 6, Day 15	No							

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0203-0004	ADIPemPlatinum	PD	Cycle 2, Day 15	Yes	06APR2018 (45)		mRECIST	SD	PD	No	PD
0203-0005	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	17MAY2018 (44)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	27JUN2018 (85)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	08AUG2018 (127)		mRECIST	SD		No	SD
			Week 24	Yes	03OCT2018 (183)		mRECIST	SD		No	SD
0203-0008	PlaceboPemPlatinum	PR	Cycle 2, Day 15	Yes	19SEP2018 (43)		mRECIST	PR		No	PR
			Cycle 4, Day 15	Yes	19OCT2018 (73)		mRECIST	PR		No	PR
			Cycle 6, Day 15	Yes	12DEC2018 (127)		mRECIST	PR		No	PR
			Week 26	Yes	06FEB2019 (183)		mRECIST	PD		Yes	PD
0203-0009	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	10OCT2018 (43)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	21NOV2018 (85)		mRECIST	SD		No	SD
			Week 22	Yes	02JAN2019 (127)		mRECIST	SD		No	SD
			Unscheduled	Yes	31JAN2019 (156)		mRECIST	NE		No	NE
0203-0013	ADIPemPlatinum	PR	Cycle 2, Day 15	Yes	24APR2019 (43)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	12JUN2019 (92)		mRECIST	PR		No	PR
			Cycle 6, Day 15	Yes	10JUL2019 (120)		mRECIST	PR		No	PR
			Week 26	Yes	28AUG2019 (169)		mRECIST	SD		No	SD
			Week 34	Yes	17OCT2019 (219)		mRECIST	SD		No	SD
			Week 38	Yes	27NOV2019 (260)		mRECIST	PR		No	PR
			Week 46	Yes	08JAN2020 (302)		mRECIST	PR		No	PR
			Week 50	Yes	04MAR2020 (358)		mRECIST	PR		No	PR

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0203-0014	ADIPemPlatinum	PR	Cycle 2, Day 15	Yes	03SEP2019 (42)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	15OCT2019 (84)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 6, Day 15	Yes	13NOV2019 (113)		mRECIST	PR	Non-CR/Non-PD	No	PR
			Week 24	Yes	08JAN2020 (169)		mRECIST	PR	Non-CR/Non-PD	No	PR
			Week 34	Yes	04MAR2020 (225)		mRECIST	PD	Non-CR/Non-PD	Yes	PD
0203-0015	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	11SEP2019 (43)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	23OCT2019 (85)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	27NOV2019 (120)		mRECIST	SD		No	SD
0203-0016	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	02OCT2019 (43)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	13NOV2019 (85)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	23DEC2019 (125)		mRECIST	SD		No	SD
0204-0001	PlaceboPemPlatinum	PR	Cycle 2, Day 15	Yes	25JUN2018 (41)		mRECIST	PR		No	PR
			Cycle 4, Day 15	Yes	01AUG2018 (78)		mRECIST	PR		No	PR
			Cycle 6, Day 15	Yes	10SEP2018 (118)		mRECIST	PR		No	PR
			Unscheduled	Yes	05NOV2018 (174)		mRECIST	PD		No	PD
0204-0002	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	22AUG2018 (43)		mRECIST	SD	Non-CR/Non-PD	No	SD
0204-0003	PlaceboPemPlatinum	PD	Cycle 2, Day 15	Yes	03SEP2018 (34)		mRECIST	PD	PD	Yes	PD
0204-0004	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	24SEP2018 (35)		mRECIST	SD		No	SD
			Unscheduled	Yes	25OCT2018 (66)		mRECIST	SD		No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0204-0005	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	23OCT2018 (35)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	03DEC2018 (76)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	14JAN2019 (118)		mRECIST	SD		No	SD
			Week 24	Yes	26FEB2019 (161)		mRECIST	SD		No	SD
			Week 34	Yes	07MAY2019 (231)		mRECIST	SD		No	SD
			Week 42	Yes	28JUN2019 (283)		mRECIST	PD		Yes	PD
0204-0006	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	07JAN2019 (34)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	19FEB2019 (77)		mRECIST	SD		No	SD
0204-0007	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	06MAR2019 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	15APR2019 (76)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	29MAY2019 (120)		mRECIST	PD		Yes	PD
0204-0008	PlaceboPemPlatinum	PR	Cycle 2, Day 15	Yes	11MAR2019 (34)		mRECIST	SD		No	SD
			Cycle 4, Day 1	Yes	09APR2019 (63)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	05JUN2019 (120)		mRECIST	PR		No	PR
			Week 26	Yes	30JUL2019 (175)		mRECIST	PR		No	PR
			Week 34	Yes	23SEP2019 (230)		mRECIST	PR		Yes	PD
			Week 42	Yes	03DEC2019 (301)		mRECIST	PR		Yes	PD
0204-0009	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	09APR2019 (35)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	28MAY2019 (84)		mRECIST	PR		No	PR
			Cycle 6, Day 15	Yes	08JUL2019 (125)		mRECIST	SD		No	SD
			Week 26	Yes	27AUG2019 (175)		mRECIST	PD		No	PD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0204-0010	ADIPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15	Yes Yes	16SEP2019 (41) 29OCT2019 (84)		mRECIST mRECIST	SD SD		No No	SD SD
0204-0011	ADIPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15 Cycle 6, Day 15	Yes Yes Yes	28OCT2019 (41) 09DEC2019 (83) 20JAN2020 (125)		mRECIST mRECIST mRECIST	SD SD PD		No No No	SD SD PD
0205-0001	ADIPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15 Cycle 6, Day 15 Week 26 Week 34	Yes Yes Yes Yes Yes	13AUG2018 (42) 25SEP2018 (85) 05NOV2018 (126) 31DEC2018 (182) 25FEB2019 (238)		RECIST 1.1 and mRECIST RECIST 1.1 and mRECIST RECIST 1.1 and mRECIST RECIST 1.1 and mRECIST RECIST 1.1 and mRECIST	SD SD SD SD PD		No No No No No	SD SD SD SD PD
0205-0002	PlaceboPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15 Cycle 6, Day 15	Yes Yes Yes	22MAY2019 (38) 03JUL2019 (80) 14AUG2019 (122)		mRECIST mRECIST mRECIST	SD SD PD		No No Yes	SD SD PD
0205-0005	PlaceboPemPlatinum	SD	Cycle 2, Day 15 Cycle 4, Day 15	Yes Yes	03OCT2019 (38) 14NOV2019 (80)		mRECIST mRECIST	SD PD		No No	SD PD
0207-0003	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	20AUG2019 (44)		mRECIST	SD		No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0207-0003	ADIPemPlatinum	SD	Cycle 4, Day 15	Yes	03OCT2019 (88)		mRECIST	SD		Yes	PD
0208-0001	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	22JUN2018 (40)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	13AUG2018 (92)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	24SEP2018 (134)		mRECIST	SD		No	SD
			Week 26	Yes	19NOV2018 (190)		mRECIST	SD		Yes	PD
0208-0002	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	11OCT2018 (38)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	21NOV2018 (79)		mRECIST	PD		No	PD
0208-0003	ADIPemPlatinum	PD	Cycle 2, Day 15	Yes	21DEC2018 (38)		mRECIST	PD		No	PD
0208-0004	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	29APR2019 (34)		mRECIST	SD		No	SD
			Cycle 4, Day 1	Yes	14JUN2019 (80)		mRECIST	SD		No	SD
			Cycle 6, Day 15	No							
			Week 24	Yes	30JUL2019 (126)		mRECIST	PD		No	PD
0208-0006	ADIPemPlatinum	SD	Cycle 2, Day 15	No	03JUL2019 (45)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	08AUG2019 (81)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	25SEP2019 (129)		mRECIST	PD		No	PD
0208-0007	ADIPemPlatinum	PD	Cycle 2, Day 15	Yes	22AUG2019 (44)		mRECIST	SD		Yes	PD
0208-0008	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	22NOV2019 (38)		RECIST 1.1 and mRECIST	SD		No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0208-0008	ADIPemPlatinum	SD	Cycle 4, Day 15	No	03JAN2020 (80)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	10FEB2020 (118)		RECIST 1.1 and mRECIST	SD		No	SD
0209-0001	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	31MAY2018 (38)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	12JUL2018 (80)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	23AUG2018 (122)		mRECIST	SD		No	SD
			Week 24	Yes	18OCT2018 (178)		mRECIST	SD		No	SD
			Week 34	Yes	13DEC2018 (234)		mRECIST	SD		No	SD
			Week 42	Yes	07FEB2019 (290)		mRECIST	PD		No	PD
			Week 50	Yes	03APR2019 (345)		mRECIST	PD		No	PD
0209-0003	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	02MAY2019 (45)		mRECIST	SD		No	SD
			Unscheduled	Yes	21MAY2019 (64)		mRECIST	SD		No	SD
0209-0004	ADIPemPlatinum	PR	Cycle 2, Day 15	Yes	11NOV2019 (41)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	23DEC2019 (83)		mRECIST	PR		No	PR
			Cycle 6, Day 15	Yes	03FEB2020 (125)		mRECIST	PR		No	PR
			Week 26	Yes	01APR2020 (183)		mRECIST	PR		No	PR
0209-0005	ADIPemPlatinum	PD	Cycle 2, Day 15	Yes	13DEC2019 (39)		mRECIST	PD		No	PD
0211-0001	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	23AUG2019 (38)		mRECIST	SD		No	SD
			Cycle 4, Day 1	Yes	04OCT2019 (80)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	15NOV2019 (122)		mRECIST	SD		No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0211-0001	PlaceboPemPlatinum	SD	Week 26	Yes	09JAN2020 (177)		mRECIST	PD		No	PD
0211-0002	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	05AUG2019 (-2)		mRECIST	SD		No	SD
			Cycle 4, Day 1	Yes	13SEP2019 (38)		mRECIST	SD		No	SD
0211-0003	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	07NOV2019 (37)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	19DEC2019 (79)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	05FEB2020 (127)		mRECIST	SD		No	SD
0211-0004	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	22NOV2019 (38)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	03JAN2020 (80)		RECIST 1.1 and mRECIST	PR		No	PR
			Cycle 6, Day 15	Yes	14FEB2020 (122)		RECIST 1.1 and mRECIST	PR		Yes	PD
0211-0005	PlaceboPemPlatinum	PD	Cycle 2, Day 15	Yes	16DEC2019 (41)		mRECIST	PD		No	PD
			Cycle 4, Day 15	Yes	14JAN2020 (70)		mRECIST	PD		No	PD
0212-0001	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	25SEP2018 (43)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	06NOV2018 (85)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	17DEC2018 (126)		mRECIST	SD		No	SD
			Week 26	Yes	11FEB2019 (182)		mRECIST	SD		No	SD
0212-0002	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	06NOV2018 (36)		mRECIST	SD		No	SD
			Unscheduled	Yes	04DEC2018 (64)		mRECIST	SD		No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0212-0003	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	14NOV2018 (36)		mRECIST	SD		No	SD
0212-0004	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	20FEB2019 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	27MAR2019 (71)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	16MAY2019 (121)		mRECIST	SD		No	SD
			Week 26	Yes	24JUN2019 (160)		mRECIST	PD		No	PD
0212-0005	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	02MAY2019 (37)		mRECIST	PR		No	PR
			Unscheduled	Yes	30MAY2019 (65)		mRECIST	PD		No	PD
0212-0006	ADIPemPlatinum	SD	Cycle 2, Day 15	No	21AUG2019 (36)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	09OCT2019 (85)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	06NOV2019 (113)		mRECIST	SD		No	SD
			Week 26	Yes	06JAN2020 (174)		mRECIST	SD		No	SD
			Week 30	Yes	26FEB2020 (225)		mRECIST	SD		No	SD
0212-0007	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	03SEP2019 (37)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	14OCT2019 (78)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	25NOV2019 (120)		mRECIST	PD		No	PD
0212-0008	ADIPemPlatinum	PD	Cycle 2, Day 15	Yes	09SEP2019 (36)		mRECIST	PD		No	PD
0301-0001	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	23JAN2019 (38)		mRECIST	SD		No	SD
0301-0002	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	23JAN2019 (38)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	07MAR2019 (81)		mRECIST	SD		No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0301-0002	PlaceboPemPlatinum	SD	Cycle 6, Day 15	Yes	17APR2019 (122)		mRECIST	SD		No	SD
			Week 26	Yes	28MAY2019 (163)		mRECIST	SD		No	SD
			Week 34	Yes	30JUL2019 (226)		mRECIST	PD		No	PD
0301-0003	PlaceboPemPlatinum	PD	Cycle 2, Day 15	Yes	06MAR2019 (37)		RECIST 1.1 and mRECIST	SD		Yes	PD
0301-0004	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	17APR2019 (37)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	29MAY2019 (79)		RECIST 1.1 and mRECIST	SD		No	SD
0301-0005	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	07AUG2019 (37)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	18SEP2019 (79)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 6, Day 15	Yes	29OCT2019 (120)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Week 26	Yes	17DEC2019 (169)		mRECIST	SD	Non-CR/Non-PD	No	SD
0301-0006	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	28AUG2019 (37)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	02OCT2019 (72)		RECIST 1.1 and mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	19NOV2019 (120)		RECIST 1.1 and mRECIST	SD		No	SD
			Week 26	Yes	14JAN2020 (176)		RECIST 1.1 and mRECIST	SD		No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0301-0006	PlaceboPemPlatinum	SD	Week 34	Yes	25FEB2020 (218)		RECIST 1.1 and mRECIST	SD		No	SD
0301-0007	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	20NOV2019 (37)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	30DEC2019 (77)		mRECIST	SD	PD	No	PD
			Cycle 6, Day 15	Yes	12FEB2020 (121)		mRECIST	SD	Non-CR/Non-PD	No	PD
0305-0001	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	31AUG2018 (33)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	12OCT2018 (75)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	21NOV2018 (115)		mRECIST	SD		No	SD
			Week 26	Yes	21JAN2019 (176)		mRECIST	SD		No	SD
			Week 34	Yes	18MAR2019 (232)		mRECIST	SD		No	SD
0305-0002	PlaceboPemPlatinum	PD	Cycle 2, Day 15	Yes	29JUL2019 (36)		mRECIST	PD		No	PD
0502-0001	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	13NOV2019 (43)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	23DEC2019 (83)		mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 6, Day 15	Yes	03FEB2020 (125)		mRECIST	PR	Non-CR/Non-PD	No	PR
			Week 26	Yes	30MAR2020 (181)		mRECIST	PD	Non-CR/Non-PD	No	PD
0502-0002	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	27NOV2019 (38)		mRECIST	SD		No	SD
			Cycle 4, Day 1	Yes	08JAN2020 (80)		mRECIST	SD		No	SD
			Cycle 6, Day 15	Yes	05FEB2020 (108)		mRECIST	SD		No	SD
			Week 26	Yes	01APR2020 (164)		mRECIST	SD		No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
0503-0001	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	16JUL2019 (51)		RECIST 1.1 and mRECIST	SD		No	SD
0506-0001	ADIPemPlatinum	SD	Cycle 2, Day 15	Yes	17JUL2019 (41)		mRECIST	SD		No	SD
0506-0002	PlaceboPemPlatinum	PR	Cycle 2, Day 15	Yes	31JUL2019 (45)		mRECIST	PR		No	PR
			Cycle 4, Day 15	Yes	18SEP2019 (94)		mRECIST	PR		No	PR
			Cycle 6, Day 15	No	30OCT2019 (136)		mRECIST	PR		No	PR
			Week 26	Yes	18DEC2019 (185)		mRECIST	PR		No	PR
			Week 34	Yes	12FEB2020 (241)		mRECIST	PR		No	PR
0509-0002	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	03NOV2018 (47)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	15DEC2018 (89)		mRECIST	PD		No	PD
0511-0001	ADIPemPlatinum	PR	Cycle 2, Day 15	Yes	21MAY2019 (43)		mRECIST	PR		No	PR
			Cycle 4, Day 15	Yes	04JUL2019 (87)		mRECIST	PR		No	PR
			Cycle 6, Day 15	Yes	19AUG2019 (133)		mRECIST	PR		No	PR
			Unscheduled	Yes	27SEP2019 (172)		mRECIST	PR		No	PR
			Week 32	Yes	22NOV2019 (228)		mRECIST	PR		Yes	PD
0511-0002	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	20JUN2019 (38)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	02AUG2019 (81)		mRECIST	SD		No	SD
0511-0003	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	17SEP2019 (43)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	24OCT2019 (80)		mRECIST	SD		No	SD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.2
Response Assessment: RECIST Criteria - Phase 2 Subjects

Subject ID	Treatment Group	Best Overall Response	Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Completion Status	Target Lesion Assessment	Target Lesion Response	Non-Target Lesion Response ^[2]	New Lesions ^[2]	Overall Tumor Response
1201-0001	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	07DEC2018 (38)		mRECIST	SD		No	SD
			Cycle 4, Day 15	Yes	18JAN2019 (80)		mRECIST	SD		No	SD
1206-0001	PlaceboPemPlatinum	SD	Cycle 2, Day 15	Yes	15MAR2018 (38)		RECIST 1.1 and mRECIST	SD	Non-CR/Non-PD	No	SD
			Cycle 4, Day 15	Yes	25APR2018 (79)		RECIST 1.1 and mRECIST	PR	Non-CR/Non-PD	No	PR
			Cycle 6, Day 15 Unscheduled	No Yes	20MAY2018 (104)		RECIST 1.1 and mRECIST	PR	Non-CR/Non-PD	No	PR
			Unscheduled	Yes	09JUL2018 (154)		RECIST 1.1 and mRECIST	PD	Non-CR/Non-PD	No	PD

Abbreviations: CR = complete response; mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease

Notes:

- At each visit, only the tumor response assessment selected by the adjudicator is displayed when the two independent reviewers disagreed.
- In case of CR or PR, the best overall response required a repeat response 4 weeks later. If the CR or PR was not confirmed best overall response was determined as SD.

^[1] Time (days) relative to date of first dose of study drug

^[2] Non-target and new lesions are assessed using RECIST 1.1.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0101-0002 Treatment Group: ADIPemPlatinum														
Screening	Yes	19FEB2018 (-9)	CT Scan	Radiologist 1	86			mRECIST	86	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	06APR2018 (38)	CT Scan	Radiologist 1	72	-16.3	-16.3	mRECIST	72	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	20
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	9
Cycle 4, Day 15	Yes	18MAY2018 (80)	CT Scan	Radiologist 1	70	-2.8	-18.6	mRECIST	70	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	9
Cycle 6, Day 15	Yes	29JUN2018 (122)	CT Scan	Radiologist 1	79	12.9	-8.1	mRECIST	79	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	20
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0101-0003 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	15MAR2018 (-13)	CT Scan	Radiologist 1	80			mRECIST	80	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	16
Cycle 2, Day 15	Yes	04MAY2018 (38)	CT Scan	Radiologist 1	78	-2.5	-2.5	mRECIST	78	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	15
Subject ID: 0101-0004 Treatment Group: ADIPemPlatinum														
Screening	Yes	03MAY2018 (-11)	CT Scan	Radiologist 2	92			mRECIST	92	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	28
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	20
Cycle 2, Day 15	Yes	20JUN2018 (38)	CT Scan	Radiologist 2	90	-2.2	-2.2	mRECIST	90	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	28
											PL004	PLEURA	Present Measurable	13

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0101-0004 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	20JUN2018 (38)	CT Scan	Radiologist 2	90	-2.2	-2.2	mRECIST	90	Pleural	PL005	PLEURA	Present Measurable	18
Cycle 4, Day 15	Yes	01AUG2018 (80)	CT Scan	Radiologist 2	90	0.0	-2.2	mRECIST	90	Pleural	PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	26
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	17
Cycle 6, Day 15	Yes	14SEP2018 (124)	CT Scan	Radiologist 2	89	-1.1	-3.3	mRECIST	89	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	27
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	15
Week 26	Yes	07NOV2018 (178)	CT Scan	Radiologist 2	101	13.5	9.8	mRECIST	101	Pleural	PL001	PLEURA	Present Measurable	34
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	22
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	18
Subject ID: 0101-0006 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	25MAR2019 (-14)	CT Scan	Radiologist 2	81			mRECIST	81	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	22
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0101-0006 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	15MAY2019 (38)	CT Scan	Radiologist 2	64	-21.0	-21.0	mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	18
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	01JUL2019 (85)	CT Scan	Radiologist 2	67	4.7	-17.3	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	14
Cycle 6, Day 15	Yes	15AUG2019 (130)	CT Scan	Radiologist 2	48	-25.0	-40.7	mRECIST	48	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	11
Unscheduled	Yes	08OCT2019 (184)	CT Scan	Radiologist 2	51	6.3	-37.0	mRECIST	51	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	11
Week 34	Yes	03DEC2019 (240)	CT Scan	Radiologist 2	83	72.9	2.5	mRECIST	83	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	19
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	24

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0101-0006 Treatment Group: PlaceboPemPlatinum														
Week 34	Yes	03DEC2019 (240)	CT Scan	Radiologist 2	83	72.9	2.5	mRECIST	83	Pleural	PL005	PLEURA	Present Measurable	20
Subject ID: 0101-0008 Treatment Group: ADIPemPlatinum														
Screening	Yes	01MAY2019 (-12)	CT Scan	Radiologist 1	235			RECIST 1.1	19	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	19
								mRECIST	216	Pleural	PL001	PLEURA	Present Measurable	32
											PL002	PLEURA	Present Measurable	54
											PL003	PLEURA	Present Measurable	24
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	33
											PL006	PLEURA	Present Measurable	57
Cycle 2, Day 15	Yes	18JUN2019 (37)	CT Scan	Radiologist 1	227	-3.4	-3.4	RECIST 1.1	13	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	13
								mRECIST	214	Pleural	PL001	PLEURA	Present Measurable	32
											PL002	PLEURA	Present Measurable	53
											PL003	PLEURA	Present Measurable	26
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	37
											PL006	PLEURA	Present Measurable	53
Subject ID: 0101-0009 Treatment Group: ADIPemPlatinum														
Screening	Yes	07JUN2019 (-12)	CT Scan	Radiologist 1	150			mRECIST	150	Pleural	PL001	PLEURA	Present Measurable	24

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0101-0009 Treatment Group: ADIPemPlatinum														
Screening	Yes	07JUN2019 (-12)	CT Scan	Radiologist 1	150			mRECIST	150	Pleural	PL002	PLEURA	Present Measurable	20
											PL003	PLEURA	Present Measurable	24
											PL004	PLEURA	Present Measurable	20
											PL005	PLEURA	Present Measurable	21
											PL006	PLEURA	Present Measurable	41
Cycle 2, Day 15	Yes	05AUG2019 (48)	CT Scan	Radiologist 1	131	-12.7	-12.7	mRECIST	131	Pleural	PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	18
											PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	42
Subject ID: 0101-0010 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	12JUL2019 (-17)	CT Scan	Radiologist 1	74			mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	09SEP2019 (43)	CT Scan	Radiologist 1	60	-18.9	-18.9	mRECIST	60	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0101-0010 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	09SEP2019 (43)	CT Scan	Radiologist 1	60	-18.9	-18.9	mRECIST	60	Pleural	PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	13
Cycle 4, Day 15	Yes	18OCT2019 (82)	CT Scan	Radiologist 1	44	-26.7	-40.5	mRECIST	44	Pleural	PL001	PLEURA	Present Measurable	5
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	8
Unscheduled	Yes	24OCT2019 (88)	CT Scan	Radiologist 1	37	-15.9	-50.0	mRECIST	37	Pleural	PL001	PLEURA	Present Measurable	4
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	4
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	7
											PL006	PLEURA	Present Measurable	8
Subject ID: 0101-0011 Treatment Group: ADIPemPlatinum														
Screening	Yes	12AUG2019 (-23)	CT Scan	Radiologist 2	38			mRECIST	38	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	12OCT2019 (39)	CT Scan	Radiologist 2	28	-26.3	-26.3	mRECIST	28	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	8
Cycle 4, Day 15	Yes	20NOV2019 (78)	CT Scan	Radiologist 2	25	-10.7	-34.2	mRECIST	25	Pleural	PL001	PLEURA	Present Measurable	14

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0101-0011 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	20NOV2019 (78)	CT Scan	Radiologist 2	25	-10.7	-34.2	mRECIST	25	Pleural	PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	6
Cycle 6, Day 15	Yes	04JAN2020 (123)	CT Scan	Radiologist 2	27	8.0	-28.9	mRECIST	27	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	6
Week 26	Yes	25FEB2020 (175)	CT Scan	Radiologist 2	27	8.0	-28.9	mRECIST	27	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	7
Subject ID: 0102-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	23AUG2017 (-14)	CT Scan	Radiologist 1	152			RECIST 1.1	103	Nodal	TN001	RETROPERITO NEAL LYMPH NODE	Present Measurable	44
											TN002	RETROPERITO NEAL LYMPH NODE	Present Measurable	34
								mRECIST	49	Non-Nodal Pleural	T001	LUNG, RIGHT	Present Measurable	25
											PL001	PLEURA	Present Measurable	27
											PL002	PLEURA	Present Measurable	22
Cycle 2, Day 15	Yes	11OCT2017 (36)	CT Scan	Radiologist 1	121	-20.4	-20.4	RECIST 1.1	85	Nodal	TN001	RETROPERITO NEAL LYMPH NODE	Present Measurable	41

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0102-0001 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	11OCT2017 (36)	CT Scan	Radiologist 1	121	-20.4	-20.4	RECIST 1.1	85	Nodal	TN002	RETROPERITO NEAL LYMPH NODE	Present Measurable	29
								mRECIST	36	Non-Nodal Pleural	T001	LUNG, RIGHT	Present Measurable	15
											PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	18
Cycle 4, Day 15	Yes	22NOV2017 (78)	CT Scan	Radiologist 1	123	1.7	-19.1	RECIST 1.1	78	Nodal	TN001	RETROPERITO NEAL LYMPH NODE	Present Measurable	38
											TN002	RETROPERITO NEAL LYMPH NODE	Present Measurable	24
								mRECIST	45	Non-Nodal Pleural	T001	LUNG, RIGHT	Present Measurable	16
											PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	25
Cycle 6, Day 15	Yes	04JAN2018 (121)	CT Scan	Radiologist 1	136	12.4	-10.5	RECIST 1.1	87	Nodal	TN001	RETROPERITO NEAL LYMPH NODE	Present Measurable	41
											TN002	RETROPERITO NEAL LYMPH NODE	Present Measurable	26
								mRECIST	49	Non-Nodal Pleural	T001	LUNG, RIGHT	Present Measurable	20
											PL001	PLEURA	Present Measurable	23
											PL002	PLEURA	Present Measurable	26

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0102-0002 Treatment Group: ADIPemPlatinum														
Screening	Yes	21DEC2017 (-6)	CT Scan	Radiologist 1	23			mRECIST	23	Pleural	PL001	PLEURA	Present Measurable	23
Cycle 2, Day 15	Yes	31JAN2018 (36)	CT Scan	Radiologist 1	22	-4.3	-4.3	mRECIST	22	Pleural	PL001	PLEURA	Present Measurable	22
Cycle 4, Day 15	Yes	14MAR2018 (78)	CT Scan	Radiologist 1	15	-31.8	-34.8	mRECIST	15	Pleural	PL001	PLEURA	Present Measurable	15
Cycle 6, Day 15	No													
Unscheduled	Yes	11APR2018 (106)	CT Scan	Radiologist 1	11	-26.7	-52.2	mRECIST	11	Pleural	PL001	PLEURA	Present Measurable	11
Week 24	Yes	06JUN2018 (162)	CT Scan	Radiologist 1	7	-36.4	-69.6	mRECIST	7	Pleural	PL001	PLEURA	Present Measurable	7
Week 32	Yes	01AUG2018 (218)	CT Scan	Radiologist 1	7	0.0	-69.6	mRECIST	7	Pleural	PL001	PLEURA	Present Measurable	7
Week 40	Yes	26SEP2018 (274)	CT Scan	Radiologist 1	7	0.0	-69.6	mRECIST	7	Pleural	PL001	PLEURA	Present Measurable	7
Week 48	Yes	21NOV2018 (330)	CT Scan	Radiologist 1	7	0.0	-69.6	mRECIST	7	Pleural	PL001	PLEURA	Present Measurable	7
Subject ID: 0102-0003 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	24JAN2018 (-7)	CT Scan	Radiologist 2	140			mRECIST	140	Pleural	PL001	PLEURA	Present Measurable	33
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	26
											PL004	PLEURA	Present Measurable	23
											PL005	PLEURA	Present Measurable	23
											PL006	PLEURA	Present Measurable	21
Cycle 2, Day 15	Yes	08MAR2018 (37)	CT Scan	Radiologist 2	190	35.7	35.7	mRECIST	190	Pleural	PL001	PLEURA	Present Measurable	37
											PL002	PLEURA	Present Measurable	19
											PL003	PLEURA	Present Measurable	40
											PL004	PLEURA	Present Measurable	26
											PL005	PLEURA	Present Measurable	50
											PL006	PLEURA	Present Measurable	18

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0102-0004 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	05FEB2018 (-8)	CT Scan	Radiologist 1	142			RECIST 1.1	70	Non-Nodal	T001	LIVER	Present Measurable	70
								mRECIST	72	Pleural	PL001	PLEURA	Present Measurable	29
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	29
Cycle 2, Day 15	Yes	21MAR2018 (37)	CT Scan	Radiologist 1	121	-14.8	-14.8	RECIST 1.1	50	Non-Nodal	T001	LIVER	Present Measurable	50
								mRECIST	71	Pleural	PL001	PLEURA	Present Measurable	30
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	25
Cycle 4, Day 15	Yes	02MAY2018 (79)	CT Scan	Radiologist 1	128	5.8	-9.9	RECIST 1.1	65	Non-Nodal	T001	LIVER	Present Measurable	65
								mRECIST	63	Pleural	PL001	PLEURA	Present Measurable	23
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	24
Subject ID: 0102-0005 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	12APR2018 (-6)	CT Scan	Radiologist 1	46			mRECIST	46	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	33
Cycle 2, Day 15	Yes	23MAY2018 (36)	CT Scan	Radiologist 1	42	-8.7	-8.7	mRECIST	42	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	30
Cycle 4, Day 15	Yes	05JUL2018 (79)	CT Scan	Radiologist 1	38	-9.5	-17.4	mRECIST	38	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	27

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0102-0006 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	28DEC2018 (-12)	CT Scan	Radiologist 1	146			RECIST 1.1	47	Nodal	TN001	RETROCRURA L LYMPH NODE	Present Measurable	47
								mRECIST	99	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	27
Cycle 2, Day 15	Yes	13FEB2019 (36)	CT Scan	Radiologist 1	135	-7.5	-7.5	RECIST 1.1	50	Nodal	TN001	RETROCRURA L LYMPH NODE	Present Measurable	50
								mRECIST	85	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	20
Subject ID: 0102-0007 Treatment Group: ADIPemPlatinum														
Screening	Yes	11JUL2019 (-6)	CT Scan	Radiologist 1	114			RECIST 1.1	23	Non-Nodal	T001	CHEST WALL	Present Measurable	23
								mRECIST	91	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	11

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0102-0007 Treatment Group: ADIPemPlatinum														
Screening	Yes	11JUL2019 (-6)	CT Scan	Radiologist 1	114			mRECIST	91	Pleural	PL003	PLEURA	Present Measurable	25
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	21AUG2019 (36)	CT Scan	Radiologist 1	123	7.9	7.9	RECIST 1.1 mRECIST	24 99	Non-Nodal Pleural	T001	CHEST WALL	Present Measurable	24
											PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	28
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	12
Subject ID: 0102-0008 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	10SEP2019 (-8)	CT Scan	Radiologist 2	118			mRECIST	118	Pleural	PL001	PLEURA	Present Measurable	22
											PL002	PLEURA	Present Measurable	34
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	19
Cycle 2, Day 15	Yes	23OCT2019 (36)	CT Scan	Radiologist 2	49	-58.5	-58.5	mRECIST	49	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	5

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0102-0008 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	23OCT2019 (36)	CT Scan	Radiologist 2	49	-58.5	-58.5	mRECIST	49	Pleural	PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	8
Cycle 4, Day 1	Yes	20NOV2019 (64)	CT Scan	Radiologist 2	77	57.1	-34.7	mRECIST	77	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	12
Subject ID: 0102-0009 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	23SEP2019 (-7)	CT Scan	Radiologist 1	54			mRECIST	54	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	21
Cycle 2, Day 15	Yes	04NOV2019 (36)	CT Scan	Radiologist 1	41	-24.1	-24.1	mRECIST	41	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	18
Cycle 4, Day 15	Yes	16DEC2019 (78)	CT Scan	Radiologist 1	40	-2.4	-25.9	mRECIST	40	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	18
Subject ID: 0103-0003 Treatment Group: ADIPemPlatinum														
Screening	Yes	13FEB2018 (-22)	CT Scan	Radiologist 1	96			mRECIST	96	Pleural	PL001	PLEURA	Present Measurable	11

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0103-0003 Treatment Group: ADIPemPlatinum														
Screening	Yes	13FEB2018 (-22)	CT Scan	Radiologist 1	96			mRECIST	96	Pleural	PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	22
Cycle 2, Day 15	Yes	17APR2018 (42)	CT Scan	Radiologist 1	76	-20.8	-20.8	mRECIST	76	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	18
Cycle 4, Day 15	Yes	23MAY2018 (78)	CT Scan	Radiologist 1	87	14.5	-9.4	mRECIST	87	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	20
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	15
Cycle 6, Day 15	Yes	05JUL2018 (121)	CT Scan	Radiologist 1	81	6.6	-15.6	mRECIST	81	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	23
											PL004	PLEURA	Present Measurable	19
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	11
Unscheduled	Yes	02AUG2018 (149)	CT Scan	Radiologist 1	74	-2.6	-22.9	mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	5

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0103-0003 Treatment Group: ADIPemPlatinum														
Unscheduled	Yes	02AUG2018 (149)	CT Scan	Radiologist 1	74	-2.6	-22.9	mRECIST	74	Pleural	PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	22
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	12
Week 26	Yes	25SEP2018 (203)	CT Scan	Radiologist 1	62	-16.2	-35.4	mRECIST	62	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	16
Subject ID: 0103-0006 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	31MAY2018 (-14)	CT Scan	Radiologist 1	82			mRECIST	82	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	12
Cycle 2, Day 15	Yes	19JUL2018 (36)	CT Scan	Radiologist 1	89	8.5	8.5	mRECIST	89	Pleural	PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	14

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0103-0006 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	19JUL2018 (36)	CT Scan	Radiologist 1	89	8.5	8.5	mRECIST	89	Pleural	PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	30AUG2018 (78)	CT Scan	Radiologist 1	89	8.5	8.5	mRECIST	89	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	21
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	13
Cycle 6, Day 15	Yes	10OCT2018 (119)	CT Scan	Radiologist 1	83	1.2	1.2	mRECIST	83	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	13
Subject ID: 0103-0009 Treatment Group: ADIPemPlatinum														
Screening	Yes	08AUG2019 (-6)	CT Scan	Radiologist 2				mRECIST		Pleural	PL001	PLEURA	Present Measurable	19
											PL002	PLEURA	Present Measurable	21
											PL003	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	26SEP2019 (44)	CT Scan	Radiologist 2	42	-22.2	-22.2	mRECIST	42	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	18
											PL003	PLEURA	Present Measurable	8

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0103-0009 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	07NOV2019 (86)	CT Scan	Radiologist 2	9	-78.6	-83.3	mRECIST	9	Pleural	PL001	PLEURA	Not Present total disappearance	0
											PL002	PLEURA	Not Present total disappearance	0
											PL003	PLEURA	Present Measurable	9
Subject ID: 0104-0001 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	23MAR2018 (-19)	CT Scan	Radiologist 1	88			mRECIST	88	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	18
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	14MAY2018 (34)	CT Scan	Radiologist 1	90	2.3	2.3	mRECIST	90	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	14
Cycle 4, Day 15	Yes	18JUN2018 (69)	CT Scan	Radiologist 1	129	46.6	46.6	mRECIST	129	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	22
											PL004	PLEURA	Present Measurable	33

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0104-0001 Treatment Group: PlaceboPemPlatinum														
Cycle 4, Day 15	Yes	18JUN2018 (69)	CT Scan	Radiologist 1	129	46.6	46.6	mRECIST	129	Pleural	PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	21
Subject ID: 0104-0004 Treatment Group: ADIPemPlatinum														
Screening	Yes	20MAY2019 (-28)	CT Scan	Radiologist 1	87			mRECIST	87	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	17
Cycle 2, Day 15	Yes	22JUL2019 (36)	CT Scan	Radiologist 1	81	-6.9	-6.9	mRECIST	81	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	14
Cycle 4, Day 15	Yes	03SEP2019 (79)	CT Scan	Radiologist 1	72	-11.1	-17.2	mRECIST	72	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	9
Cycle 6, Day 15	Yes	14OCT2019 (120)	CT Scan	Radiologist 1	67	-6.9	-23.0	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	9

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0104-0004 Treatment Group: ADIPemPlatinum														
Cycle 6, Day 15	Yes	14OCT2019 (120)	CT Scan	Radiologist 1	67	-6.9	-23.0	mRECIST	67	Pleural	PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	6
Week 22	Yes	11NOV2019 (148)	CT Scan	Radiologist 1	76	13.4	-12.6	mRECIST	76	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	7
Week 26	Yes	09DEC2019 (176)	CT Scan	Radiologist 1	55	-17.9	-36.8	mRECIST	55	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	5
											PL006	PLEURA	Present Measurable	4
Week 34	Yes	03FEB2020 (232)	CT Scan	Radiologist 1	67	21.8	-23.0	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	18
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	7
											PL006	PLEURA	Present Measurable	2

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0104-0006 Treatment Group: ADIPemPlatinum														
Screening	Yes	09OCT2019 (-26)	CT Scan	Radiologist 1	67			mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	09DEC2019 (36)	CT Scan	Radiologist 1	60	-10.4	-10.4	mRECIST	60	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	14
Cycle 4, Day 15	Yes	20JAN2020 (78)	CT Scan	Radiologist 1	53	-11.7	-20.9	mRECIST	53	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	8
Cycle 6, Day 15	Yes	02MAR2020 (120)	CT Scan	Radiologist 1	39	-26.4	-41.8	mRECIST	39	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	6
											PL006	PLEURA	Present Measurable	6

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0104-0006 Treatment Group: ADIPemPlatinum														
Week 24	Yes	13APR2020 (162)	CT Scan	Radiologist 1	47	20.5	-29.9	mRECIST	47	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	6
Subject ID: 0107-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	21MAR2018 (-20)	CT Scan	Radiologist 1	95			mRECIST	95	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	17
Cycle 2, Day 15	Yes	17MAY2018 (38)	CT Scan	Radiologist 1	97	2.1	2.1	mRECIST	97	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	19
Cycle 4, Day 15	Yes	02JUL2018 (84)	CT Scan	Radiologist 1	103	8.4	8.4	mRECIST	103	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	20

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0107-0001 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	02JUL2018 (84)	CT Scan	Radiologist 1	103	8.4	8.4	mRECIST	103	Pleural	PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	21
Cycle 6, Day 15	Yes	13AUG2018 (126)	CT Scan	Radiologist 1	109	14.7	14.7	mRECIST	109	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	22
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	19
Unscheduled	Yes	11SEP2018 (155)	CT Scan	Radiologist 1	123	29.5	29.5	mRECIST	123	Pleural	PL001	PLEURA	Present Measurable	23
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	25
											PL004	PLEURA	Present Measurable	18
											PL005	PLEURA	Present Measurable	22
											PL006	PLEURA	Present Measurable	21
Subject ID: 0107-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	09AUG2018 (-13)	CT Scan	Radiologist 1	23			RECIST 1.1	23	Non-Nodal	T001	LUNG, RIGHT	Present Measurable	11
											T002	LUNG, RIGHT	Present Measurable	12
Cycle 2, Day 15	Yes	02OCT2018 (42)	CT Scan	Radiologist 1	16	-30.4	-30.4	RECIST 1.1	16	Non-Nodal	T001	LUNG, RIGHT	Present Measurable	8
											T002	LUNG, RIGHT	Present Measurable	8
Cycle 4, Day 15	Yes	09NOV2018 (80)	CT Scan	Radiologist 1	13	-18.8	-43.5	RECIST 1.1	13	Non-Nodal	T001	LUNG, RIGHT	Present Measurable	6
											T002	LUNG, RIGHT	Present Measurable	7

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0107-0002 Treatment Group: PlaceboPemPlatinum														
Cycle 6, Day 15	Yes	27DEC2018 (128)	CT Scan	Radiologist 1	10	-23.1	-56.5	RECIST 1.1	10	Non-Nodal	T001	LUNG, RIGHT	Present Measurable	5
Week 26	Yes	30JAN2019 (162)	CT Scan	Radiologist 1	0	-100.0	-100.0	RECIST 1.1	0	Non-Nodal	T002	LUNG, RIGHT	Present Measurable	5
											T001	LUNG, RIGHT	Not Present total disappearance	0
Week 34	Yes	08APR2019 (230)	CT Scan	Radiologist 1	0	0.0	-100.0	RECIST 1.1	0	Non-Nodal	T002	LUNG, RIGHT	Not Present total disappearance	0
											T001	LUNG, RIGHT	Not Present total disappearance	0
Week 42	Yes	06JUN2019 (289)	CT Scan	Radiologist 1	0	0.0	-100.0	RECIST 1.1	0	Non-Nodal	T002	LUNG, RIGHT	Not Present total disappearance	0
											T001	LUNG, RIGHT	Not Present total disappearance	0
Week 50	Yes	29JUL2019 (342)	CT Scan	Radiologist 1	0	0.0	-100.0	RECIST 1.1	0	Non-Nodal	T002	LUNG, RIGHT	Not Present total disappearance	0
											T001	LUNG, RIGHT	Not Present total disappearance	0
Week 58	Yes	24SEP2019 (399)	CT Scan	Radiologist 1	9	999.9	-60.9	RECIST 1.1	9	Non-Nodal	T002	LUNG, RIGHT	Not Present total disappearance	0
											T001	LUNG, RIGHT	Not Present total disappearance	0
Week 66	Yes	19NOV2019 (455)	CT Scan	Radiologist 1	16	999.9	-30.4	RECIST 1.1	16	Non-Nodal	T002	LUNG, RIGHT	Present Measurable	9
											T001	LUNG, RIGHT	Present Measurable	6
											T002	LUNG, RIGHT	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0107-0004 Treatment Group: ADIPemPlatinum														
Screening	Yes	11DEC2018 (-7)	CT Scan	Radiologist 1	37			mRECIST	37	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	25JAN2019 (39)	CT Scan	Radiologist 1	38	2.7	2.7	mRECIST	38	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	13
Cycle 4, Day 15	Yes	08MAR2019 (81)	CT Scan	Radiologist 1	40	8.1	8.1	mRECIST	40	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	13
Cycle 6, Day 15	Yes	19APR2019 (123)	CT Scan	Radiologist 1	42	13.5	13.5	mRECIST	42	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	13
Subject ID: 0107-0005 Treatment Group: ADIPemPlatinum														
Screening	Yes	12FEB2019 (-7)	CT Scan	Radiologist 2	64			mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	04APR2019 (45)	CT Scan	Radiologist 2	67	4.7	4.7	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0107-0005 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	04APR2019 (45)	CT Scan	Radiologist 2	67	4.7	4.7	mRECIST	67	Pleural	PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	11
Cycle 4, Day 15	Yes	13MAY2019 (84)	CT Scan	Radiologist 2	68	6.3	6.3	mRECIST	68	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	10
Cycle 6, Day 15	Yes	24JUN2019 (126)	CT Scan	Radiologist 2	71	10.9	10.9	mRECIST	71	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	10
Week 26	Yes	12AUG2019 (175)	CT Scan	Radiologist 2	71	10.9	10.9	mRECIST	71	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	12
Week 34	Yes	07OCT2019 (231)	CT Scan	Radiologist 2	92	43.8	43.8	mRECIST	92	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	15

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0107-0005 Treatment Group: ADIPemPlatinum														
Week 34	Yes	07OCT2019 (231)	CT Scan	Radiologist 2	92	43.8	43.8	mRECIST	92	Pleural	PL004	PLEURA	Present Measurable	20
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	14
Subject ID: 0107-0006 Treatment Group: ADIPemPlatinum														
Screening	Yes	28FEB2019 (-13)	CT Scan	Radiologist 2	125			mRECIST	125	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	37
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	22
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	17
Cycle 2, Day 15	Yes	19APR2019 (38)	CT Scan	Radiologist 2	117	-6.4	-6.4	mRECIST	117	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	45
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	14
Cycle 4, Day 15	Yes	31MAY2019 (80)	CT Scan	Radiologist 2	135	15.4	8.0	mRECIST	135	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	64
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	22
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	13

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0107-0007 Treatment Group: ADIPemPlatinum														
Screening	Yes	14OCT2019 (-7)	CT Scan	Radiologist 1	94			mRECIST	94	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	28
Cycle 2, Day 15	Yes	26NOV2019 (37)	CT Scan	Radiologist 1	104	10.6	10.6	mRECIST	104	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	33
Subject ID: 0107-0008 Treatment Group: ADIPemPlatinum														
Screening	Yes	22OCT2019 (-7)	CT Scan	Radiologist 1	105			mRECIST	105	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	19
											PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	24
Cycle 2, Day 15	Yes	06DEC2019 (39)	CT Scan	Radiologist 1	96	-8.6	-8.6	mRECIST	96	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	16

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0107-0008 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	06DEC2019 (39)	CT Scan	Radiologist 1	96	-8.6	-8.6	mRECIST	96	Pleural	PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	19
Cycle 4, Day 15	Yes	21JAN2020 (85)	CT Scan	Radiologist 1	78	-18.8	-25.7	mRECIST	78	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	16
Cycle 6, Day 15	Yes	25FEB2020 (120)	CT Scan	Radiologist 1	65	-16.7	-38.1	mRECIST	65	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	15
Week 26	Yes	21APR2020 (176)	CT Scan	Radiologist 1	58	-10.8	-44.8	mRECIST	58	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	14

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0107-0010 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	19NOV2019 (-6)	CT Scan	Radiologist 1	94			mRECIST	94	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	18
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	15
Cycle 2, Day 15	Yes	05JAN2020 (42)	CT Scan	Radiologist 1	70	-25.5	-25.5	mRECIST	70	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	9
Cycle 4, Day 15	Yes	14FEB2020 (82)	CT Scan	Radiologist 1	61	-12.9	-35.1	mRECIST	61	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	9
Cycle 6, Day 15	Yes	24MAR2020 (121)	CT Scan	Radiologist 1	66	8.2	-29.8	mRECIST	66	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0108-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	21JAN2019 (-9)	CT Scan	Radiologist 1	125			mRECIST	125	Pleural	PL001	PLEURA	Present Measurable	26
											PL002	PLEURA	Present Measurable	26
											PL003	PLEURA	Present Measurable	21
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	22
											PL006	PLEURA	Present Measurable	16
Cycle 2, Day 15	Yes	08MAR2019 (38)	CT Scan	Radiologist 1	178	42.4	42.4	mRECIST	178	Pleural	PL001	PLEURA	Present Measurable	36
											PL002	PLEURA	Present Measurable	33
											PL003	PLEURA	Present Measurable	26
											PL004	PLEURA	Present Measurable	19
											PL005	PLEURA	Present Measurable	23
											PL006	PLEURA	Present Measurable	41
Subject ID: 0108-0003 Treatment Group: ADIPemPlatinum														
Screening	Yes	16FEB2019 (-25)	CT Scan	Radiologist 1	81			RECIST 1.1	81	Non-Nodal	T001	PLEURA	Present Measurable	53
											T002	PLEURA	Present Measurable	28
Cycle 2, Day 15	Yes	23APR2019 (42)	CT Scan	Radiologist 1	70	-13.6	-13.6	RECIST 1.1	70	Non-Nodal	T001	PLEURA	Present Measurable	45
											T002	PLEURA	Present Measurable	25
Subject ID: 0108-0004 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	24APR2019 (-7)	CT Scan	Radiologist 1	74			mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	13

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0108-0004 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	24APR2019 (-7)	CT Scan	Radiologist 1	74			mRECIST	74	Pleural	PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	10
Cycle 2, Day 15	Yes	06JUN2019 (37)	CT Scan	Radiologist 1	112	51.4	51.4	mRECIST	112	Pleural	PL001	PLEURA	Present Measurable	19
											PL002	PLEURA	Present Measurable	21
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	18
											PL005	PLEURA	Present Measurable	25
											PL006	PLEURA	Present Measurable	13
Subject ID: 0108-0006 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	09OCT2019 (-21)	CT Scan	Radiologist 2	31			mRECIST	31	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	20
Cycle 2, Day 15	Yes	10DEC2019 (42)	CT Scan	Radiologist 2	45	45.2	45.2	mRECIST	45	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	33
Subject ID: 0110-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	19JUL2018 (-12)	CT Scan	Radiologist 1	123			RECIST 1.1	41	Nodal	TN001	HILAR LYMPH NODE	Present Measurable	20

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0110-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	19JUL2018 (-12)	CT Scan	Radiologist 1	123			RECIST 1.1	41	Nodal	TN002	DIAPHRAGMA TIC LYMPH NODE	Present Measurable	21
								mRECIST	82	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	18
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	11SEP2018 (43)	CT Scan	Radiologist 1	124	0.8	0.8	RECIST 1.1	50	Nodal	TN001	HILAR LYMPH NODE	Present Measurable	28
											TN002	DIAPHRAGMA TIC LYMPH NODE	Present Measurable	22
								mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	23
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	11
Cycle 4, Day 15	Yes	23OCT2018 (85)	CT Scan	Radiologist 1	99	-19.5	-19.5	RECIST 1.1	42	Nodal	TN001	HILAR LYMPH NODE	Present Measurable	20

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0110-0001 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	23OCT2018 (85)	CT Scan	Radiologist 1	99	-19.5	-19.5	RECIST 1.1	42	Nodal	TN002	DIAPHRAGMA TIC LYMPH NODE	Present Measurable	22
								mRECIST	57	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	10
Subject ID: 0110-0002 Treatment Group: ADIPemPlatinum														
Screening	Yes	25JAN2019 (-18)	CT Scan	Radiologist 1	53			mRECIST	53	Pleural	PL001	PLEURA	Present Measurable	25
											PL002	PLEURA	Present Measurable	28
Cycle 2, Day 15	Yes	25MAR2019 (42)	CT Scan	Radiologist 1	56	5.7	5.7	mRECIST	56	Pleural	PL001	PLEURA	Present Measurable	26
											PL002	PLEURA	Present Measurable	30
Cycle 4, Day 15	Yes	06MAY2019 (84)	CT Scan	Radiologist 1	56	5.7	5.7	mRECIST	56	Pleural	PL001	PLEURA	Present Measurable	25
											PL002	PLEURA	Present Measurable	31
Subject ID: 0112-0003 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	19SEP2019 (-5)	CT Scan	Radiologist 1	161			RECIST 1.1	59	Nodal	TN001	HILAR LYMPH NODE	Present Measurable	28

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0112-0003 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	19SEP2019 (-5)	CT Scan	Radiologist 1	161			RECIST 1.1	59	Nodal	TN002	MEDIASTINAL LYMPH NODE	Present Measurable	31
								mRECIST	102	Pleural	PL001	PLEURA	Present Measurable	27
											PL002	PLEURA	Present Measurable	24
											PL003	PLEURA	Present Measurable	27
											PL004	PLEURA	Present Measurable	24
Cycle 2, Day 15	Yes	29OCT2019 (36)	CT Scan	Radiologist 1	133	-17.4	-17.4	RECIST 1.1	50	Nodal	TN001	HILAR LYMPH NODE	Present Measurable	25
											TN002	MEDIASTINAL LYMPH NODE	Present Measurable	25
								mRECIST	83	Pleural	PL001	PLEURA	Present Measurable	26
											PL002	PLEURA	Present Measurable	19
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	19
Cycle 4, Day 1	Yes	10DEC2019 (78)	CT Scan	Radiologist 1	119	-10.5	-26.1	RECIST 1.1	61	Nodal	TN001	HILAR LYMPH NODE	Present Measurable	34
											TN002	MEDIASTINAL LYMPH NODE	Present Measurable	27
								mRECIST	58	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	18
Cycle 6, Day 15	Yes	21JAN2020 (120)	CT Scan	Radiologist 1	121	1.7	-24.8	RECIST 1.1	69	Nodal	TN001	HILAR LYMPH NODE	Present Measurable	40

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)		
Subject ID: 0112-0003 Treatment Group: PlaceboPemPlatinum																
Cycle 6, Day 15	Yes	21JAN2020 (120)	CT Scan	Radiologist 1	121	1.7	-24.8	RECIST 1.1	69	Nodal	TN002	MEDIASTINAL LYMPH NODE	Present Measurable	29		
								mRECIST	52	Pleural	PL001	PLEURA	Present Measurable	7		
													PL002	PLEURA	Present Measurable	11
													PL003	PLEURA	Present Measurable	14
													PL004	PLEURA	Present Measurable	20
Subject ID: 0201-0001 Treatment Group: PlaceboPemPlatinum																
Screening	Yes	19JUL2017 (-14)	CT Scan	Radiologist 1	75			mRECIST	75	Pleural	PL001	PLEURA	Present Measurable	17		
											PL002	PLEURA	Present Measurable	24		
											PL003	PLEURA	Present Measurable	14		
											PL004	PLEURA	Present Measurable	20		
Cycle 2, Day 15	Yes	06SEP2017 (36)	CT Scan	Radiologist 1	40	-46.7	-46.7	mRECIST	40	Pleural	PL001	PLEURA	Present Measurable	12		
											PL002	PLEURA	Present Measurable	9		
											PL003	PLEURA	Present Measurable	9		
											PL004	PLEURA	Present Measurable	10		
Cycle 4, Day 15	Yes	18OCT2017 (78)	CT Scan	Radiologist 1	43	7.5	-42.7	mRECIST	43	Pleural	PL001	PLEURA	Present Measurable	8		
											PL002	PLEURA	Present Measurable	8		
											PL003	PLEURA	Present Measurable	16		
											PL004	PLEURA	Present Measurable	11		
Cycle 6, Day 15	Yes	29NOV2017 (120)	CT Scan	Radiologist 1	44	10.0	-41.3	mRECIST	44	Pleural	PL001	PLEURA	Present Measurable	12		
											PL002	PLEURA	Present Measurable	7		
											PL003	PLEURA	Present Measurable	13		

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0001 Treatment Group: PlaceboPemPlatinum														
Cycle 6, Day 15	Yes	29NOV2017 (120)	CT Scan	Radiologist 1	44	10.0	-41.3	mRECIST	44	Pleural	PL004	PLEURA	Present Measurable	12
Subject ID: 0201-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	25JUL2017 (-15)	CT Scan	Radiologist 1	312			mRECIST	312	Pleural	PL001	PLEURA	Present Measurable	68
											PL002	PLEURA	Present Measurable	57
											PL003	PLEURA	Present Measurable	50
											PL004	PLEURA	Present Measurable	65
											PL005	PLEURA	Present Measurable	38
											PL006	PLEURA	Present Measurable	34
Cycle 2, Day 15	Yes	12SEP2017 (35)	CT Scan	Radiologist 1	321	2.9	2.9	mRECIST	321	Pleural	PL001	PLEURA	Present Measurable	66
											PL002	PLEURA	Present Measurable	65
											PL003	PLEURA	Present Measurable	62
											PL004	PLEURA	Present Measurable	61
											PL005	PLEURA	Present Measurable	33
											PL006	PLEURA	Present Measurable	34
Subject ID: 0201-0004 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	23AUG2017 (-14)	CT Scan	Radiologist 1	157			RECIST 1.1	20	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	20
								mRECIST	137	Pleural	PL001	PLEURA	Present Measurable	29
											PL002	PLEURA	Present Measurable	26
											PL003	PLEURA	Present Measurable	25

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0004 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	23AUG2017 (-14)	CT Scan	Radiologist 1	157			mRECIST	137	Pleural	PL004	PLEURA	Present Measurable	21
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	16
Cycle 2, Day 15	Yes	18OCT2017 (43)	CT Scan	Radiologist 1	148	-5.7	-5.7	RECIST 1.1	20	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	20
								mRECIST	128	Pleural	PL001	PLEURA	Present Measurable	24
											PL002	PLEURA	Present Measurable	30
											PL003	PLEURA	Present Measurable	22
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	15
Subject ID: 0201-0005 Treatment Group: ADIPemPlatinum														
Screening	Yes	30AUG2017 (-14)	CT Scan	Radiologist 1	73			mRECIST	73	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	19OCT2017 (37)	CT Scan	Radiologist 1	67	-8.2	-8.2	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	11

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0005 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	19OCT2017 (37)	CT Scan	Radiologist 1	67	-8.2	-8.2	mRECIST	67	Pleural	PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	11
Cycle 4, Day 15	Yes	30NOV2017 (79)	CT Scan	Radiologist 1	62	-7.5	-15.1	mRECIST	62	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	13
Cycle 6, Day 15	Yes	11JAN2018 (121)	CT Scan	Radiologist 1	67	8.1	-8.2	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	12
Week 24	Yes	21FEB2018 (162)	CT Scan	Radiologist 1	69	11.3	-5.5	mRECIST	69	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	13
Week 32	Yes	18APR2018 (218)	CT Scan	Radiologist 1	82	32.3	12.3	mRECIST	82	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0005 Treatment Group: ADIPemPlatinum														
Week 32	Yes	18APR2018 (218)	CT Scan	Radiologist 1	82	32.3	12.3	mRECIST	82	Pleural	PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	13
Subject ID: 0201-0006 Treatment Group: ADIPemPlatinum														
Screening	Yes	01SEP2017 (-12)	CT Scan	Radiologist 1	323			mRECIST	323	Pleural	PL001	PLEURA	Present Measurable	61
											PL002	PLEURA	Present Measurable	65
											PL003	PLEURA	Present Measurable	37
											PL004	PLEURA	Present Measurable	70
											PL005	PLEURA	Present Measurable	51
											PL006	PLEURA	Present Measurable	39
Cycle 2, Day 15	Yes	18OCT2017 (36)	CT Scan	Radiologist 1	295	-8.7	-8.7	mRECIST	295	Pleural	PL001	PLEURA	Present Measurable	54
											PL002	PLEURA	Present Measurable	59
											PL003	PLEURA	Present Measurable	35
											PL004	PLEURA	Present Measurable	63
											PL005	PLEURA	Present Measurable	49
											PL006	PLEURA	Present Measurable	35
Cycle 4, Day 15	Yes	29NOV2017 (78)	CT Scan	Radiologist 1	337	14.2	4.3	mRECIST	337	Pleural	PL001	PLEURA	Present Measurable	61
											PL002	PLEURA	Present Measurable	66
											PL003	PLEURA	Present Measurable	38
											PL004	PLEURA	Present Measurable	66
											PL005	PLEURA	Present Measurable	55
											PL006	PLEURA	Present Measurable	51
Cycle 6, Day 15	Yes	10JAN2018 (120)	CT Scan	Radiologist 1	357	21.0	10.5	mRECIST	357	Pleural	PL001	PLEURA	Present Measurable	70

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0006 Treatment Group: ADIPemPlatinum														
Cycle 6, Day 15	Yes	10JAN2018 (120)	CT Scan	Radiologist 1	357	21.0	10.5	mRECIST	357	Pleural	PL002	PLEURA	Present Measurable	73
											PL003	PLEURA	Present Measurable	36
											PL004	PLEURA	Present Measurable	66
											PL005	PLEURA	Present Measurable	55
											PL006	PLEURA	Present Measurable	57
Subject ID: 0201-0007 Treatment Group: ADIPemPlatinum														
Screening	Yes	27SEP2017 (-14)	CT Scan	Radiologist 1	49			mRECIST	49	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	15
Cycle 2, Day 15	Yes	15NOV2017 (36)	CT Scan	Radiologist 1	45	-8.2	-8.2	mRECIST	45	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	12
Subject ID: 0201-0008 Treatment Group: ADIPemPlatinum														
Screening	Yes	19JUL2018 (-6)	CT Scan	Radiologist 1	90			mRECIST	90	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	22
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	15
Cycle 2, Day 15	Yes	30AUG2018 (37)	CT Scan	Radiologist 1	85	-5.6	-5.6	mRECIST	85	Pleural	PL001	PLEURA	Present Measurable	16

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0008 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	30AUG2018 (37)	CT Scan	Radiologist 1	85	-5.6	-5.6	mRECIST	85	Pleural	PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	19
Cycle 4, Day 15	Yes	11OCT2018 (79)	CT Scan	Radiologist 1	86	1.2	-4.4	mRECIST	86	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	22
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	12
Cycle 6, Day 15	Yes	22NOV2018 (121)	CT Scan	Radiologist 1	96	12.9	6.7	mRECIST	96	Pleural	PL006	PLEURA	Present Measurable	22
											PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	21
											PL004	PLEURA	Present Measurable	11
Week 26	Yes	17JAN2019 (177)	CT Scan	Radiologist 1	86	1.2	-4.4	mRECIST	86	Pleural	PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	22
											PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	19
Week 34	Yes	13MAR2019 (232)	CT Scan	Radiologist 1	84	-1.2	-6.7	mRECIST	84	Pleural	PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	20
											PL001	PLEURA	Present Measurable	7

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0008 Treatment Group: ADIPemPlatinum														
Week 34	Yes	13MAR2019 (232)	CT Scan	Radiologist 1	84	-1.2	-6.7	mRECIST	84	Pleural	PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	23
Week 40	Yes	08MAY2019 (288)	CT Scan	Radiologist 1	87	3.6	-3.3	mRECIST	87	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	16
Subject ID: 0201-0009 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	13OCT2017 (-12)	CT Scan	Radiologist 1	94			mRECIST	94	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	20
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	30NOV2017 (37)	CT Scan	Radiologist 1	82	-12.8	-12.8	mRECIST	82	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	21
											PL004	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0009 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	30NOV2017 (37)	CT Scan	Radiologist 1	82	-12.8	-12.8	mRECIST	82	Pleural	PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	11
Cycle 4, Day 15	Yes	11JAN2018 (79)	CT Scan	Radiologist 1	74	-9.8	-21.3	mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	11
Cycle 6, Day 15	Yes	21FEB2018 (120)	CT Scan	Radiologist 1	77	4.1	-18.1	mRECIST	77	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	15
Week 24	Yes	12APR2018 (170)	CT Scan	Radiologist 1	71	-4.1	-24.5	mRECIST	71	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	12
Week 34	Yes	13JUN2018 (232)	CT Scan	Radiologist 1	60	-15.5	-36.2	mRECIST	60	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	11

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0009 Treatment Group: PlaceboPemPlatinum														
Week 34	Yes	13JUN2018 (232)	CT Scan	Radiologist 1	60	-15.5	-36.2	mRECIST	60	Pleural	PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	8
Week 38	Yes	11JUL2018 (260)	CT Scan	Radiologist 1	63	5.0	-33.0	mRECIST	63	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	9
Week 46	Yes	05SEP2018 (316)	CT Scan	Radiologist 1	60	0.0	-36.2	mRECIST	60	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	8
Week 54	Yes	31OCT2018 (372)	CT Scan	Radiologist 1	77	28.3	-18.1	mRECIST	77	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	11
Week 62	Yes	24DEC2018 (426)	CT Scan	Radiologist 1	77	28.3	-18.1	mRECIST	77	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	21

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0009 Treatment Group: PlaceboPemPlatinum														
Week 62	Yes	24DEC2018 (426)	CT Scan	Radiologist 1	77	28.3	-18.1	mRECIST	77	Pleural	PL005 PL006	PLEURA PLEURA	Present Measurable Present Measurable	13 6
Subject ID: 0201-0011 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	22NOV2017 (-21)	CT Scan	Radiologist 1	22			mRECIST	22	Pleural	PL001	PLEURA	Present Measurable	22
Cycle 2, Day 15	Yes	17JAN2018 (36)	CT Scan	Radiologist 1	22	0.0	0.0	mRECIST	22	Pleural	PL001	PLEURA	Present Measurable	22
Cycle 4, Day 15	Yes	28FEB2018 (78)	CT Scan	Radiologist 1	18	-18.2	-18.2	mRECIST	18	Pleural	PL001	PLEURA	Present Measurable	18
Cycle 6, Day 15	Yes	04APR2018 (113)	CT Scan	Radiologist 1	17	-5.6	-22.7	mRECIST	17	Pleural	PL001	PLEURA	Present Measurable	17
Week 24	Yes	06JUN2018 (176)	CT Scan	Radiologist 1	41	141.2	86.4	mRECIST	41	Pleural	PL001	PLEURA	Present Measurable	41
Subject ID: 0201-0013 Treatment Group: ADIPemPlatinum														
Screening	Yes	22JAN2018 (-9)	CT Scan	Radiologist 1	125			mRECIST	125	Pleural	PL001 PL002 PL003 PL004 PL005 PL006	PLEURA PLEURA PLEURA PLEURA PLEURA PLEURA	Present Measurable Present Measurable Present Measurable Present Measurable Present Measurable Present Measurable	29 15 24 16 26 15
Cycle 2, Day 15	Yes	07MAR2018 (36)	CT Scan	Radiologist 1	113	-9.6	-9.6	mRECIST	113	Pleural	PL001 PL002 PL003 PL004 PL005	PLEURA PLEURA PLEURA PLEURA PLEURA	Present Measurable Present Measurable Present Measurable Present Measurable Present Measurable	26 13 26 14 21

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0013 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	07MAR2018 (36)	CT Scan	Radiologist 1	113	-9.6	-9.6	mRECIST	113	Pleural	PL006	PLEURA	Present Measurable	13
Cycle 4, Day 15	Yes	18APR2018 (78)	CT Scan	Radiologist 1	111	-1.8	-11.2	mRECIST	111	Pleural	PL001	PLEURA	Present Measurable	25
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	22
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	18
											PL006	PLEURA	Present Measurable	14
Cycle 6, Day 15	Yes	30MAY2018 (120)	CT Scan	Radiologist 1	128	15.3	2.4	mRECIST	128	Pleural	PL001	PLEURA	Present Measurable	29
											PL002	PLEURA	Present Measurable	20
											PL003	PLEURA	Present Measurable	20
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	23
											PL006	PLEURA	Present Measurable	21
Subject ID: 0201-0014 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	07FEB2018 (-7)	CT Scan	Radiologist 2	156			RECIST 1.1	87	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	15
								mRECIST	69	Non-Nodal	T001	LIVER	Present Measurable	72
										Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	15

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0014 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	21MAR2018 (36)	CT Scan	Radiologist 2	140	-10.3	-10.3	RECIST 1.1	84	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	13
								mRECIST	56	Non-Nodal Pleural	T001	LIVER	Present Measurable	71
											PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	11
Unscheduled	Yes	27APR2018 (73)	CT Scan	Radiologist 2	169	20.7	8.3	RECIST 1.1	110	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	11
								mRECIST	59	Non-Nodal Pleural	T001	LIVER	Present Measurable	99
											PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	11
Subject ID: 0201-0015 Treatment Group: ADIPemPlatinum														
Screening	Yes	05MAR2018 (-9)	CT Scan	Radiologist 1	213			mRECIST	213	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	29
											PL003	PLEURA	Present Measurable	29
											PL004	PLEURA	Present Measurable	46
											PL005	PLEURA	Present Measurable	32

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0015 Treatment Group: ADIPemPlatinum														
Screening	Yes	05MAR2018 (-9)	CT Scan	Radiologist 1	213			mRECIST	213	Pleural	PL006	PLEURA	Present Measurable	56
Cycle 2, Day 15	Yes	18APR2018 (36)	CT Scan	Radiologist 1	238	11.7	11.7	mRECIST	238	Pleural	PL001	PLEURA	Present Measurable	23
											PL002	PLEURA	Present Measurable	32
											PL003	PLEURA	Present Measurable	39
											PL004	PLEURA	Present Measurable	52
											PL005	PLEURA	Present Measurable	29
											PL006	PLEURA	Present Measurable	63
Cycle 4, Day 15	Yes	29MAY2018 (77)	CT Scan	Radiologist 1	245	15.0	15.0	mRECIST	245	Pleural	PL001	PLEURA	Present Measurable	24
											PL002	PLEURA	Present Measurable	38
											PL003	PLEURA	Present Measurable	41
											PL004	PLEURA	Present Measurable	58
											PL005	PLEURA	Present Measurable	22
											PL006	PLEURA	Present Measurable	62
Cycle 6, Day 15	Yes	13JUL2018 (122)	CT Scan	Radiologist 1	254	19.2	19.2	mRECIST	254	Pleural	PL001	PLEURA	Present Measurable	29
											PL002	PLEURA	Present Measurable	34
											PL003	PLEURA	Present Measurable	42
											PL004	PLEURA	Present Measurable	48
											PL005	PLEURA	Present Measurable	38
											PL006	PLEURA	Present Measurable	63
Week 26	Yes	06SEP2018 (177)	CT Scan	Radiologist 1	360	69.0	69.0	mRECIST	360	Pleural	PL001	PLEURA	Present Measurable	52
											PL002	PLEURA	Present Measurable	45
											PL003	PLEURA	Present Measurable	68
											PL004	PLEURA	Present Measurable	62
											PL005	PLEURA	Present Measurable	60

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0015 Treatment Group: ADIPemPlatinum														
Week 26	Yes	06SEP2018 (177)	CT Scan	Radiologist 1	360	69.0	69.0	mRECIST	360	Pleural	PL006	PLEURA	Present Measurable	73
Subject ID: 0201-0016 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	14MAR2018 (-21)	CT Scan	Radiologist 1	78			RECIST 1.1	17	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	17
								mRECIST	61	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	08MAY2018 (35)	CT Scan	Radiologist 1	66	-15.4	-15.4	RECIST 1.1	17	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	17
								mRECIST	49	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	10
Cycle 4, Day 15	Yes	19JUN2018 (77)	CT Scan	Radiologist 1	58	-12.1	-25.6	RECIST 1.1	12	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	12
								mRECIST	46	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	9

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0016 Treatment Group: PlaceboPemPlatinum														
Cycle 4, Day 15	Yes	19JUN2018 (77)	CT Scan	Radiologist 1	58	-12.1	-25.6	mRECIST	46	Pleural	PL005	PLEURA	Present Measurable	10
Cycle 6, Day 15	Yes	31JUL2018 (119)	CT Scan	Radiologist 1	54	-6.9	-30.8	RECIST 1.1	11	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	11
								mRECIST	43	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	6
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	11
Week 22	Yes	28AUG2018 (147)	CT Scan	Radiologist 1	61	13.0	-21.8	RECIST 1.1	15	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	15
								mRECIST	46	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	12
Week 30	Yes	23OCT2018 (203)	CT Scan	Radiologist 1	63	16.7	-19.2	RECIST 1.1	15	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	15
								mRECIST	48	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	10
Week 38	Yes	18DEC2018 (259)	CT Scan	Radiologist 1	62	14.8	-20.5	RECIST 1.1	12	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0016 Treatment Group: PlaceboPemPlatinum														
Week 38	Yes	18DEC2018 (259)	CT Scan	Radiologist 1	62	14.8	-20.5	mRECIST	50	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	11
Unscheduled	Yes	16JAN2019 (288)	CT Scan	Radiologist 1	63	16.7	-19.2	RECIST 1.1	11	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	11
								mRECIST	52	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	10
Week 46	Yes	12FEB2019 (315)	CT Scan	Radiologist 1	61	13.0	-21.8	RECIST 1.1	10	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	10
								mRECIST	51	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	11
Subject ID: 0201-0017 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	24APR2018 (-1)	CT Scan	Radiologist 2	86			mRECIST	86	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	15

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0017 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	24APR2018 (-1)	CT Scan	Radiologist 2	86			mRECIST	86	Pleural	PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	29MAY2018 (35)	CT Scan	Radiologist 2	64	-25.6	-25.6	mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	7
Cycle 4, Day 15	Yes	10JUL2018 (77)	CT Scan	Radiologist 2	61	-4.7	-29.1	mRECIST	61	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	7
Cycle 6, Day 15	Yes	07AUG2018 (105)	CT Scan	Radiologist 2	58	-4.9	-32.6	mRECIST	58	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	7
											PL006	PLEURA	Present Measurable	7

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0018 Treatment Group: ADIPemPlatinum														
Screening	Yes	09APR2018 (-22)	CT Scan	Radiologist 1	131			mRECIST	131	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	38
											PL004	PLEURA	Present Measurable	27
											PL005	PLEURA	Present Measurable	21
											PL006	PLEURA	Present Measurable	15
Cycle 2, Day 15	Yes	05JUN2018 (36)	CT Scan	Radiologist 1	111	-15.3	-15.3	mRECIST	111	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	31
											PL004	PLEURA	Present Measurable	22
											PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	15
Cycle 4, Day 15	Yes	17JUL2018 (78)	CT Scan	Radiologist 1	120	8.1	-8.4	mRECIST	120	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	31
											PL004	PLEURA	Present Measurable	24
											PL005	PLEURA	Present Measurable	24
											PL006	PLEURA	Present Measurable	16
Cycle 6, Day 15	Yes	28AUG2018 (120)	CT Scan	Radiologist 1	128	15.3	-2.3	mRECIST	128	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	31
											PL004	PLEURA	Present Measurable	25
											PL005	PLEURA	Present Measurable	21
											PL006	PLEURA	Present Measurable	19

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0018 Treatment Group: ADIPemPlatinum														
Week 26	Yes	23OCT2018 (176)	CT Scan	Radiologist 1	119	7.2	-9.2	mRECIST	119	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	33
											PL004	PLEURA	Present Measurable	24
											PL005	PLEURA	Present Measurable	24
											PL006	PLEURA	Present Measurable	16
Week 34	Yes	18DEC2018 (232)	CT Scan	Radiologist 1	112	0.9	-14.5	mRECIST	112	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	26
											PL004	PLEURA	Present Measurable	26
											PL005	PLEURA	Present Measurable	24
											PL006	PLEURA	Present Measurable	14
Week 40	Yes	12FEB2019 (288)	CT Scan	Radiologist 1	127	14.4	-3.1	mRECIST	127	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	32
											PL004	PLEURA	Present Measurable	27
											PL005	PLEURA	Present Measurable	24
											PL006	PLEURA	Present Measurable	17
Week 50	Yes	09APR2019 (344)	CT Scan	Radiologist 1	134	20.7	2.3	mRECIST	134	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	23
											PL004	PLEURA	Present Measurable	49
											PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	14

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0019 Treatment Group: ADIPemPlatinum														
Screening	Yes	25APR2018 (-14)	CT Scan	Radiologist 1	88			mRECIST	88	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	15
Cycle 2, Day 15	Yes	13JUN2018 (36)	CT Scan	Radiologist 1	78	-11.4	-11.4	mRECIST	78	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	14
Cycle 4, Day 15	Yes	25JUL2018 (78)	CT Scan	Radiologist 1	50	-35.9	-43.2	mRECIST	50	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	11
Unscheduled	Yes	22AUG2018 (106)	CT Scan	Radiologist 1	61	22.0	-30.7	mRECIST	61	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	15

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0019 Treatment Group: ADIPemPlatinum														
Week 24	Yes	17OCT2018 (162)	CT Scan	Radiologist 1	82	64.0	-6.8	mRECIST	82	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	18
											PL006	PLEURA	Present Measurable	19
Subject ID: 0201-0020 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	11MAY2018 (-26)	CT Scan	Radiologist 1	72			mRECIST	72	Pleural	PL001	PLEURA	Present Measurable	51
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	10
Cycle 2, Day 15	Yes	11JUL2018 (36)	CT Scan	Radiologist 1	65	-9.7	-9.7	mRECIST	65	Pleural	PL001	PLEURA	Present Measurable	44
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	11
Cycle 4, Day 15	Yes	22AUG2018 (78)	CT Scan	Radiologist 1	62	-4.6	-13.9	mRECIST	62	Pleural	PL001	PLEURA	Present Measurable	42
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	10
Cycle 6, Day 15	Yes	03OCT2018 (120)	CT Scan	Radiologist 1	76	22.6	5.6	mRECIST	76	Pleural	PL001	PLEURA	Present Measurable	54
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	13

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0021 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	13JUN2018 (-14)	CT Scan	Radiologist 1	33			mRECIST	33	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	01AUG2018 (36)	CT Scan	Radiologist 1	32	-3.0	-3.0	mRECIST	32	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	12SEP2018 (78)	CT Scan	Radiologist 1	32	0.0	-3.0	mRECIST	32	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	11
Cycle 6, Day 15	Yes	25OCT2018 (121)	CT Scan	Radiologist 1	28	-12.5	-15.2	mRECIST	28	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	11
Week 24	Yes	05DEC2018 (162)	CT Scan	Radiologist 1	32	14.3	-3.0	mRECIST	32	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	14
Subject ID: 0201-0023 Treatment Group: ADIPemPlatinum														
Screening	Yes	27JUN2018 (-21)	CT Scan	Radiologist 1	56			mRECIST	56	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	18
Cycle 2, Day 15	Yes	22AUG2018 (36)	CT Scan	Radiologist 1	53	-5.4	-5.4	mRECIST	53	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	16

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0023 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	03OCT2018 (78)	CT Scan	Radiologist 1	52	-1.9	-7.1	mRECIST	52	Pleural	PL001	PLEURA	Present Measurable	22
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	16
Cycle 6, Day 15	Yes	14NOV2018 (120)	CT Scan	Radiologist 1	50	-3.8	-10.7	mRECIST	50	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	18
Week 26	Yes	09JAN2019 (176)	CT Scan	Radiologist 1	52	4.0	-7.1	mRECIST	52	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	19
Week 32	Yes	06MAR2019 (232)	CT Scan	Radiologist 1	45	-10.0	-19.6	mRECIST	45	Pleural	PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	14
Week 40	Yes	01MAY2019 (288)	CT Scan	Radiologist 1	45	0.0	-19.6	mRECIST	45	Pleural	PL001	PLEURA	Present Measurable	19
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	13
Unscheduled	Yes	25JUN2019 (343)	CT Scan	Radiologist 1	45	0.0	-19.6	mRECIST	45	Pleural	PL001	PLEURA	Present Measurable	19
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	14
Subject ID: 0201-0024 Treatment Group: ADIPemPlatinum														
Screening	Yes	18JUL2018 (-14)	CT Scan	Radiologist 1	82			mRECIST	82	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	15

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0024 Treatment Group: ADIPemPlatinum														
Screening	Yes	18JUL2018 (-14)	CT Scan	Radiologist 1	82			mRECIST	82	Pleural	PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	05SEP2018 (36)	CT Scan	Radiologist 1	71	-13.4	-13.4	mRECIST	71	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	13
Cycle 4, Day 15	Yes	17OCT2018 (78)	CT Scan	Radiologist 1	69	-2.8	-15.9	mRECIST	69	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	6
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	11
Cycle 6, Day 15	Yes	28NOV2018 (120)	CT Scan	Radiologist 1	77	11.6	-6.1	mRECIST	77	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	12
Unscheduled	Yes	05JAN2019 (158)	CT Scan	Radiologist 1	69	0.0	-15.9	mRECIST	69	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0024 Treatment Group: ADIPemPlatinum														
Unscheduled	Yes	05JAN2019 (158)	CT Scan	Radiologist 1	69	0.0	-15.9	mRECIST	69	Pleural	PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	12
Subject ID: 0201-0025 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	17OCT2018 (-28)	CT Scan	Radiologist 1	27			mRECIST	27	Pleural	PL001	PLEURA	Present Measurable	27
Cycle 2, Day 15	Yes	19DEC2018 (36)	CT Scan	Radiologist 1	25	-7.4	-7.4	mRECIST	25	Pleural	PL001	PLEURA	Present Measurable	25
Cycle 4, Day 15	Yes	30JAN2019 (78)	CT Scan	Radiologist 1	26	4.0	-3.7	mRECIST	26	Pleural	PL001	PLEURA	Present Measurable	26
Cycle 6, Day 15	Yes	13MAR2019 (120)	CT Scan	Radiologist 1	27	8.0	0.0	mRECIST	27	Pleural	PL001	PLEURA	Present Measurable	27
Week 26	Yes	07MAY2019 (175)	CT Scan	Radiologist 1	27	8.0	0.0	mRECIST	27	Pleural	PL001	PLEURA	Present Measurable	27
Week 34	Yes	02JUL2019 (231)	CT Scan	Radiologist 1	26	4.0	-3.7	mRECIST	26	Pleural	PL001	PLEURA	Present Measurable	26
Week 42	Yes	27AUG2019 (287)	CT Scan	Radiologist 1	27	8.0	0.0	mRECIST	27	Pleural	PL001	PLEURA	Present Measurable	27
Subject ID: 0201-0026 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	15AUG2018 (-21)	CT Scan	Radiologist 1	191			RECIST 1.1	16	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	16
								mRECIST	175	Pleural	PL001	PLEURA	Present Measurable	29
											PL002	PLEURA	Present Measurable	30
											PL003	PLEURA	Present Measurable	43
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	38
											PL006	PLEURA	Present Measurable	20

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0026 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	11OCT2018 (37)	CT Scan	Radiologist 1	176	-7.9	-7.9	RECIST 1.1	21	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	21
								mRECIST	155	Pleural	PL001	PLEURA	Present Measurable	26
											PL002	PLEURA	Present Measurable	21
											PL003	PLEURA	Present Measurable	37
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	38
											PL006	PLEURA	Present Measurable	19
Subject ID: 0201-0027 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	12SEP2018 (-20)	CT Scan	Radiologist 1	53			mRECIST	53	Pleural	PL001	PLEURA	Present Measurable	23
											PL002	PLEURA	Present Measurable	18
											PL003	PLEURA	Present Measurable	12
Cycle 2, Day 15	Yes	06NOV2018 (36)	CT Scan	Radiologist 1	39	-26.4	-26.4	mRECIST	39	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	11
Cycle 4, Day 15	No	11DEC2018 (71)	CT Scan	Radiologist 1	48	23.1	-9.4	mRECIST	48	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	14
Unscheduled	Yes	24DEC2018 (84)	CT Scan	Radiologist 1	53	35.9	0.0	mRECIST	53	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	21
											PL003	PLEURA	Present Measurable	16

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0028 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	01OCT2018 (-16)	CT Scan	Radiologist 2	115			mRECIST	115	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	26
											PL004	PLEURA	Present Measurable	18
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	22
Cycle 2, Day 15	Yes	21NOV2018 (36)	CT Scan	Radiologist 2	132	14.8	14.8	mRECIST	132	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	19
											PL003	PLEURA	Present Measurable	31
											PL004	PLEURA	Present Measurable	21
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	29
Cycle 4, Day 1	Yes	21DEC2018 (66)	CT Scan	Radiologist 2	130	13.0	13.0	mRECIST	130	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	18
											PL003	PLEURA	Present Measurable	29
											PL004	PLEURA	Present Measurable	21
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	26
Subject ID: 0201-0030 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	05OCT2018 (-12)	CT Scan	Radiologist 2	129			mRECIST	129	Pleural	PL001	PLEURA	Present Measurable	28
											PL002	PLEURA	Present Measurable	25
											PL003	PLEURA	Present Measurable	50

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0030 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	05OCT2018 (-12)	CT Scan	Radiologist 2	129			mRECIST	129	Pleural	PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	21NOV2018 (36)	CT Scan	Radiologist 2	115	-10.9	-10.9	mRECIST	115	Pleural	PL001	PLEURA	Present Measurable	25
											PL002	PLEURA	Present Measurable	22
											PL003	PLEURA	Present Measurable	49
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	11
Cycle 4, Day 15	Yes	02JAN2019 (78)	CT Scan	Radiologist 2	124	7.8	-3.9	mRECIST	124	Pleural	PL001	PLEURA	Present Measurable	28
											PL002	PLEURA	Present Measurable	23
											PL003	PLEURA	Present Measurable	47
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	13
Cycle 6, Day 15	No													
Subject ID: 0201-0031 Treatment Group: ADIPemPlatinum														
Screening	Yes	10OCT2018 (-21)	CT Scan	Radiologist 1	94			mRECIST	94	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	20
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	05DEC2018 (36)	CT Scan	Radiologist 1	92	-2.1	-2.1	mRECIST	92	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0031 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	05DEC2018 (36)	CT Scan	Radiologist 1	92	-2.1	-2.1	mRECIST	92	Pleural	PL003	PLEURA	Present Measurable	21
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	16
Cycle 4, Day 15	Yes	16JAN2019 (78)	CT Scan	Radiologist 1	82	-10.9	-12.8	mRECIST	82	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	23
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	14
Cycle 6, Day 15	Yes	27FEB2019 (120)	CT Scan	Radiologist 1	73	-11.0	-22.3	mRECIST	73	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	11
Week 26	Yes	24APR2019 (176)	CT Scan	Radiologist 1	64	-12.3	-31.9	mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	11
Week 30	Yes	22MAY2019 (204)	CT Scan	Radiologist 1	64	0.0	-31.9	mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	8

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0031 Treatment Group: ADIPemPlatinum														
Week 30	Yes	22MAY2019 (204)	CT Scan	Radiologist 1	64	0.0	-31.9	mRECIST	64	Pleural	PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	15
Week 38	Yes	17JUL2019 (260)	CT Scan	Radiologist 1	55	-14.1	-41.5	mRECIST	55	Pleural	PL001	PLEURA	Present Measurable	5
											PL002	PLEURA	Present Measurable	6
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	13
Week 46	Yes	17SEP2019 (322)	CT Scan	Radiologist 1	52	-5.5	-44.7	mRECIST	52	Pleural	PL001	PLEURA	Present Measurable	4
											PL002	PLEURA	Present Measurable	4
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	12
Week 54	Yes	12NOV2019 (378)	CT Scan	Radiologist 1	46	-11.5	-51.1	mRECIST	46	Pleural	PL001	PLEURA	Present Measurable	4
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	10
Week 62	Yes	07JAN2020 (434)	CT Scan	Radiologist 1	43	-6.5	-54.3	mRECIST	43	Pleural	PL001	PLEURA	Present Measurable	4
											PL002	PLEURA	Present Measurable	2

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0031 Treatment Group: ADIPemPlatinum														
Week 62	Yes	07JAN2020 (434)	CT Scan	Radiologist 1	43	-6.5	-54.3	mRECIST	43	Pleural	PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	9
Week 72	Yes	03MAR2020 (490)	CT Scan	Radiologist 1	38	-11.6	-59.6	mRECIST	38	Pleural	PL001	PLEURA	Present Measurable	3
											PL002	PLEURA	Present Measurable	3
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	8
Week 82	Yes	26MAY2020 (574)	CT Scan	Radiologist 1	45	18.4	-52.1	mRECIST	45	Pleural	PL001	PLEURA	Present Measurable	4
											PL002	PLEURA	Present Measurable	4
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	8
Subject ID: 0201-0033 Treatment Group: ADIPemPlatinum														
Screening	Yes	24DEC2018 (-23)	CT Scan	Radiologist 1	76			mRECIST	76	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	16

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0033 Treatment Group: ADIPemPlatinum														
Screening	Yes	24DEC2018 (-23)	CT Scan	Radiologist 1	76			mRECIST	76	Pleural	PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	20FEB2019 (36)	CT Scan	Radiologist 1	73	-3.9	-3.9	mRECIST	73	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	9
Cycle 4, Day 15	Yes	03APR2019 (78)	CT Scan	Radiologist 1	82	12.3	7.9	mRECIST	82	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	16
Cycle 6, Day 15	Yes	15MAY2019 (120)	CT Scan	Radiologist 1	75	2.7	-1.3	mRECIST	75	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	12
Week 26	Yes	10JUL2019 (176)	CT Scan	Radiologist 1	79	8.2	3.9	mRECIST	79	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0033 Treatment Group: ADIPemPlatinum														
Week 26	Yes	10JUL2019 (176)	CT Scan	Radiologist 1	79	8.2	3.9	mRECIST	79	Pleural	PL006	PLEURA	Present Measurable	10
Subject ID: 0201-0034 Treatment Group: ADIPemPlatinum														
Screening	Yes	28NOV2018 (-7)	CT Scan	Radiologist 1	99			RECIST 1.1	46	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	46
								mRECIST	53	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	10
Cycle 2, Day 15	Yes	21JAN2019 (48)	CT Scan	Radiologist 1	57	-42.4	-42.4	RECIST 1.1	25	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	25
								mRECIST	32	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	6
Cycle 4, Day 15	Yes	20FEB2019 (78)	CT Scan	Radiologist 1	51	-10.5	-48.5	RECIST 1.1	21	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	21
								mRECIST	30	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	2
Cycle 6, Day 15	No	25APR2019 (142)	CT Scan	Radiologist 1	42	-17.6	-57.6	RECIST 1.1	18	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	18

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0034 Treatment Group: ADIPemPlatinum														
Cycle 6, Day 15	No	25APR2019 (142)	CT Scan	Radiologist 1	42	-17.6	-57.6	mRECIST	24	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	3
Week 24	Yes	23MAY2019 (170)	CT Scan	Radiologist 1	41	-2.4	-58.6	RECIST 1.1	18	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	18
								mRECIST	23	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	4
Week 34	Yes	18JUL2019 (226)	CT Scan	Radiologist 1	46	12.2	-53.5	RECIST 1.1	20	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	20
								mRECIST	26	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	3
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	7
Week 42	Yes	25SEP2019 (295)	CT Scan	Radiologist 1	44	7.3	-55.6	RECIST 1.1	18	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	18
								mRECIST	26	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	2
											PL003	PLEURA	Present Measurable	5
											PL004	PLEURA	Present Measurable	8
Week 50	Yes	19NOV2019 (350)	CT Scan	Radiologist 1	44	7.3	-55.6	RECIST 1.1	20	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	20

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0034 Treatment Group: ADIPemPlatinum														
Week 50	Yes	19NOV2019 (350)	CT Scan	Radiologist 1	44	7.3	-55.6	mRECIST	24	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	3
											PL003	PLEURA	Present Measurable	5
											PL004	PLEURA	Present Measurable	6
Week 58	Yes	21JAN2020 (413)	CT Scan	Radiologist 1	40	-2.4	-59.6	RECIST 1.1	18	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	18
								mRECIST	22	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	4
											PL003	PLEURA	Present Measurable	4
											PL004	PLEURA	Present Measurable	3
Week 66	Yes	17MAR2020 (469)	CT Scan	Radiologist 1	43	7.5	-56.6	RECIST 1.1	19	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	19
								mRECIST	24	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	4
											PL003	PLEURA	Present Measurable	5
											PL004	PLEURA	Present Measurable	4
Week 74	Yes	19MAY2020 (532)	CT Scan	Radiologist 1	39	-2.5	-60.6	RECIST 1.1	20	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	20
								mRECIST	19	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Not Present total disappearance	0
											PL003	PLEURA	Present Measurable	4
											PL004	PLEURA	Present Measurable	6

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0035 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	04DEC2018 (-1)	CT Scan	Radiologist 2	39			mRECIST	39	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	16JAN2019 (43)	CT Scan	Radiologist 2	33	-15.4	-15.4	mRECIST	33	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	21FEB2019 (79)	CT Scan	Radiologist 2	34	3.0	-12.8	mRECIST	34	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	10
Cycle 6, Day 15	Yes	03APR2019 (120)	CT Scan	Radiologist 2	36	9.1	-7.7	mRECIST	36	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	12
Week 26	Yes	29MAY2019 (176)	CT Scan	Radiologist 2	34	3.0	-12.8	mRECIST	34	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	8
Subject ID: 0201-0036 Treatment Group: ADIPemPlatinum														
Screening	Yes	21NOV2018 (-14)	CT Scan	Radiologist 1	71			mRECIST	71	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	14

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0036 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	22JAN2019 (49)	CT Scan	Radiologist 1	64	-9.9	-9.9	mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	6
Subject ID: 0201-0038 Treatment Group: ADIPemPlatinum														
Screening	Yes	09JAN2019 (-7)	CT Scan	Radiologist 1	378			mRECIST	378	Pleural	PL001	PLEURA	Present Measurable	41
											PL002	PLEURA	Present Measurable	33
											PL003	PLEURA	Present Measurable	92
											PL004	PLEURA	Present Measurable	113
											PL005	PLEURA	Present Measurable	43
											PL006	PLEURA	Present Measurable	56
Cycle 2, Day 15	Yes	20FEB2019 (36)	CT Scan	Radiologist 1	374	-1.1	-1.1	mRECIST	374	Pleural	PL001	PLEURA	Present Measurable	46
											PL002	PLEURA	Present Measurable	47
											PL003	PLEURA	Present Measurable	84
											PL004	PLEURA	Present Measurable	111
											PL005	PLEURA	Present Measurable	36
											PL006	PLEURA	Present Measurable	50
Cycle 4, Day 15	Yes	03APR2019 (78)	CT Scan	Radiologist 1	332	-11.2	-12.2	mRECIST	332	Pleural	PL001	PLEURA	Present Measurable	39
											PL002	PLEURA	Present Measurable	43
											PL003	PLEURA	Present Measurable	78

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0038 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	03APR2019 (78)	CT Scan	Radiologist 1	332	-11.2	-12.2	mRECIST	332	Pleural	PL004	PLEURA	Present Measurable	98
											PL005	PLEURA	Present Measurable	37
											PL006	PLEURA	Present Measurable	37
Cycle 6, Day 1	Yes	01MAY2019 (106)	CT Scan	Radiologist 1	328	-1.2	-13.2	mRECIST	328	Pleural	PL001	PLEURA	Present Measurable	35
											PL002	PLEURA	Present Measurable	34
											PL003	PLEURA	Present Measurable	84
											PL004	PLEURA	Present Measurable	98
											PL005	PLEURA	Present Measurable	36
											PL006	PLEURA	Present Measurable	41
Week 24	Yes	25JUN2019 (161)	CT Scan	Radiologist 1	288	-12.2	-23.8	mRECIST	288	Pleural	PL001	PLEURA	Present Measurable	24
											PL002	PLEURA	Present Measurable	24
											PL003	PLEURA	Present Measurable	84
											PL004	PLEURA	Present Measurable	101
											PL005	PLEURA	Present Measurable	24
											PL006	PLEURA	Present Measurable	31
Week 30	Yes	06AUG2019 (203)	CT Scan	Radiologist 1	307	6.6	-18.8	mRECIST	307	Pleural	PL001	PLEURA	Present Measurable	30
											PL002	PLEURA	Present Measurable	27
											PL003	PLEURA	Present Measurable	93
											PL004	PLEURA	Present Measurable	107
											PL005	PLEURA	Present Measurable	21
											PL006	PLEURA	Present Measurable	29
Week 38	Yes	01OCT2019 (259)	CT Scan	Radiologist 1	453	57.3	19.8	mRECIST	453	Pleural	PL001	PLEURA	Present Measurable	53
											PL002	PLEURA	Present Measurable	45
											PL003	PLEURA	Present Measurable	124

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0038 Treatment Group: ADIPemPlatinum														
Week 38	Yes	01OCT2019 (259)	CT Scan	Radiologist 1	453	57.3	19.8	mRECIST	453	Pleural	PL004	PLEURA	Present Measurable	139
											PL005	PLEURA	Present Measurable	46
											PL006	PLEURA	Present Measurable	46
Subject ID: 0201-0039 Treatment Group: ADIPemPlatinum														
Screening	Yes	23JAN2019 (-7)	CT Scan	Radiologist 1	74			mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	19
											PL002	PLEURA	Present Measurable	20
											PL003	PLEURA	Present Measurable	21
											PL004	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	07MAR2019 (37)	CT Scan	Radiologist 1	60	-18.9	-18.9	mRECIST	60	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	20
											PL004	PLEURA	Present Measurable	14
Cycle 4, Day 15	Yes	18APR2019 (79)	CT Scan	Radiologist 1	53	-11.7	-28.4	mRECIST	53	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	13
Cycle 6, Day 15	Yes	30MAY2019 (121)	CT Scan	Radiologist 1	40	-24.5	-45.9	mRECIST	40	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	9
Week 22	Yes	26JUN2019 (148)	CT Scan	Radiologist 1	55	37.5	-25.7	mRECIST	55	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0039 Treatment Group: ADIPemPlatinum														
Week 22	Yes	26JUN2019 (148)	CT Scan	Radiologist 1	55	37.5	-25.7	mRECIST	55	Pleural	PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	14
Week 30	Yes	20AUG2019 (203)	CT Scan	Radiologist 1	76	90.0	2.7	mRECIST	76	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	24
											PL004	PLEURA	Present Measurable	25
Subject ID: 0201-0040 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	30JAN2019 (-13)	CT Scan	Radiologist 2	74			mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	12
Cycle 2, Day 15	Yes	19MAR2019 (36)	CT Scan	Radiologist 2	51	-31.1	-31.1	mRECIST	51	Pleural	PL001	PLEURA	Present Measurable	5
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	6
Cycle 4, Day 15	Yes	30APR2019 (78)	CT Scan	Radiologist 2	49	-3.9	-33.8	mRECIST	49	Pleural	PL001	PLEURA	Present Measurable	5
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0040 Treatment Group: PlaceboPemPlatinum														
Cycle 4, Day 15	Yes	30APR2019 (78)	CT Scan	Radiologist 2	49	-3.9	-33.8	mRECIST	49	Pleural	PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	9
Cycle 6, Day 15	Yes	28MAY2019 (106)	CT Scan	Radiologist 2	49	0.0	-33.8	mRECIST	49	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	7
Week 24	Yes	23JUL2019 (162)	CT Scan	Radiologist 2	51	4.1	-31.1	mRECIST	51	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	6
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	9
Week 34	Yes	17SEP2019 (218)	CT Scan	Radiologist 2	56	14.3	-24.3	mRECIST	56	Pleural	PL001	PLEURA	Present Measurable	5
											PL002	PLEURA	Present Measurable	6
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	18
											PL006	PLEURA	Present Measurable	9
Week 40	Yes	12NOV2019 (274)	CT Scan	Radiologist 2	59	20.4	-20.3	mRECIST	59	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	8

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0040 Treatment Group: PlaceboPemPlatinum														
Week 40	Yes	12NOV2019 (274)	CT Scan	Radiologist 2	59	20.4	-20.3	mRECIST	59	Pleural	PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	12
Week 48	Yes	06JAN2020 (329)	CT Scan	Radiologist 2	68	38.8	-8.1	mRECIST	68	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	15
Week 56	Yes	03MAR2020 (386)	CT Scan	Radiologist 2	73	49.0	-1.4	mRECIST	73	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	13
Subject ID: 0201-0041 Treatment Group: ADIPemPlatinum														
Screening	Yes	27MAR2019 (-7)	CT Scan	Radiologist 1	153			mRECIST	153	Pleural	PL001	PLEURA	Present Measurable	43
											PL002	PLEURA	Present Measurable	32
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	25
											PL006	PLEURA	Present Measurable	19

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0041 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	09MAY2019 (37)	CT Scan	Radiologist 1	121	-20.9	-20.9	mRECIST	121	Pleural	PL001	PLEURA	Present Measurable	37
											PL002	PLEURA	Present Measurable	23
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	21
											PL006	PLEURA	Present Measurable	14
Cycle 4, Day 15	Yes	19JUN2019 (78)	CT Scan	Radiologist 1	86	-28.9	-43.8	mRECIST	86	Pleural	PL001	PLEURA	Present Measurable	26
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	12
Cycle 6, Day 1	Yes	17JUL2019 (106)	CT Scan	Radiologist 1	82	-4.7	-46.4	mRECIST	82	Pleural	PL001	PLEURA	Present Measurable	25
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	11
Week 24	Yes	11SEP2019 (162)	CT Scan	Radiologist 1	75	-8.5	-51.0	mRECIST	75	Pleural	PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	9

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0041 Treatment Group: ADIPemPlatinum														
Week 32	Yes	06NOV2019 (218)	CT Scan	Radiologist 1	127	69.3	-17.0	mRECIST	127	Pleural	PL001	PLEURA	Present Measurable	24
											PL002	PLEURA	Present Measurable	22
											PL003	PLEURA	Present Measurable	31
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	22
											PL006	PLEURA	Present Measurable	17
Subject ID: 0201-0043 Treatment Group: ADIPemPlatinum														
Screening	Yes	01MAY2019 (-7)	CT Scan	Radiologist 1	67			mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	12JUN2019 (36)	CT Scan	Radiologist 1	40	-40.3	-40.3	mRECIST	40	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	1
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	8
Cycle 4, Day 15	Yes	30JUL2019 (84)	CT Scan	Radiologist 1	33	-17.5	-50.7	mRECIST	33	Pleural	PL001	PLEURA	Present Measurable	5
											PL002	PLEURA	Present Measurable	2
											PL003	PLEURA	Present Measurable	7

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0043 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	30JUL2019 (84)	CT Scan	Radiologist 1	33	-17.5	-50.7	mRECIST	33	Pleural	PL004	PLEURA	Present Measurable	5
											PL005	PLEURA	Present Measurable	7
											PL006	PLEURA	Present Measurable	7
Week 22	Yes	21SEP2019 (137)	CT Scan	Radiologist 1	31	-6.1	-53.7	mRECIST	31	Pleural	PL001	PLEURA	Present Measurable	5
											PL002	PLEURA	Present Measurable	2
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	5
											PL005	PLEURA	Present Measurable	7
											PL006	PLEURA	Present Measurable	6
Week 26	Yes	30OCT2019 (176)	CT Scan	Radiologist 1	61	96.8	-9.0	mRECIST	61	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	6
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	20
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	9
Subject ID: 0201-0044 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	08MAY2019 (-7)	CT Scan	Radiologist 1	94			mRECIST	94	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	25
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	23

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0044 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	19JUN2019 (36)	CT Scan	Radiologist 1	69	-26.6	-26.6	mRECIST	69	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	5
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	18
Cycle 4, Day 15	Yes	31JUL2019 (78)	CT Scan	Radiologist 1	57	-17.4	-39.4	mRECIST	57	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	4
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	7
											PL006	PLEURA	Present Measurable	12
Cycle 6, Day 15	Yes	11SEP2019 (120)	CT Scan	Radiologist 1	60	5.3	-36.2	mRECIST	60	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	4
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	15
Week 26	Yes	06NOV2019 (176)	CT Scan	Radiologist 1	58	1.8	-38.3	mRECIST	58	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	5
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0044 Treatment Group: PlaceboPemPlatinum														
Unscheduled	Yes	11DEC2019 (211)	CT Scan	Radiologist 1	59	3.5	-37.2	mRECIST	59	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	5
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	9
Week 38	Yes	05FEB2020 (267)	CT Scan	Radiologist 1	50	-12.3	-46.8	mRECIST	50	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	3
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	9
Week 48	Yes	01APR2020 (323)	CT Scan	Radiologist 1	54	8.0	-42.6	mRECIST	54	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	8
Subject ID: 0201-0045 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	17APR2019 (-7)	CT Scan	Radiologist 1	43			mRECIST	43	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	16

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0045 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	29MAY2019 (36)	CT Scan	Radiologist 1	37	-14.0	-14.0	mRECIST	37	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	16
Cycle 4, Day 15	Yes	10JUL2019 (78)	CT Scan	Radiologist 1	36	-2.7	-16.3	mRECIST	36	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	15
Cycle 6, Day 15	Yes	21AUG2019 (120)	CT Scan	Radiologist 1	29	-19.4	-32.6	mRECIST	29	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	13
Week 22	Yes	18SEP2019 (148)	CT Scan	Radiologist 1	27	-6.9	-37.2	mRECIST	27	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	10
Week 30	Yes	13NOV2019 (204)	CT Scan	Radiologist 1	35	29.6	-18.6	mRECIST	35	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	15
Week 38	Yes	08JAN2020 (260)	CT Scan	Radiologist 1	31	14.8	-27.9	mRECIST	31	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	12
Week 46	Yes	04MAR2020 (316)	CT Scan	Radiologist 1	29	7.4	-32.6	mRECIST	29	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	9
Week 54	Yes	29APR2020 (372)	CT Scan	Radiologist 1	30	11.1	-30.2	mRECIST	30	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	9

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0046 Treatment Group: ADIPemPlatinum														
Screening	Yes	08MAY2019 (-7)	CT Scan	Radiologist 2	99			mRECIST	99	Pleural	PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	20
Cycle 2, Day 15	Yes	19JUN2019 (36)	CT Scan	Radiologist 2	110	11.1	11.1	mRECIST	110	Pleural	PL001	PLEURA	Present Measurable	27
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	21
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	23
Cycle 4, Day 15	Yes	31JUL2019 (78)	CT Scan	Radiologist 2	109	10.1	10.1	mRECIST	109	Pleural	PL001	PLEURA	Present Measurable	23
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	28
Cycle 6, Day 15	Yes	11SEP2019 (120)	CT Scan	Radiologist 2	126	27.3	27.3	mRECIST	126	Pleural	PL001	PLEURA	Present Measurable	26
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	19
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	34

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0047 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	02MAY2019 (-13)	CT Scan	Radiologist 1	107			RECIST 1.1	17	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	17
								mRECIST	90	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	31
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	19JUN2019 (36)	CT Scan	Radiologist 1	97	-9.3	-9.3	RECIST 1.1	13	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	13
								mRECIST	84	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	30
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	9
Cycle 4, Day 15	Yes	31JUL2019 (78)	CT Scan	Radiologist 1	97	0.0	-9.3	RECIST 1.1	13	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	13
								mRECIST	84	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	30
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	9

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0047 Treatment Group: PlaceboPemPlatinum														
Cycle 6, Day 15	Yes	11SEP2019 (120)	CT Scan	Radiologist 1	105	8.2	-1.9	RECIST 1.1	13	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	13
								mRECIST	92	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	34
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	7
											PL006	PLEURA	Present Measurable	11
Subject ID: 0201-0048 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	20MAY2019 (-15)	CT Scan	Radiologist 1	38			mRECIST	38	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	21
Unscheduled	Yes	20JUL2019 (47)	CT Scan	Radiologist 1	35	-7.9	-7.9	mRECIST	35	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	18
Subject ID: 0201-0049 Treatment Group: ADIPemPlatinum														
Screening	Yes	11JUN2019 (-14)	CT Scan	Radiologist 1	218			mRECIST	218	Pleural	PL001	PLEURA	Present Measurable	94
											PL002	PLEURA	Present Measurable	30
											PL003	PLEURA	Present Measurable	26
											PL004	PLEURA	Present Measurable	30
											PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	19

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0049 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	08AUG2019 (45)	CT Scan	Radiologist 1	192	-11.9	-11.9	mRECIST	192	Pleural	PL001	PLEURA	Present Measurable	80
											PL002	PLEURA	Present Measurable	24
											PL003	PLEURA	Present Measurable	30
											PL004	PLEURA	Present Measurable	19
											PL005	PLEURA	Present Measurable	24
											PL006	PLEURA	Present Measurable	15
Subject ID: 0201-0050 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	26JUN2019 (-27)	CT Scan	Radiologist 1	97			mRECIST	97	Pleural	PL001	PLEURA	Present Measurable	23
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	19
Cycle 2, Day 15	Yes	29AUG2019 (38)	CT Scan	Radiologist 1	77	-20.6	-20.6	mRECIST	77	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	15
Cycle 4, Day 15	Yes	10OCT2019 (80)	CT Scan	Radiologist 1	66	-14.3	-32.0	mRECIST	66	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0050 Treatment Group: PlaceboPemPlatinum														
Cycle 4, Day 15	Yes	10OCT2019 (80)	CT Scan	Radiologist 1	66	-14.3	-32.0	mRECIST	66	Pleural	PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	12
Cycle 6, Day 15	Yes	20NOV2019 (121)	CT Scan	Radiologist 1	69	4.5	-28.9	mRECIST	69	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	14
Subject ID: 0201-0051 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	12JUN2019 (-20)	CT Scan	Radiologist 1	89			RECIST 1.1	15	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	15
								mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	06AUG2019 (36)	CT Scan	Radiologist 1	68	-23.6	-23.6	RECIST 1.1	10	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	10
								mRECIST	58	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0051 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	06AUG2019 (36)	CT Scan	Radiologist 1	68	-23.6	-23.6	mRECIST	58	Pleural	PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	6
											PL006	PLEURA	Present Measurable	6
Cycle 4, Day 15	Yes	17SEP2019 (78)	CT Scan	Radiologist 1	53	-22.1	-40.4	RECIST 1.1	9	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	9
								mRECIST	44	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	6
Cycle 6, Day 1	Yes	25OCT2019 (116)	CT Scan	Radiologist 1	52	-1.9	-41.6	RECIST 1.1	11	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	11
								mRECIST	41	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	6
Week 24	Yes	10DEC2019 (162)	CT Scan	Radiologist 1	53	1.9	-40.4	RECIST 1.1	11	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	11
								mRECIST	42	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	6

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0051 Treatment Group: PlaceboPemPlatinum														
Week 24	Yes	10DEC2019 (162)	CT Scan	Radiologist 1	53	1.9	-40.4	mRECIST	42	Pleural	PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	5
											PL006	PLEURA	Present Measurable	5
Subject ID: 0201-0052 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	10JUL2019 (-7)	CT Scan	Radiologist 1	125			RECIST 1.1	125	Non-Nodal	T001	PLEURA	Present Measurable	125
Cycle 2, Day 15	Yes	21AUG2019 (36)	CT Scan	Radiologist 1	124	-0.8	-0.8	RECIST 1.1	124	Non-Nodal	T001	PLEURA	Present Measurable	124
Subject ID: 0201-0053 Treatment Group: ADIPemPlatinum														
Screening	Yes	10JUL2019 (-7)	CT Scan	Radiologist 1	93			mRECIST	93	Pleural	PL001	PLEURA	Present Measurable	25
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	21AUG2019 (36)	CT Scan	Radiologist 1	85	-8.6	-8.6	mRECIST	85	Pleural	PL001	PLEURA	Present Measurable	26
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	8

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0053 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	No	01OCT2019 (77)	CT Scan	Radiologist 1	67	-21.2	-28.0	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	6
Cycle 6, Day 15	Yes	12NOV2019 (119)	CT Scan	Radiologist 1	75	11.9	-19.4	mRECIST	75	Pleural	PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	7
Week 26	Yes	15JAN2020 (183)	CT Scan	Radiologist 1	70	4.5	-24.7	mRECIST	70	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	8
Week 34	Yes	11MAR2020 (239)	CT Scan	Radiologist 1	64	-4.5	-31.2	mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	7
											PL006	PLEURA	Present Measurable	8

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0053 Treatment Group: ADIPemPlatinum														
Week 42	Yes	06MAY2020 (295)	CT Scan	Radiologist 1	66	3.1	-29.0	mRECIST	66	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	7
Subject ID: 0201-0054 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	07AUG2019 (-14)	CT Scan	Radiologist 1	74			mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	10
Cycle 2, Day 15	Yes	25SEP2019 (36)	CT Scan	Radiologist 1	68	-8.1	-8.1	mRECIST	68	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	06NOV2019 (78)	CT Scan	Radiologist 1	65	-4.4	-12.2	mRECIST	65	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	8

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0201-0054 Treatment Group: PlaceboPemPlatinum														
Cycle 4, Day 15	Yes	06NOV2019 (78)	CT Scan	Radiologist 1	65	-4.4	-12.2	mRECIST	65	Pleural	PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	14
Cycle 6, Day 15	Yes	18DEC2019 (120)	CT Scan	Radiologist 1	60	-7.7	-18.9	mRECIST	60	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	11
Week 26	Yes	12FEB2020 (176)	CT Scan	Radiologist 1	62	3.3	-16.2	mRECIST	62	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	11
Week 34	Yes	08APR2020 (232)	CT Scan	Radiologist 1	64	6.7	-13.5	mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0202-0001 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	13MAR2018 (-22)	CT Scan	Radiologist 1	82			RECIST 1.1	17	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	17
								mRECIST	65	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	16MAY2018 (43)	CT Scan	Radiologist 1	79	-3.7	-3.7	RECIST 1.1	13	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	13
								mRECIST	66	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	10
Cycle 4, Day 15	Yes	25JUN2018 (83)	CT Scan	Radiologist 1	84	6.3	2.4	RECIST 1.1	12	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	12
								mRECIST	72	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0202-0001 Treatment Group: PlaceboPemPlatinum														
Cycle 6, Day 15	Yes	06AUG2018 (125)	CT Scan	Radiologist 1	76	-3.8	-7.3	RECIST 1.1	12	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	12
								mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	8
Subject ID: 0202-0002 Treatment Group: ADIPemPlatinum														
Screening	Yes	29AUG2018 (-14)	CT Scan	Radiologist 1	13			mRECIST	13	Pleural	PL001	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	31OCT2018 (50)	CT Scan	Radiologist 1	9	-30.8	-30.8	mRECIST	9	Pleural	PL001	PLEURA	Present Measurable	9
Cycle 4, Day 15	Yes	03DEC2018 (83)	CT Scan	Radiologist 1	8	-11.1	-38.5	mRECIST	8	Pleural	PL001	PLEURA	Present Measurable	8
Cycle 6, Day 15	Yes	16JAN2019 (127)	CT Scan	Radiologist 1	8	0.0	-38.5	mRECIST	8	Pleural	PL001	PLEURA	Present Measurable	8
Subject ID: 0202-0003 Treatment Group: ADIPemPlatinum														
Screening	Yes	29APR2019 (-22)	CT Scan	Radiologist 2	74			mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	15

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0202-0003 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	01JUL2019 (42)	CT Scan	Radiologist 2	69	-6.8	-6.8	mRECIST	69	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	13
Cycle 4, Day 15	Yes	13AUG2019 (85)	CT Scan	Radiologist 2	67	-2.9	-9.5	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	12
Cycle 6, Day 15	Yes	28SEP2019 (131)	CT Scan	Radiologist 2	65	-3.0	-12.2	mRECIST	65	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	12
Week 26	Yes	19NOV2019 (183)	CT Scan	Radiologist 2	80	23.1	8.1	mRECIST	80	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	4
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	15

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0202-0004 Treatment Group: ADIPemPlatinum														
Screening	Yes	16APR2019 (-22)	CT Scan	Radiologist 1	94			RECIST 1.1	16	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	16
								mRECIST	78	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	12JUN2019 (36)	CT Scan	Radiologist 1	52	-44.7	-44.7	RECIST 1.1	14	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	14
								mRECIST	38	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Not Present total disappearance	0
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	5
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Not Present total disappearance	0
Cycle 4, Day 15	Yes	24JUL2019 (78)	CT Scan	Radiologist 1	46	-11.5	-51.1	RECIST 1.1	13	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	13
								mRECIST	33	Pleural	PL001	PLEURA	Present Measurable	5
											PL002	PLEURA	Present Measurable	4
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	4

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0202-0004 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	24JUL2019 (78)	CT Scan	Radiologist 1	46	-11.5	-51.1	mRECIST	33	Pleural	PL005 PL006	PLEURA PLEURA	Present Measurable Not Present total disappearance	8 0
Cycle 6, Day 15	Yes	28AUG2019 (113)	CT Scan	Radiologist 1	47	2.2	-50.0	RECIST 1.1	13	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	13
								mRECIST	34	Pleural	PL001 PL002 PL003 PL004 PL005 PL006	PLEURA PLEURA PLEURA PLEURA PLEURA PLEURA	Present Measurable Present Measurable Present Measurable Present Measurable Present Measurable Present Measurable	8 1 12 2 10 1
Week 24	Yes	23OCT2019 (169)	CT Scan	Radiologist 1	45	-2.2	-52.1	RECIST 1.1	12	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	12
								mRECIST	33	Pleural	PL001 PL002 PL003 PL004 PL005 PL006	PLEURA PLEURA PLEURA PLEURA PLEURA PLEURA	Present Measurable Present Measurable Present Measurable Present Measurable Present Measurable Present Measurable	7 3 11 2 9 1
Week 30	Yes	04DEC2019 (211)	CT Scan	Radiologist 1	48	6.7	-48.9	RECIST 1.1	11	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	11
								mRECIST	37	Pleural	PL001 PL002 PL003	PLEURA PLEURA PLEURA	Present Measurable Present Measurable Present Measurable	7 4 13

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0202-0004 Treatment Group: ADIPemPlatinum														
Week 30	Yes	04DEC2019 (211)	CT Scan	Radiologist 1	48	6.7	-48.9	mRECIST	37	Pleural	PL004	PLEURA	Present Measurable	4
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	1
Week 38	Yes	15JAN2020 (253)	CT Scan	Radiologist 1	44	-2.2	-53.2	RECIST 1.1	10	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	10
								mRECIST	34	Pleural	PL001	PLEURA	Present Measurable	3
											PL002	PLEURA	Present Measurable	4
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	3
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	1
Week 42	Yes	26FEB2020 (295)	CT Scan	Radiologist 1	44	0.0	-53.2	RECIST 1.1	11	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	11
								mRECIST	33	Pleural	PL001	PLEURA	Present Measurable	3
											PL002	PLEURA	Present Measurable	2
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	2
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	2
Week 50	Yes	08APR2020 (337)	CT Scan	Radiologist 1	48	9.1	-48.9	RECIST 1.1	10	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	10
								mRECIST	38	Pleural	PL001	PLEURA	Present Measurable	5
											PL002	PLEURA	Present Measurable	3
											PL003	PLEURA	Present Measurable	15

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0202-0004 Treatment Group: ADIPemPlatinum														
Week 50	Yes	08APR2020 (337)	CT Scan	Radiologist 1	48	9.1	-48.9	mRECIST	38	Pleural	PL004	PLEURA	Present Measurable	4
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Not Present total disappearance	0
Week 54	Yes	20MAY2020 (379)	CT Scan	Radiologist 1	49	11.4	-47.9	RECIST 1.1	13	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	13
								mRECIST	36	Pleural	PL001	PLEURA	Present Measurable	3
											PL002	PLEURA	Present Measurable	4
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	3
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Not Present total disappearance	0
Subject ID: 0202-0005 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	23OCT2019 (-21)	CT Scan	Radiologist 1	101			RECIST 1.1	16	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	16
								mRECIST	85	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	11

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0202-0005 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	30DEC2019 (48)	CT Scan	Radiologist 1	106	5.0	5.0	RECIST 1.1	16	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	16
								mRECIST	90	Pleural	PL001	PLEURA	Present Measurable	23
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	11
Cycle 4, Day 15	Yes	12FEB2020 (92)	CT Scan	Radiologist 1	91	-9.9	-9.9	RECIST 1.1	13	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	13
								mRECIST	78	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	11
Cycle 6, Day 15	Yes	18MAR2020 (127)	CT Scan	Radiologist 1	98	7.7	-3.0	RECIST 1.1	15	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	15
								mRECIST	83	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0202-0005 Treatment Group: PlaceboPemPlatinum														
Week 24	Yes	30APR2020 (170)	CT Scan	Radiologist 1	119	30.8	17.8	RECIST 1.1	17	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	17
								mRECIST	102	Pleural	PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	20
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	13
Subject ID: 0203-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	22NOV2017 (-13)	CT Scan	Radiologist 1	66			mRECIST	66	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	21
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	11
Cycle 2, Day 15	No	18JAN2018 (45)	CT Scan	Radiologist 1	67	1.5	1.5	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	19
											PL002	PLEURA	Present Measurable	20
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	28FEB2018 (86)	CT Scan	Radiologist 1	72	9.1	9.1	mRECIST	72	Pleural	PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	20
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	15
Cycle 6, Day 15	Yes	28MAR2018 (114)	CT Scan	Radiologist 1	68	3.0	3.0	mRECIST	68	Pleural	PL001	PLEURA	Present Measurable	20

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0203-0001 Treatment Group: ADIPemPlatinum														
Cycle 6, Day 15	Yes	28MAR2018 (114)	CT Scan	Radiologist 1	68	3.0	3.0	mRECIST	68	Pleural	PL002	PLEURA	Present Measurable	19
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	13
Subject ID: 0203-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	20DEC2017 (-13)	CT Scan	Radiologist 2	88			mRECIST	88	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	21
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	12
Cycle 2, Day 15	Yes	14FEB2018 (44)	CT Scan	Radiologist 2	81	-8.0	-8.0	mRECIST	81	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	18
											PL006	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	28MAR2018 (86)	CT Scan	Radiologist 2	67	-17.3	-23.9	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	9

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0203-0002 Treatment Group: PlaceboPemPlatinum														
Cycle 6, Day 15 No														
Subject ID: 0203-0004 Treatment Group: ADIPemPlatinum														
Screening	Yes	09FEB2018 (-12)	CT Scan	Radiologist 2	94			mRECIST	94	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	20
Cycle 2, Day 15	Yes	06APR2018 (45)	CT Scan	Radiologist 2	102	8.5	8.5	mRECIST	102	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	25
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	21
Subject ID: 0203-0005 Treatment Group: ADIPemPlatinum														
Screening	Yes	21MAR2018 (-14)	CT Scan	Radiologist 2	74			mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0203-0005 Treatment Group: ADIPemPlatinum														
Screening	Yes	21MAR2018 (-14)	CT Scan	Radiologist 2	74			mRECIST	74	Pleural	PL006	PLEURA	Present Measurable	12
Cycle 2, Day 15	Yes	17MAY2018 (44)	CT Scan	Radiologist 2	67	-9.5	-9.5	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	9
Cycle 4, Day 15	Yes	27JUN2018 (85)	CT Scan	Radiologist 2	73	9.0	-1.4	mRECIST	73	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	10
Cycle 6, Day 15	Yes	08AUG2018 (127)	CT Scan	Radiologist 2	72	7.5	-2.7	mRECIST	72	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	12
Week 24	Yes	03OCT2018 (183)	CT Scan	Radiologist 2	69	3.0	-6.8	mRECIST	69	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	13

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0203-0005 Treatment Group: ADIPemPlatinum														
Week 24	Yes	03OCT2018 (183)	CT Scan	Radiologist 2	69	3.0	-6.8	mRECIST	69	Pleural	PL006	PLEURA	Present Measurable	10
Subject ID: 0203-0008 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	26JUL2018 (-13)	CT Scan	Radiologist 1	99			mRECIST	99	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	18
Cycle 2, Day 15	Yes	19SEP2018 (43)	CT Scan	Radiologist 1	60	-39.4	-39.4	mRECIST	60	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	19OCT2018 (73)	CT Scan	Radiologist 1	52	-13.3	-47.5	mRECIST	52	Pleural	PL001	PLEURA	Present Measurable	3
											PL002	PLEURA	Present Measurable	6
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	12
Cycle 6, Day 15	Yes	12DEC2018 (127)	CT Scan	Radiologist 1	56	7.7	-43.4	mRECIST	56	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	6

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0203-0008 Treatment Group: PlaceboPemPlatinum														
Cycle 6, Day 15	Yes	12DEC2018 (127)	CT Scan	Radiologist 1	56	7.7	-43.4	mRECIST	56	Pleural	PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	7
											PL006	PLEURA	Present Measurable	10
Week 26	Yes	06FEB2019 (183)	CT Scan	Radiologist 1	86	65.4	-13.1	mRECIST	86	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	16
Subject ID: 0203-0009 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	16AUG2018 (-13)	CT Scan	Radiologist 2	102			mRECIST	102	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	19
Cycle 2, Day 15	Yes	10OCT2018 (43)	CT Scan	Radiologist 2	98	-3.9	-3.9	mRECIST	98	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	18

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0203-0009 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	10OCT2018 (43)	CT Scan	Radiologist 2	98	-3.9	-3.9	mRECIST	98	Pleural	PL006	PLEURA	Present Measurable	21
Cycle 4, Day 15	Yes	21NOV2018 (85)	CT Scan	Radiologist 2	103	5.1	1.0	mRECIST	103	Pleural	PL001	PLEURA	Present Measurable	25
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	21
Week 22	Yes	02JAN2019 (127)	CT Scan	Radiologist 2	110	12.2	7.8	mRECIST	110	Pleural	PL001	PLEURA	Present Measurable	24
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	18
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	19
Unscheduled	Yes	31JAN2019 (156)		Radiologist 2				mRECIST		Pleural	PL001	PLEURA	Not Evaluable - insufficient anatomical coverage	
											PL002	PLEURA	Not Evaluable - insufficient anatomical coverage	
											PL003	PLEURA	Not Evaluable - insufficient anatomical coverage	

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0203-0009 Treatment Group: PlaceboPemPlatinum														
Unscheduled	Yes	31JAN2019 (156)		Radiologist 2				mRECIST		Pleural	PL004	PLEURA	Not Evaluable - insufficient anatomical coverage	
											PL005	PLEURA	Not Evaluable - insufficient anatomical coverage	
											PL006	PLEURA	Not Evaluable - insufficient anatomical coverage	
Subject ID: 0203-0013 Treatment Group: ADIPemPlatinum														
Screening	Yes	06MAR2019 (-7)	CT Scan	Radiologist 1	66			mRECIST	66	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	24APR2019 (43)	CT Scan	Radiologist 1	59	-10.6	-10.6	mRECIST	59	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	11

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0203-0013 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	12JUN2019 (92)	CT Scan	Radiologist 1	43	-27.1	-34.8	mRECIST	43	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	9
Cycle 6, Day 15	Yes	10JUL2019 (120)	CT Scan	Radiologist 1	42	-2.3	-36.4	mRECIST	42	Pleural	PL001	PLEURA	Present Measurable	5
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	7
											PL006	PLEURA	Present Measurable	10
Week 26	Yes	28AUG2019 (169)	CT Scan	Radiologist 1	49	16.7	-25.8	mRECIST	49	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	10
Week 34	Yes	17OCT2019 (219)	CT Scan	Radiologist 1	47	11.9	-28.8	mRECIST	47	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	8

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0203-0013 Treatment Group: ADIPemPlatinum														
Week 38	Yes	27NOV2019 (260)	CT Scan	Radiologist 1	44	4.8	-33.3	mRECIST	44	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	6
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	6
											PL006	PLEURA	Present Measurable	8
Week 46	Yes	08JAN2020 (302)	CT Scan	Radiologist 1	42	0.0	-36.4	mRECIST	42	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	6
Week 50	Yes	04MAR2020 (358)	CT Scan	Radiologist 1	41	-2.4	-37.9	mRECIST	41	Pleural	PL001	PLEURA	Present Measurable	4
											PL002	PLEURA	Present Measurable	6
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	7
Subject ID: 0203-0014 Treatment Group: ADIPemPlatinum														
Screening	Yes	18JUL2019 (-6)	CT Scan	Radiologist 1	42			RECIST 1.1	42	Nodal	TN001	RETROPERITO NEAL LYMPH NODE	Present Measurable	20

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0203-0014 Treatment Group: ADIPemPlatinum														
Screening	Yes	18JUL2019 (-6)	CT Scan	Radiologist 1	42			RECIST 1.1	42	Nodal	TN002	RETROPERITO NEAL LYMPH NODE	Present Measurable	22
Cycle 2, Day 15	Yes	03SEP2019 (42)	CT Scan	Radiologist 1	33	-21.4	-21.4	RECIST 1.1	33	Nodal	TN001	RETROPERITO NEAL LYMPH NODE	Present Measurable	19
											TN002	RETROPERITO NEAL LYMPH NODE	Present Measurable	14
Cycle 4, Day 15	Yes	15OCT2019 (84)	CT Scan	Radiologist 1	30	-9.1	-28.6	RECIST 1.1	30	Nodal	TN001	RETROPERITO NEAL LYMPH NODE	Present Measurable	15
											TN002	RETROPERITO NEAL LYMPH NODE	Present Measurable	15
Cycle 6, Day 15	Yes	13NOV2019 (113)	CT Scan	Radiologist 1	24	-20.0	-42.9	RECIST 1.1	24	Nodal	TN001	RETROPERITO NEAL LYMPH NODE	Present Measurable	12
											TN002	RETROPERITO NEAL LYMPH NODE	Present Measurable	12
Week 24	Yes	08JAN2020 (169)	CT Scan	Radiologist 1	26	8.3	-38.1	RECIST 1.1	26	Nodal	TN001	RETROPERITO NEAL LYMPH NODE	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0203-0014 Treatment Group: ADIPemPlatinum														
Week 24	Yes	08JAN2020 (169)	CT Scan	Radiologist 1	26	8.3	-38.1	RECIST 1.1	26	Nodal	TN002	RETROPERITO NEAL LYMPH NODE	Present Measurable	14
Week 34	Yes	04MAR2020 (225)	CT Scan	Radiologist 1	37	54.2	-11.9	RECIST 1.1	37	Nodal	TN001	RETROPERITO NEAL LYMPH NODE	Present Measurable	18
											TN002	RETROPERITO NEAL LYMPH NODE	Present Measurable	19
Subject ID: 0203-0015 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	19JUL2019 (-12)	CT Scan	Radiologist 1	136			mRECIST	136	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	55
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	21
Cycle 2, Day 15	Yes	11SEP2019 (43)	CT Scan	Radiologist 1	133	-2.2	-2.2	mRECIST	133	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	56
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	20

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

		Date of Response			Total Sum	% Change	% Change		Sum of		Lesion			
Visit	Scan	Assessment		Evaluator	of Diameters	from	from	Assessment	Diameter	Lesion	Lesion	Location	Tumor State	Diameter ^[2]
	Done?	(Study Day ^[1])	Modality		(mm)	Nadir	Baseline		(mm)	Type	ID			(mm)
Subject ID: 0203-0015 Treatment Group: PlaceboPemPlatinum														
Cycle 4, Day 15	Yes	23OCT2019 (85)	CT Scan	Radiologist 1	130	-2.3	-4.4	mRECIST	130	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	59
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	22
Cycle 6, Day 15	Yes	27NOV2019 (120)	CT Scan	Radiologist 1	148	13.8	8.8	mRECIST	148	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	68
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	24
Subject ID: 0203-0016 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	25JUL2019 (-27)	CT Scan	Radiologist 1	69			mRECIST	69	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	02OCT2019 (43)	CT Scan	Radiologist 1	64	-7.2	-7.2	mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	11

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0203-0016 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	02OCT2019 (43)	CT Scan	Radiologist 1	64	-7.2	-7.2	mRECIST	64	Pleural	PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	13NOV2019 (85)	CT Scan	Radiologist 1	59	-7.8	-14.5	mRECIST	59	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	14
Cycle 6, Day 15	Yes	23DEC2019 (125)	CT Scan	Radiologist 1	53	-10.2	-23.2	mRECIST	53	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	6
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	7
Subject ID: 0204-0001 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	09MAY2018 (-7)	CT Scan	Radiologist 1	174			mRECIST	174	Pleural	PL001	PLEURA	Present Measurable	30
											PL002	PLEURA	Present Measurable	22
											PL003	PLEURA	Present Measurable	34
											PL004	PLEURA	Present Measurable	21
											PL005	PLEURA	Present Measurable	38
											PL006	PLEURA	Present Measurable	29

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0204-0001 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	25JUN2018 (41)	CT Scan	Radiologist 1	80	-54.0	-54.0	mRECIST	80	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	16
Cycle 4, Day 15	Yes	01AUG2018 (78)	CT Scan	Radiologist 1	65	-18.8	-62.6	mRECIST	65	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	10
Cycle 6, Day 15	Yes	10SEP2018 (118)	CT Scan	Radiologist 1	64	-1.5	-63.2	mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	9
Unscheduled	Yes	05NOV2018 (174)	CT Scan	Radiologist 1	186	190.6	6.9	mRECIST	186	Pleural	PL001	PLEURA	Present Measurable	26
											PL002	PLEURA	Present Measurable	28
											PL003	PLEURA	Present Measurable	36
											PL004	PLEURA	Present Measurable	18
											PL005	PLEURA	Present Measurable	53
											PL006	PLEURA	Present Measurable	25

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0204-0002 Treatment Group: ADIPemPlatinum														
Screening	Yes	04JUL2018 (-7)	CT Scan	Radiologist 1	118			mRECIST	118	Pleural	PL001	PLEURA	Present Measurable	33
											PL002	PLEURA	Present Measurable	18
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	21
											PL006	PLEURA	Present Measurable	15
Cycle 2, Day 15	Yes	22AUG2018 (43)	CT Scan	Radiologist 1	111	-5.9	-5.9	mRECIST	111	Pleural	PL001	PLEURA	Present Measurable	30
											PL002	PLEURA	Present Measurable	20
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	12
Subject ID: 0204-0003 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	18JUL2018 (-14)	CT Scan	Radiologist 1	142			mRECIST	142	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	19
											PL003	PLEURA	Present Measurable	36
											PL004	PLEURA	Present Measurable	21
											PL005	PLEURA	Present Measurable	27
											PL006	PLEURA	Present Measurable	26
Cycle 2, Day 15	Yes	03SEP2018 (34)	CT Scan	Radiologist 1	182	28.2	28.2	mRECIST	182	Pleural	PL001	PLEURA	Present Measurable	34
											PL002	PLEURA	Present Measurable	30
											PL003	PLEURA	Present Measurable	41

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0204-0003 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	03SEP2018 (34)	CT Scan	Radiologist 1	182	28.2	28.2	mRECIST	182	Pleural	PL004	PLEURA	Present Measurable	29
											PL005	PLEURA	Present Measurable	26
											PL006	PLEURA	Present Measurable	22
Subject ID: 0204-0004 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	06AUG2018 (-15)	CT Scan	Radiologist 1	99			mRECIST	99	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	19
Cycle 2, Day 15	Yes	24SEP2018 (35)	CT Scan	Radiologist 1	91	-8.1	-8.1	mRECIST	91	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	20
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	16
Unscheduled	Yes	25OCT2018 (66)	CT Scan	Radiologist 1	105	15.4	6.1	mRECIST	105	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	18
											PL005	PLEURA	Present Measurable	22
											PL006	PLEURA	Present Measurable	24

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0204-0005 Treatment Group: ADIPemPlatinum														
Screening	Yes	12SEP2018 (-7)	CT Scan	Radiologist 1	71			mRECIST	71	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	12
Cycle 2, Day 15	Yes	23OCT2018 (35)	CT Scan	Radiologist 1	75	5.6	5.6	mRECIST	75	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	14
Cycle 4, Day 15	Yes	03DEC2018 (76)	CT Scan	Radiologist 1	50	-29.6	-29.6	mRECIST	50	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	4
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	8
Cycle 6, Day 15	Yes	14JAN2019 (118)	CT Scan	Radiologist 1	52	4.0	-26.8	mRECIST	52	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	8

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0204-0005 Treatment Group: ADIPemPlatinum														
Week 24	Yes	26FEB2019 (161)	CT Scan	Radiologist 1	55	10.0	-22.5	mRECIST	55	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	8
Week 34	Yes	07MAY2019 (231)	CT Scan	Radiologist 1	54	8.0	-23.9	mRECIST	54	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	8
Week 42	Yes	28JUN2019 (283)	CT Scan	Radiologist 1	70	40.0	-1.4	mRECIST	70	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	7
Subject ID: 0204-0006 Treatment Group: ADIPemPlatinum														
Screening	Yes	28NOV2018 (-7)	CT Scan	Radiologist 1	563			mRECIST	563	Pleural	PL001	PLEURA	Present Measurable	67
											PL002	PLEURA	Present Measurable	93
											PL003	PLEURA	Present Measurable	80

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0204-0006 Treatment Group: ADIPemPlatinum														
Screening	Yes	28NOV2018 (-7)	CT Scan	Radiologist 1	563			mRECIST	563	Pleural	PL004	PLEURA	Present Measurable	111
											PL005	PLEURA	Present Measurable	87
											PL006	PLEURA	Present Measurable	125
Cycle 2, Day 15	Yes	07JAN2019 (34)	CT Scan	Radiologist 1	569	1.1	1.1	mRECIST	569	Pleural	PL001	PLEURA	Present Measurable	73
											PL002	PLEURA	Present Measurable	87
											PL003	PLEURA	Present Measurable	85
											PL004	PLEURA	Present Measurable	102
											PL005	PLEURA	Present Measurable	103
											PL006	PLEURA	Present Measurable	119
Cycle 4, Day 15	Yes	19FEB2019 (77)	CT Scan	Radiologist 1	635	12.8	12.8	mRECIST	635	Pleural	PL001	PLEURA	Present Measurable	92
											PL002	PLEURA	Present Measurable	107
											PL003	PLEURA	Present Measurable	89
											PL004	PLEURA	Present Measurable	119
											PL005	PLEURA	Present Measurable	103
											PL006	PLEURA	Present Measurable	125
Subject ID: 0204-0007 Treatment Group: ADIPemPlatinum														
Screening	Yes	02JAN2019 (-28)	CT Scan	Radiologist 2	74			mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	17

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0204-0007 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	06MAR2019 (36)	CT Scan	Radiologist 2	65	-12.2	-12.2	mRECIST	65	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	15
Cycle 4, Day 15	Yes	15APR2019 (76)	CT Scan	Radiologist 2	55	-15.4	-25.7	mRECIST	55	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	5
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	16
Cycle 6, Day 15	Yes	29MAY2019 (120)	CT Scan	Radiologist 2	66	20.0	-10.8	mRECIST	66	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	15
Subject ID: 0204-0008 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	28JAN2019 (-9)	CT Scan	Radiologist 1	122			mRECIST	122	Pleural	PL001	PLEURA	Present Measurable	32
											PL002	PLEURA	Present Measurable	28
											PL003	PLEURA	Present Measurable	18

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0204-0008 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	28JAN2019 (-9)	CT Scan	Radiologist 1	122			mRECIST	122	Pleural	PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	11MAR2019 (34)	CT Scan	Radiologist 1	99	-18.9	-18.9	mRECIST	99	Pleural	PL001	PLEURA	Present Measurable	33
											PL002	PLEURA	Present Measurable	29
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	5
Cycle 4, Day 1	Yes	09APR2019 (63)	CT Scan	Radiologist 1	92	-7.1	-24.6	mRECIST	92	Pleural	PL001	PLEURA	Present Measurable	31
											PL002	PLEURA	Present Measurable	24
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	7
Cycle 6, Day 15	Yes	05JUN2019 (120)	CT Scan	Radiologist 1	80	-13.0	-34.4	mRECIST	80	Pleural	PL001	PLEURA	Present Measurable	32
											PL002	PLEURA	Present Measurable	25
											PL003	PLEURA	Present Measurable	5
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	5
											PL006	PLEURA	Present Measurable	6
Week 26	Yes	30JUL2019 (175)	CT Scan	Radiologist 1	82	2.5	-32.8	mRECIST	82	Pleural	PL001	PLEURA	Present Measurable	32
											PL002	PLEURA	Present Measurable	30
											PL003	PLEURA	Present Measurable	7

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0204-0008 Treatment Group: PlaceboPemPlatinum														
Week 26	Yes	30JUL2019 (175)	CT Scan	Radiologist 1	82	2.5	-32.8	mRECIST	82	Pleural	PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	4
											PL006	PLEURA	Present Measurable	3
Week 34	Yes	23SEP2019 (230)	CT Scan	Radiologist 1	73	-8.8	-40.2	mRECIST	73	Pleural	PL001	PLEURA	Present Measurable	31
											PL002	PLEURA	Present Measurable	24
											PL003	PLEURA	Present Measurable	5
											PL004	PLEURA	Present Measurable	5
											PL005	PLEURA	Present Measurable	5
											PL006	PLEURA	Present Measurable	3
Week 42	Yes	03DEC2019 (301)	CT Scan	Radiologist 1	76	4.1	-37.7	mRECIST	76	Pleural	PL001	PLEURA	Present Measurable	32
											PL002	PLEURA	Present Measurable	26
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	5
											PL005	PLEURA	Present Measurable	5
											PL006	PLEURA	Present Measurable	2
Subject ID: 0204-0009 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	20FEB2019 (-14)	CT Scan	Radiologist 1	35			mRECIST	35	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	12
Cycle 2, Day 15	Yes	09APR2019 (35)	CT Scan	Radiologist 1	32	-8.6	-8.6	mRECIST	32	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0204-0009 Treatment Group: PlaceboPemPlatinum														
Cycle 4, Day 15	Yes	28MAY2019 (84)	CT Scan	Radiologist 1	22	-31.3	-37.1	mRECIST	22	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	6
Cycle 6, Day 15	Yes	08JUL2019 (125)	CT Scan	Radiologist 1	25	13.6	-28.6	mRECIST	25	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	9
Week 26	Yes	27AUG2019 (175)	CT Scan	Radiologist 1	28	27.3	-20.0	mRECIST	28	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	11
Subject ID: 0204-0010 Treatment Group: ADIPemPlatinum														
Screening	Yes	29JUL2019 (-9)	CT Scan	Radiologist 1	95			mRECIST	95	Pleural	PL001	PLEURA	Present Measurable	22
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	19
Cycle 2, Day 15	Yes	16SEP2019 (41)	CT Scan	Radiologist 1	101	6.3	6.3	mRECIST	101	Pleural	PL001	PLEURA	Present Measurable	23
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	17
											PL006	PLEURA	Present Measurable	20

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0204-0010 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	29OCT2019 (84)	CT Scan	Radiologist 1	111	16.8	16.8	mRECIST	111	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	27
											PL006	PLEURA	Present Measurable	14
Subject ID: 0204-0011 Treatment Group: ADIPemPlatinum														
Screening	Yes	09SEP2019 (-9)	CT Scan	Radiologist 1	247			mRECIST	247	Pleural	PL001	PLEURA	Present Measurable	37
											PL002	PLEURA	Present Measurable	26
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	48
											PL005	PLEURA	Present Measurable	57
											PL006	PLEURA	Present Measurable	63
Cycle 2, Day 15	Yes	28OCT2019 (41)	CT Scan	Radiologist 1	236	-4.5	-4.5	mRECIST	236	Pleural	PL001	PLEURA	Present Measurable	35
											PL002	PLEURA	Present Measurable	20
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	46
											PL005	PLEURA	Present Measurable	58
											PL006	PLEURA	Present Measurable	60
Cycle 4, Day 15	Yes	09DEC2019 (83)	CT Scan	Radiologist 1	250	5.9	1.2	mRECIST	250	Pleural	PL001	PLEURA	Present Measurable	36
											PL002	PLEURA	Present Measurable	24
											PL003	PLEURA	Present Measurable	22

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0204-0011 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	09DEC2019 (83)	CT Scan	Radiologist 1	250	5.9	1.2	mRECIST	250	Pleural	PL004	PLEURA	Present Measurable	36
											PL005	PLEURA	Present Measurable	63
											PL006	PLEURA	Present Measurable	69
Cycle 6, Day 15	Yes	20JAN2020 (125)	CT Scan	Radiologist 1	295	25.0	19.4	mRECIST	295	Pleural	PL001	PLEURA	Present Measurable	38
											PL002	PLEURA	Present Measurable	35
											PL003	PLEURA	Present Measurable	22
											PL004	PLEURA	Present Measurable	54
											PL005	PLEURA	Present Measurable	69
											PL006	PLEURA	Present Measurable	77
Subject ID: 0205-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	14JUN2018 (-19)	CT Scan	Radiologist 1	123			RECIST 1.1	47	Non-Nodal	T001	LIVER, LEFT LOBE	Present Measurable	20
											T002	ADRENAL GLAND	Present Measurable	27
Cycle 2, Day 15	Yes	13AUG2018 (42)	CT Scan	Radiologist 1	112	-8.9	-8.9	mRECIST	76	Pleural	PL001	PLEURA	Present Measurable	76
								RECIST 1.1	51	Non-Nodal	T001	LIVER, LEFT LOBE	Present Measurable	20
											T002	ADRENAL GLAND	Present Measurable	31
Cycle 4, Day 15	Yes	25SEP2018 (85)	CT Scan	Radiologist 1	109	-2.7	-11.4	mRECIST	61	Pleural	PL001	PLEURA	Present Measurable	61
								RECIST 1.1	49	Non-Nodal	T001	LIVER, LEFT LOBE	Present Measurable	15

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0205-0001 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	25SEP2018 (85)	CT Scan	Radiologist 1	109	-2.7	-11.4	RECIST 1.1	49	Non-Nodal	T002	ADRENAL GLAND	Present Measurable	34
Cycle 6, Day 15	Yes	05NOV2018 (126)	CT Scan	Radiologist 1	103	-5.5	-16.3	mRECIST	60	Pleural	PL001	PLEURA	Present Measurable	60
								RECIST 1.1	50		T001	LIVER, LEFT LOBE	Present Measurable	14
											T002	ADRENAL GLAND	Present Measurable	36
Week 26	Yes	31DEC2018 (182)	CT Scan	Radiologist 1	99	-3.9	-19.5	mRECIST	53	Pleural	PL001	PLEURA	Present Measurable	53
								RECIST 1.1	43		T001	LIVER, LEFT LOBE	Not Present total disappearance	0
											T002	ADRENAL GLAND	Present Measurable	43
Week 34	Yes	25FEB2019 (238)	CT Scan	Radiologist 1	127	28.3	3.3	mRECIST	56	Pleural	PL001	PLEURA	Present Measurable	56
								RECIST 1.1	70		T001	LIVER, LEFT LOBE	Present Measurable	19
											T002	ADRENAL GLAND	Present Measurable	51
								mRECIST	57	Pleural	PL001	PLEURA	Present Measurable	57
Subject ID: 0205-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	02APR2019 (-13)	CT Scan	Radiologist 2	74			mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	13

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0205-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	02APR2019 (-13)	CT Scan	Radiologist 2	74			mRECIST	74	Pleural	PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	12
Cycle 2, Day 15	Yes	22MAY2019 (38)	CT Scan	Radiologist 2	65	-12.2	-12.2	mRECIST	65	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	03JUL2019 (80)	CT Scan	Radiologist 2	53	-18.5	-28.4	mRECIST	53	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	9
Cycle 6, Day 15	Yes	14AUG2019 (122)	CT Scan	Radiologist 2	68	28.3	-8.1	mRECIST	68	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0205-0005 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	16AUG2019 (-11)	CT Scan	Radiologist 1	148			mRECIST	148	Pleural	PL001	PLEURA	Present Measurable	35
											PL002	PLEURA	Present Measurable	27
											PL003	PLEURA	Present Measurable	24
											PL004	PLEURA	Present Measurable	18
											PL005	PLEURA	Present Measurable	24
											PL006	PLEURA	Present Measurable	20
Cycle 2, Day 15	Yes	03OCT2019 (38)	CT Scan	Radiologist 1	167	12.8	12.8	mRECIST	167	Pleural	PL001	PLEURA	Present Measurable	41
											PL002	PLEURA	Present Measurable	36
											PL003	PLEURA	Present Measurable	25
											PL004	PLEURA	Present Measurable	19
											PL005	PLEURA	Present Measurable	25
											PL006	PLEURA	Present Measurable	21
Cycle 4, Day 15	Yes	14NOV2019 (80)	CT Scan	Radiologist 1	207	39.9	39.9	mRECIST	207	Pleural	PL001	PLEURA	Present Measurable	57
											PL002	PLEURA	Present Measurable	53
											PL003	PLEURA	Present Measurable	23
											PL004	PLEURA	Present Measurable	22
											PL005	PLEURA	Present Measurable	22
											PL006	PLEURA	Present Measurable	30
Subject ID: 0207-0003 Treatment Group: ADIPemPlatinum														
Screening	Yes	17JUN2019 (-21)	CT Scan	Radiologist 1	114			mRECIST	114	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	23

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0207-0003 Treatment Group: ADIPemPlatinum														
Screening	Yes	17JUN2019 (-21)	CT Scan	Radiologist 1	114			mRECIST	114	Pleural	PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	30
											PL006	PLEURA	Present Measurable	19
Cycle 2, Day 15	Yes	20AUG2019 (44)	CT Scan	Radiologist 1	99	-13.2	-13.2	mRECIST	99	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	20
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	24
											PL006	PLEURA	Present Measurable	15
Cycle 4, Day 15	Yes	03OCT2019 (88)	CT Scan	Radiologist 1	110	11.1	-3.5	mRECIST	110	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	22
											PL004	PLEURA	Present Measurable	23
											PL005	PLEURA	Present Measurable	21
											PL006	PLEURA	Present Measurable	13
Subject ID: 0208-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	24APR2018 (-20)	CT Scan	Radiologist 1	64			mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	18
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	22JUN2018 (40)	CT Scan	Radiologist 1	51	-20.3	-20.3	mRECIST	51	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0208-0001 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	22JUN2018 (40)	CT Scan	Radiologist 1	51	-20.3	-20.3	mRECIST	51	Pleural	PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	13AUG2018 (92)	CT Scan	Radiologist 1	54	5.9	-15.6	mRECIST	54	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	12
Cycle 6, Day 15	Yes	24SEP2018 (134)	CT Scan	Radiologist 1	50	-2.0	-21.9	mRECIST	50	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	11
Week 26	Yes	19NOV2018 (190)	CT Scan	Radiologist 1	51	2.0	-20.3	mRECIST	51	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	11
Subject ID: 0208-0002 Treatment Group: ADIPemPlatinum														
Screening	Yes	28AUG2018 (-7)	CT Scan	Radiologist 1	139			mRECIST	139	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	23
											PL005	PLEURA	Present Measurable	18
											PL006	PLEURA	Present Measurable	48
Cycle 2, Day 15	Yes	11OCT2018 (38)	CT Scan	Radiologist 1	149	7.2	7.2	mRECIST	149	Pleural	PL001	PLEURA	Present Measurable	19

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0208-0002 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	11OCT2018 (38)	CT Scan	Radiologist 1	149	7.2	7.2	mRECIST	149	Pleural	PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	21
											PL004	PLEURA	Present Measurable	27
											PL005	PLEURA	Present Measurable	21
											PL006	PLEURA	Present Measurable	52
Cycle 4, Day 15	Yes	21NOV2018 (79)	CT Scan	Radiologist 1	245	76.3	76.3	mRECIST	245	Pleural	PL001	PLEURA	Present Measurable	25
											PL002	PLEURA	Present Measurable	45
											PL003	PLEURA	Present Measurable	38
											PL004	PLEURA	Present Measurable	43
											PL005	PLEURA	Present Measurable	38
											PL006	PLEURA	Present Measurable	56
Subject ID: 0208-0003 Treatment Group: ADIPemPlatinum														
Screening	Yes	31OCT2018 (-14)	CT Scan	Radiologist 1	89			mRECIST	89	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	15
Cycle 2, Day 15	Yes	21DEC2018 (38)	CT Scan	Radiologist 1	124	39.3	39.3	mRECIST	124	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	21
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	22

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0208-0003 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	21DEC2018 (38)	CT Scan	Radiologist 1	124	39.3	39.3	mRECIST	124	Pleural	PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	21
Subject ID: 0208-0004 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	18MAR2019 (-9)	CT Scan	Radiologist 1	75			mRECIST	75	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	12
Cycle 2, Day 15	Yes	29APR2019 (34)	CT Scan	Radiologist 1	65	-13.3	-13.3	mRECIST	65	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	4
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	14
Cycle 4, Day 1	Yes	14JUN2019 (80)	CT Scan	Radiologist 1	73	12.3	-2.7	mRECIST	73	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	6
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	18
											PL006	PLEURA	Present Measurable	14
Cycle 6, Day 15	No													

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0208-0004 Treatment Group: PlaceboPemPlatinum														
Week 24	Yes	30JUL2019 (126)	CT Scan	Radiologist 1	80	23.1	6.7	mRECIST	80	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	14
Subject ID: 0208-0006 Treatment Group: ADIPemPlatinum														
Screening	Yes	10MAY2019 (-10)	CT Scan	Radiologist 1	86			mRECIST	86	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	25
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	No	03JUL2019 (45)	CT Scan	Radiologist 1	78	-9.3	-9.3	mRECIST	78	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	10
Cycle 4, Day 15	Yes	08AUG2019 (81)	CT Scan	Radiologist 1	72	-7.7	-16.3	mRECIST	72	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0208-0006 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	08AUG2019 (81)	CT Scan	Radiologist 1	72	-7.7	-16.3	mRECIST	72	Pleural	PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	21
											PL006	PLEURA	Present Measurable	9
Cycle 6, Day 15	Yes	25SEP2019 (129)	CT Scan	Radiologist 1	87	20.8	1.2	mRECIST	87	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	32
											PL006	PLEURA	Present Measurable	9
Subject ID: 0208-0007 Treatment Group: ADIPemPlatinum														
Screening	Yes	05JUL2019 (-5)	CT Scan	Radiologist 2	81			mRECIST	81	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	18
											PL006	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	22AUG2019 (44)	CT Scan	Radiologist 2	79	-2.5	-2.5	mRECIST	79	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	18
											PL006	PLEURA	Present Measurable	13

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0208-0008 Treatment Group: ADIPemPlatinum														
Screening	Yes	08OCT2019 (-8)	CT Scan	Radiologist 1	184			RECIST 1.1	41	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	18
											TN002	ABDOMINAL LYMPH NODE	Present Measurable	23
								mRECIST	143	Pleural	PL001	PLEURA	Present Measurable	35
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	24
											PL004	PLEURA	Present Measurable	26
											PL005	PLEURA	Present Measurable	30
											PL006	PLEURA	Present Measurable	16
Cycle 2, Day 15	Yes	22NOV2019 (38)	CT Scan	Radiologist 1	168	-8.7	-8.7	RECIST 1.1	37	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	19
											TN002	ABDOMINAL LYMPH NODE	Present Measurable	18
								mRECIST	131	Pleural	PL001	PLEURA	Present Measurable	30
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	26
											PL005	PLEURA	Present Measurable	26
											PL006	PLEURA	Present Measurable	20
Cycle 4, Day 15	No	03JAN2020 (80)	CT Scan	Radiologist 1	141	-16.1	-23.4	RECIST 1.1	27	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	12
											TN002	ABDOMINAL LYMPH NODE	Present Measurable	15

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0208-0008 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	No	03JAN2020 (80)	CT Scan	Radiologist 1	141	-16.1	-23.4	mRECIST	114	Pleural	PL001	PLEURA	Present Measurable	27
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	19
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	18
Cycle 6, Day 15	Yes	10FEB2020 (118)	CT Scan	Radiologist 1	139	-1.4	-24.5	RECIST 1.1	25	Nodal	TN001	MEDIASTINAL LYMPH NODE	Present Measurable	15
											TN002	ABDOMINAL LYMPH NODE	Present Measurable	10
								mRECIST	114	Pleural	PL001	PLEURA	Present Measurable	28
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	23
											PL006	PLEURA	Present Measurable	19
								mRECIST	77	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	11

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0209-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	13APR2018 (-11)	CT Scan	Radiologist 1	77			mRECIST	77	Pleural	PL006	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	31MAY2018 (38)	CT Scan	Radiologist 1	68	-11.7	-11.7	mRECIST	68	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	14
Cycle 4, Day 15	Yes	12JUL2018 (80)	CT Scan	Radiologist 1	70	2.9	-9.1	mRECIST	70	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	13
Cycle 6, Day 15	Yes	23AUG2018 (122)	CT Scan	Radiologist 1	68	0.0	-11.7	mRECIST	68	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	11
Week 24	Yes	18OCT2018 (178)	CT Scan	Radiologist 1	65	-4.4	-15.6	mRECIST	65	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0209-0001 Treatment Group: ADIPemPlatinum														
Week 24	Yes	18OCT2018 (178)	CT Scan	Radiologist 1	65	-4.4	-15.6	mRECIST	65	Pleural	PL006	PLEURA	Present Measurable	12
Week 34	Yes	13DEC2018 (234)	CT Scan	Radiologist 1	76	16.9	-1.3	mRECIST	76	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	13
Week 42	Yes	07FEB2019 (290)	CT Scan	Radiologist 1	89	36.9	15.6	mRECIST	89	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	20
											PL004	PLEURA	Present Measurable	18
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	17
Week 50	Yes	03APR2019 (345)	CT Scan	Radiologist 1	87	33.8	13.0	mRECIST	87	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	19
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	16
Subject ID: 0209-0003 Treatment Group: ADIPemPlatinum														
Screening	Yes	07MAR2019 (-12)	CT Scan	Radiologist 1	78			mRECIST	78	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	15

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0209-0003 Treatment Group: ADIPemPlatinum														
Screening	Yes	07MAR2019 (-12)	CT Scan	Radiologist 1	78			mRECIST	78	Pleural	PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	02MAY2019 (45)	CT Scan	Radiologist 1	60	-23.1	-23.1	mRECIST	60	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	7
Unscheduled	Yes	21MAY2019 (64)	CT Scan	Radiologist 1	66	10.0	-15.4	mRECIST	66	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	8
Subject ID: 0209-0004 Treatment Group: ADIPemPlatinum														
Screening	Yes	03SEP2019 (-29)	CT Scan	Radiologist 1	147			mRECIST	147	Pleural	PL001	PLEURA	Present Measurable	22
											PL002	PLEURA	Present Measurable	23
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	23
											PL005	PLEURA	Present Measurable	48

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0209-0004 Treatment Group: ADIPemPlatinum														
Screening	Yes	03SEP2019 (-29)	CT Scan	Radiologist 1	147			mRECIST	147	Pleural	PL006	PLEURA	Present Measurable	17
Cycle 2, Day 15	Yes	11NOV2019 (41)	CT Scan	Radiologist 1	125	-15.0	-15.0	mRECIST	125	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	18
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	44
											PL006	PLEURA	Present Measurable	16
Cycle 4, Day 15	Yes	23DEC2019 (83)	CT Scan	Radiologist 1	86	-31.2	-41.5	mRECIST	86	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	30
											PL006	PLEURA	Present Measurable	13
Cycle 6, Day 15	Yes	03FEB2020 (125)	CT Scan	Radiologist 1	61	-29.1	-58.5	mRECIST	61	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	4
											PL005	PLEURA	Present Measurable	26
											PL006	PLEURA	Present Measurable	12
Week 26	Yes	01APR2020 (183)	CT Scan	Radiologist 1	55	-9.8	-62.6	mRECIST	55	Pleural	PL001	PLEURA	Present Measurable	5
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	6
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	21

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0209-0004 Treatment Group: ADIPemPlatinum														
Week 26	Yes	01APR2020 (183)	CT Scan	Radiologist 1	55	-9.8	-62.6	mRECIST	55	Pleural	PL006	PLEURA	Present Measurable	10
Subject ID: 0209-0005 Treatment Group: ADIPemPlatinum														
Screening	Yes	10OCT2019 (-26)	CT Scan	Radiologist 2	163			mRECIST	163	Pleural	PL001	PLEURA	Present Measurable	22
											PL002	PLEURA	Present Measurable	22
											PL003	PLEURA	Present Measurable	24
											PL004	PLEURA	Present Measurable	28
											PL005	PLEURA	Present Measurable	30
											PL006	PLEURA	Present Measurable	37
Cycle 2, Day 15	Yes	13DEC2019 (39)	CT Scan	Radiologist 2	205	25.8	25.8	mRECIST	205	Pleural	PL001	PLEURA	Present Measurable	27
											PL002	PLEURA	Present Measurable	28
											PL003	PLEURA	Present Measurable	33
											PL004	PLEURA	Present Measurable	31
											PL005	PLEURA	Present Measurable	38
											PL006	PLEURA	Present Measurable	48
Subject ID: 0211-0001 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	06JUL2019 (-11)	CT Scan	Radiologist 1	113			mRECIST	113	Pleural	PL001	PLEURA	Present Measurable	22
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	22
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	24

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0211-0001 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	06JUL2019 (-11)	CT Scan	Radiologist 1	113			mRECIST	113	Pleural	PL006	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	23AUG2019 (38)	CT Scan	Radiologist 1	105	-7.1	-7.1	mRECIST	105	Pleural	PL001	PLEURA	Present Measurable	25
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	20
											PL006	PLEURA	Present Measurable	13
Cycle 4, Day 1	Yes	04OCT2019 (80)	CT Scan	Radiologist 1	91	-13.3	-19.5	mRECIST	91	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	21
											PL006	PLEURA	Present Measurable	10
Cycle 6, Day 15	Yes	15NOV2019 (122)	CT Scan	Radiologist 1	100	9.9	-11.5	mRECIST	100	Pleural	PL001	PLEURA	Present Measurable	25
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	22
											PL006	PLEURA	Present Measurable	13
Week 26	Yes	09JAN2020 (177)	CT Scan	Radiologist 1	131	44.0	15.9	mRECIST	131	Pleural	PL001	PLEURA	Present Measurable	33
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	29
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	24

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0211-0001 Treatment Group: PlaceboPemPlatinum														
Week 26	Yes	09JAN2020 (177)	CT Scan	Radiologist 1	131	44.0	15.9	mRECIST	131	Pleural	PL006	PLEURA	Present Measurable	17
Subject ID: 0211-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	06JUL2019 (-32)	CT Scan	Radiologist 1	111			mRECIST	111	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	26
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	23
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	26
Cycle 2, Day 15	Yes	05AUG2019 (-2)	CT Scan	Radiologist 1	126	13.5	13.5	mRECIST	126	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	26
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	30
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	30
Cycle 4, Day 1	Yes	13SEP2019 (38)	CT Scan	Radiologist 1	118	6.3	6.3	mRECIST	118	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	29
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	28
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	24

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0211-0003 Treatment Group: ADIPemPlatinum														
Screening	Yes	20SEP2019 (-12)	CT Scan	Radiologist 1	69			mRECIST	69	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	10
Cycle 2, Day 15	Yes	07NOV2019 (37)	CT Scan	Radiologist 1	62	-10.1	-10.1	mRECIST	62	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	8
Cycle 4, Day 15	Yes	19DEC2019 (79)	CT Scan	Radiologist 1	59	-4.8	-14.5	mRECIST	59	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	9
											PL006	PLEURA	Present Measurable	9
Cycle 6, Day 15	Yes	05FEB2020 (127)	CT Scan	Radiologist 1	54	-8.5	-21.7	mRECIST	54	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	8
											PL006	PLEURA	Present Measurable	8

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0211-0004 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	04OCT2019 (-12)	CT Scan	Radiologist 1	114			RECIST 1.1	21	Nodal	TN001	CELIAC LYMPH NODE	Present Measurable	21
								mRECIST	93	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	22NOV2019 (38)	CT Scan	Radiologist 1	94	-17.5	-17.5	RECIST 1.1	23	Nodal	TN001	CELIAC LYMPH NODE	Present Measurable	23
								mRECIST	71	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	10
Cycle 4, Day 15	Yes	03JAN2020 (80)	CT Scan	Radiologist 1	64	-31.9	-43.9	RECIST 1.1	11	Nodal	TN001	CELIAC LYMPH NODE	Present Measurable	11
								mRECIST	53	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	4
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	6
											PL006	PLEURA	Present Measurable	6

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0211-0004 Treatment Group: PlaceboPemPlatinum														
Cycle 6, Day 15	Yes	14FEB2020 (122)	CT Scan	Radiologist 1	68	6.3	-40.4	RECIST 1.1	12	Nodal	TN001	CELIAC LYMPH NODE	Present Measurable	12
								mRECIST	56	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	5
											PL006	PLEURA	Present Measurable	8
Subject ID: 0211-0005 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	17OCT2019 (-20)	CT Scan	Radiologist 1	143			mRECIST	143	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	30
											PL005	PLEURA	Present Measurable	23
											PL006	PLEURA	Present Measurable	39
Cycle 2, Day 15	Yes	16DEC2019 (41)	CT Scan	Radiologist 1	172	20.3	20.3	mRECIST	172	Pleural	PL001	PLEURA	Present Measurable	23
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	35
											PL005	PLEURA	Present Measurable	29
											PL006	PLEURA	Present Measurable	50
Cycle 4, Day 15	Yes	14JAN2020 (70)	CT Scan	Radiologist 1	194	35.7	35.7	mRECIST	194	Pleural	PL001	PLEURA	Present Measurable	22

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0211-0005 Treatment Group: PlaceboPemPlatinum														
Cycle 4, Day 15	Yes	14JAN2020 (70)	CT Scan	Radiologist 1	194	35.7	35.7	mRECIST	194	Pleural	PL002	PLEURA	Present Measurable	24
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	45
											PL005	PLEURA	Present Measurable	31
											PL006	PLEURA	Present Measurable	56
Subject ID: 0212-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	30JUL2018 (-15)	CT Scan	Radiologist 1	64			mRECIST	64	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	25SEP2018 (43)	CT Scan	Radiologist 1	53	-17.2	-17.2	mRECIST	53	Pleural	PL006	PLEURA	Present Measurable	10
											PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	7
Cycle 4, Day 15	Yes	06NOV2018 (85)	CT Scan	Radiologist 1	56	5.7	-12.5	mRECIST	56	Pleural	PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	7
											PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	7

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0212-0001 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	06NOV2018 (85)	CT Scan	Radiologist 1	56	5.7	-12.5	mRECIST	56	Pleural	PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	9
Cycle 6, Day 15	Yes	17DEC2018 (126)	CT Scan	Radiologist 1	59	11.3	-7.8	mRECIST	59	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	10
Week 26	Yes	11FEB2019 (182)	CT Scan	Radiologist 1	60	13.2	-6.3	mRECIST	60	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	8
Subject ID: 0212-0002 Treatment Group: ADIPemPlatinum														
Screening	Yes	14SEP2018 (-18)	CT Scan	Radiologist 2	83			mRECIST	83	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	06NOV2018 (36)	CT Scan	Radiologist 2	67	-19.3	-19.3	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	8

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0212-0002 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	06NOV2018 (36)	CT Scan	Radiologist 2	67	-19.3	-19.3	mRECIST	67	Pleural	PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	4
Unscheduled	Yes	04DEC2018 (64)	CT Scan	Radiologist 2	63	-6.0	-24.1	mRECIST	63	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	4
Subject ID: 0212-0003 Treatment Group: ADIPemPlatinum														
Screening	Yes	01OCT2018 (-9)	CT Scan	Radiologist 1	131			mRECIST	131	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	19
											PL003	PLEURA	Present Measurable	22
											PL004	PLEURA	Present Measurable	24
											PL005	PLEURA	Present Measurable	21
Cycle 2, Day 15	Yes	14NOV2018 (36)	CT Scan	Radiologist 1	125	-4.6	-4.6	mRECIST	125	Pleural	PL006	PLEURA	Present Measurable	28
											PL001	PLEURA	Present Measurable	19
											PL002	PLEURA	Present Measurable	21
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	19

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0212-0003 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	14NOV2018 (36)	CT Scan	Radiologist 1	125	-4.6	-4.6	mRECIST	125	Pleural	PL005	PLEURA	Present Measurable	27
											PL006	PLEURA	Present Measurable	22
Subject ID: 0212-0004 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	07JAN2019 (-9)	CT Scan	Radiologist 1	212			mRECIST	212	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	41
											PL005	PLEURA	Present Measurable	58
											PL006	PLEURA	Present Measurable	76
Cycle 2, Day 15	Yes	20FEB2019 (36)	CT Scan	Radiologist 1	190	-10.4	-10.4	mRECIST	190	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	35
											PL005	PLEURA	Present Measurable	55
											PL006	PLEURA	Present Measurable	64
Cycle 4, Day 15	Yes	27MAR2019 (71)	CT Scan	Radiologist 1	176	-7.4	-17.0	mRECIST	176	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	42
											PL005	PLEURA	Present Measurable	50
											PL006	PLEURA	Present Measurable	57
Cycle 6, Day 15	Yes	16MAY2019 (121)	CT Scan	Radiologist 1	201	14.2	-5.2	mRECIST	201	Pleural	PL001	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0212-0004 Treatment Group: PlaceboPemPlatinum														
Cycle 6, Day 15	Yes	16MAY2019 (121)	CT Scan	Radiologist 1	201	14.2	-5.2	mRECIST	201	Pleural	PL002	PLEURA	Present Measurable	4
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	38
											PL005	PLEURA	Present Measurable	56
											PL006	PLEURA	Present Measurable	75
Week 26	Yes	24JUN2019 (160)	CT Scan	Radiologist 1	262	48.9	23.6	mRECIST	262	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	25
											PL004	PLEURA	Present Measurable	46
											PL005	PLEURA	Present Measurable	80
											PL006	PLEURA	Present Measurable	96
Subject ID: 0212-0005 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	13MAR2019 (-14)	CT Scan	Radiologist 1	81			mRECIST	81	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	16
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	02MAY2019 (37)	CT Scan	Radiologist 1	55	-32.1	-32.1	mRECIST	55	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	5
											PL004	PLEURA	Present Measurable	5

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0212-0005 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	02MAY2019 (37)	CT Scan	Radiologist 1	55	-32.1	-32.1	mRECIST	55	Pleural	PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	7
Unscheduled	Yes	30MAY2019 (65)	CT Scan	Radiologist 1	67	21.8	-17.3	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	7
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	18
											PL006	PLEURA	Present Measurable	11
Subject ID: 0212-0006 Treatment Group: ADIPemPlatinum														
Screening	Yes	02JUL2019 (-15)	CT Scan	Radiologist 1	45			mRECIST	45	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	11
Cycle 2, Day 15	No	21AUG2019 (36)	CT Scan	Radiologist 1	45	0.0	0.0	mRECIST	45	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	8
Cycle 4, Day 15	Yes	09OCT2019 (85)	CT Scan	Radiologist 1	33	-26.7	-26.7	mRECIST	33	Pleural	PL001	PLEURA	Present Measurable	8
											PL002	PLEURA	Present Measurable	8
											PL003	PLEURA	Present Measurable	9
											PL004	PLEURA	Present Measurable	8
Cycle 6, Day 15	Yes	06NOV2019 (113)	CT Scan	Radiologist 1	38	15.2	-15.6	mRECIST	38	Pleural	PL001	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0212-0006 Treatment Group: ADIPemPlatinum														
Cycle 6, Day 15	Yes	06NOV2019 (113)	CT Scan	Radiologist 1	38	15.2	-15.6	mRECIST	38	Pleural	PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	9
Week 26	Yes	06JAN2020 (174)	CT Scan	Radiologist 1	33	0.0	-26.7	mRECIST	33	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	9
Week 30	Yes	26FEB2020 (225)	CT Scan	Radiologist 1	38	15.2	-15.6	mRECIST	38	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	8
Subject ID: 0212-0007 Treatment Group: ADIPemPlatinum														
Screening	Yes	19JUL2019 (-10)	CT Scan	Radiologist 1	86			mRECIST	86	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	03SEP2019 (37)	CT Scan	Radiologist 1	75	-12.8	-12.8	mRECIST	75	Pleural	PL001	PLEURA	Present Measurable	19
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0212-0007 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	03SEP2019 (37)	CT Scan	Radiologist 1	75	-12.8	-12.8	mRECIST	75	Pleural	PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	11
Cycle 4, Day 15	Yes	14OCT2019 (78)	CT Scan	Radiologist 1	71	-5.3	-17.4	mRECIST	71	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	5
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	14
Cycle 6, Day 15	Yes	25NOV2019 (120)	CT Scan	Radiologist 1	91	28.2	5.8	mRECIST	91	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	4
											PL005	PLEURA	Present Measurable	24
											PL006	PLEURA	Present Measurable	18
Subject ID: 0212-0008 Treatment Group: ADIPemPlatinum														
Screening	Yes	22JUL2019 (-14)	CT Scan	Radiologist 1	98			mRECIST	98	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	24
											PL006	PLEURA	Present Measurable	21
Cycle 2, Day 15	Yes	09SEP2019 (36)	CT Scan	Radiologist 1	135	37.8	37.8	mRECIST	135	Pleural	PL001	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0212-0008 Treatment Group: ADIPemPlatinum														
Cycle 2, Day 15	Yes	09SEP2019 (36)	CT Scan	Radiologist 1	135	37.8	37.8	mRECIST	135	Pleural	PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	11
											PL004	PLEURA	Present Measurable	23
											PL005	PLEURA	Present Measurable	38
											PL006	PLEURA	Present Measurable	38
Subject ID: 0301-0001 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	04DEC2018 (-13)	CT Scan	Radiologist 1	129			mRECIST	129	Pleural	PL001	PLEURA	Present Measurable	19
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	48
											PL006	PLEURA	Present Measurable	16
Cycle 2, Day 15	Yes	23JAN2019 (38)	CT Scan	Radiologist 1	147	14.0	14.0	mRECIST	147	Pleural	PL001	PLEURA	Present Measurable	24
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	20
											PL004	PLEURA	Present Measurable	20
											PL005	PLEURA	Present Measurable	51
											PL006	PLEURA	Present Measurable	20
Subject ID: 0301-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	04DEC2018 (-13)	CT Scan	Radiologist 1	84			mRECIST	84	Pleural	PL001	PLEURA	Present Measurable	22

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0301-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	04DEC2018 (-13)	CT Scan	Radiologist 1	84			mRECIST	84	Pleural	PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	23JAN2019 (38)	CT Scan	Radiologist 1	89	6.0	6.0	mRECIST	89	Pleural	PL001	PLEURA	Present Measurable	23
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	14
Cycle 4, Day 15	Yes	07MAR2019 (81)	CT Scan	Radiologist 1	88	4.8	4.8	mRECIST	88	Pleural	PL001	PLEURA	Present Measurable	22
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	15
Cycle 6, Day 15	Yes	17APR2019 (122)	CT Scan	Radiologist 1	90	7.1	7.1	mRECIST	90	Pleural	PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	14
Week 26	Yes	28MAY2019 (163)	CT Scan	Radiologist 1	93	10.7	10.7	mRECIST	93	Pleural	PL001	PLEURA	Present Measurable	20

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0301-0002 Treatment Group: PlaceboPemPlatinum														
Week 26	Yes	28MAY2019 (163)	CT Scan	Radiologist 1	93	10.7	10.7	mRECIST	93	Pleural	PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	17
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	14
Week 34	Yes	30JUL2019 (226)	CT Scan	Radiologist 1	103	22.6	22.6	mRECIST	103	Pleural	PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	19
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	19
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	15
Subject ID: 0301-0003 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	16JAN2019 (-13)	CT Scan	Radiologist 1	217			RECIST 1.1	63	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	29
										Non-Nodal	T001	ADRENAL GLAND	Present Measurable	34
								mRECIST	154	Pleural	PL001	PLEURA	Present Measurable	31
											PL002	PLEURA	Present Measurable	40
											PL003	PLEURA	Present Measurable	31
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	21
											PL006	PLEURA	Present Measurable	17

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0301-0003 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	06MAR2019 (37)	CT Scan	Radiologist 1	259	19.4	19.4	RECIST 1.1	75	Nodal	TN001	PERICARDIAL LYMPH NODE	Present Measurable	35
										Non-Nodal	T001	ADRENAL GLAND	Present Measurable	40
								mRECIST	184	Pleural	PL001	PLEURA	Present Measurable	36
											PL002	PLEURA	Present Measurable	49
											PL003	PLEURA	Present Measurable	30
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	27
											PL006	PLEURA	Present Measurable	29
Subject ID: 0301-0004 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	27FEB2019 (-13)	CT Scan	Radiologist 1	133			RECIST 1.1	133	Non-Nodal	T001	PLEURA	Present Measurable	133
Cycle 2, Day 15	Yes	17APR2019 (37)	CT Scan	Radiologist 1	133	0.0	0.0	RECIST 1.1	133	Non-Nodal	T001	PLEURA	Present Measurable	133
Cycle 4, Day 15	Yes	29MAY2019 (79)	CT Scan	Radiologist 1	136	2.3	2.3	RECIST 1.1	136	Non-Nodal	T001	PLEURA	Present Measurable	136
Subject ID: 0301-0005 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	17JUN2019 (-15)	CT Scan	Radiologist 1	33			mRECIST	33	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	21
Cycle 2, Day 15	Yes	07AUG2019 (37)	CT Scan	Radiologist 1	29	-12.1	-12.1	mRECIST	29	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	18
Cycle 4, Day 15	Yes	18SEP2019 (79)	CT Scan	Radiologist 1	25	-13.8	-24.2	mRECIST	25	Pleural	PL001	PLEURA	Present Measurable	9

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0301-0005 Treatment Group: PlaceboPemPlatinum														
Cycle 4, Day 15	Yes	18SEP2019 (79)	CT Scan	Radiologist 1	25	-13.8	-24.2	mRECIST	25	Pleural	PL002	PLEURA	Present Measurable	16
Cycle 6, Day 15	Yes	29OCT2019 (120)	CT Scan	Radiologist 1	24	-4.0	-27.3	mRECIST	24	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	17
Week 26	Yes	17DEC2019 (169)	CT Scan	Radiologist 1	25	4.2	-24.2	mRECIST	25	Pleural	PL001	PLEURA	Present Measurable	6
											PL002	PLEURA	Present Measurable	19
Subject ID: 0301-0006 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	03JUL2019 (-20)	CT Scan	Radiologist 1	92			RECIST 1.1	16	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	16
								mRECIST	76	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	10
Cycle 2, Day 15	Yes	28AUG2019 (37)	CT Scan	Radiologist 1	86	-6.5	-6.5	RECIST 1.1	12	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	12
								mRECIST	74	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	16
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0301-0006 Treatment Group: PlaceboPemPlatinum														
Cycle 4, Day 15	Yes	02OCT2019 (72)	CT Scan	Radiologist 1	95	10.5	3.3	RECIST 1.1	13	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	13
								mRECIST	82	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	13
											PL003	PLEURA	Present Measurable	16
											PL004	PLEURA	Present Measurable	13
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	10
Cycle 6, Day 15	Yes	19NOV2019 (120)	CT Scan	Radiologist 1	86	0.0	-6.5	RECIST 1.1	15	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	15
								mRECIST	71	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	9
Week 26	Yes	14JAN2020 (176)	CT Scan	Radiologist 1	91	5.8	-1.1	RECIST 1.1	16	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	16
								mRECIST	75	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	10

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0301-0006 Treatment Group: PlaceboPemPlatinum														
Week 34	Yes	25FEB2020 (218)	CT Scan	Radiologist 1	99	15.1	7.6	RECIST 1.1	14	Nodal	TN001	SUBCARINAL LYMPH NODE	Present Measurable	14
								mRECIST	85	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	10
Subject ID: 0301-0007 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	01OCT2019 (-14)	CT Scan	Radiologist 1	76			mRECIST	76	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	13
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	20NOV2019 (37)	CT Scan	Radiologist 1	70	-7.9	-7.9	mRECIST	70	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	30DEC2019 (77)	CT Scan	Radiologist 1	77	10.0	1.3	mRECIST	77	Pleural	PL001	PLEURA	Present Measurable	13

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0301-0007 Treatment Group: PlaceboPemPlatinum														
Cycle 4, Day 15	Yes	30DEC2019 (77)	CT Scan	Radiologist 1	77	10.0	1.3	mRECIST	77	Pleural	PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	12
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	14
											PL006	PLEURA	Present Measurable	15
Cycle 6, Day 15	Yes	12FEB2020 (121)	CT Scan	Radiologist 1	83	18.6	9.2	mRECIST	83	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	15
											PL006	PLEURA	Present Measurable	14
Subject ID: 0305-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	05JUL2018 (-25)	CT Scan	Radiologist 2	25			mRECIST	25	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	31AUG2018 (33)	CT Scan	Radiologist 2	23	-8.0	-8.0	mRECIST	23	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	10
Cycle 4, Day 15	Yes	12OCT2018 (75)	CT Scan	Radiologist 2	23	0.0	-8.0	mRECIST	23	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	9
Cycle 6, Day 15	Yes	21NOV2018 (115)	CT Scan	Radiologist 2	26	13.0	4.0	mRECIST	26	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	11
Week 26	Yes	21JAN2019 (176)	CT Scan	Radiologist 2	26	13.0	4.0	mRECIST	26	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	12

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0305-0001 Treatment Group: ADIPemPlatinum														
Week 34	Yes	18MAR2019 (232)	CT Scan	Radiologist 2	24	4.3	-4.0	mRECIST	24	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	12
Subject ID: 0305-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	11JUN2019 (-13)	CT Scan	Radiologist 1	48			mRECIST	48	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	10
Cycle 2, Day 15	Yes	29JUL2019 (36)	CT Scan	Radiologist 1	131	172.9	172.9	mRECIST	131	Pleural	PL001	PLEURA	Present Measurable	44
											PL002	PLEURA	Present Measurable	41
											PL003	PLEURA	Present Measurable	25
											PL004	PLEURA	Present Measurable	21
Subject ID: 0502-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	13SEP2019 (-19)	CT Scan	Radiologist 1	77			mRECIST	77	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	42
Cycle 2, Day 15	Yes	13NOV2019 (43)	CT Scan	Radiologist 1	57	-26.0	-26.0	mRECIST	57	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	32
Cycle 4, Day 15	Yes	23DEC2019 (83)	CT Scan	Radiologist 1	54	-5.3	-29.9	mRECIST	54	Pleural	PL001	PLEURA	Present Measurable	11
											PL002	PLEURA	Present Measurable	8

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0502-0001 Treatment Group: ADIPemPlatinum														
Cycle 4, Day 15	Yes	23DEC2019 (83)	CT Scan	Radiologist 1	54	-5.3	-29.9	mRECIST	54	Pleural	PL003	PLEURA	Present Measurable	35
Cycle 6, Day 15	Yes	03FEB2020 (125)	CT Scan	Radiologist 1	50	-7.4	-35.1	mRECIST	50	Pleural	PL001	PLEURA	Present Measurable	9
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	34
Week 26	Yes	30MAR2020 (181)	CT Scan	Radiologist 1	63	26.0	-18.2	mRECIST	63	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	39
Subject ID: 0502-0002 Treatment Group: ADIPemPlatinum														
Screening	Yes	27SEP2019 (-24)	CT Scan	Radiologist 2	12			mRECIST	12	Pleural	PL001	PLEURA	Present Measurable	12
Cycle 2, Day 15	Yes	27NOV2019 (38)	CT Scan	Radiologist 2	10	-16.7	-16.7	mRECIST	10	Pleural	PL001	PLEURA	Present Measurable	10
Cycle 4, Day 1	Yes	08JAN2020 (80)	CT Scan	Radiologist 2	10	0.0	-16.7	mRECIST	10	Pleural	PL001	PLEURA	Present Measurable	10
Cycle 6, Day 15	Yes	05FEB2020 (108)	CT Scan	Radiologist 2	11	10.0	-8.3	mRECIST	11	Pleural	PL001	PLEURA	Present Measurable	11
Week 26	Yes	01APR2020 (164)	CT Scan	Radiologist 2	11	10.0	-8.3	mRECIST	11	Pleural	PL001	PLEURA	Present Measurable	11
Subject ID: 0503-0001 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	02MAY2019 (-25)	CT Scan	Radiologist 1	204			RECIST 1.1	99	Non-Nodal	T001	DIAPHRAGM	Present Measurable	99
								mRECIST	105	Pleural	PL001	PLEURA	Present Measurable	20
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	13
											PL004	PLEURA	Present Measurable	19
											PL005	PLEURA	Present Measurable	23

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0503-0001 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	02MAY2019 (-25)	CT Scan	Radiologist 1	204			mRECIST	105	Pleural	PL006	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	16JUL2019 (51)	CT Scan	Radiologist 1	200	-2.0	-2.0	RECIST 1.1	92	Non-Nodal	T001	DIAPHRAGM	Present Measurable	92
								mRECIST	108	Pleural	PL001	PLEURA	Present Measurable	17
											PL002	PLEURA	Present Measurable	12
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	23
											PL005	PLEURA	Present Measurable	28
											PL006	PLEURA	Present Measurable	13
Subject ID: 0506-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	10MAY2019 (-28)	CT Scan	Radiologist 1	97			mRECIST	97	Pleural	PL001	PLEURA	Present Measurable	16
											PL002	PLEURA	Present Measurable	15
											PL003	PLEURA	Present Measurable	31
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	12
											PL006	PLEURA	Present Measurable	12
Cycle 2, Day 15	Yes	17JUL2019 (41)	CT Scan	Radiologist 1	69	-28.9	-28.9	mRECIST	69	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	14
											PL003	PLEURA	Present Measurable	14
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	11
											PL006	PLEURA	Present Measurable	8

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0506-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	13JUN2019 (-4)	CT Scan	Radiologist 2	122			mRECIST	122	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	15
											PL005	PLEURA	Present Measurable	39
											PL006	PLEURA	Present Measurable	17
Cycle 2, Day 15	Yes	31JUL2019 (45)	CT Scan	Radiologist 2	84	-31.1	-31.1	mRECIST	84	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	15
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	29
											PL006	PLEURA	Present Measurable	11
Cycle 4, Day 15	Yes	18SEP2019 (94)	CT Scan	Radiologist 2	63	-25.0	-48.4	mRECIST	63	Pleural	PL001	PLEURA	Present Measurable	4
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	18
											PL006	PLEURA	Present Measurable	12
Cycle 6, Day 15	No	30OCT2019 (136)	CT Scan	Radiologist 2	67	6.3	-45.1	mRECIST	67	Pleural	PL001	PLEURA	Present Measurable	7
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	12
											PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	14

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0506-0002 Treatment Group: PlaceboPemPlatinum														
Week 26	Yes	18DEC2019 (185)	CT Scan	Radiologist 2	59	-6.3	-51.6	mRECIST	59	Pleural	PL001	PLEURA	Present Measurable	4
											PL002	PLEURA	Present Measurable	6
											PL003	PLEURA	Present Measurable	10
											PL004	PLEURA	Present Measurable	6
											PL005	PLEURA	Present Measurable	21
											PL006	PLEURA	Present Measurable	12
Week 34	Yes	12FEB2020 (241)	CT Scan	Radiologist 2	59	0.0	-51.6	mRECIST	59	Pleural	PL001	PLEURA	Present Measurable	4
											PL002	PLEURA	Present Measurable	5
											PL003	PLEURA	Present Measurable	8
											PL004	PLEURA	Present Measurable	7
											PL005	PLEURA	Present Measurable	19
											PL006	PLEURA	Present Measurable	16
Subject ID: 0509-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	08SEP2018 (-10)	Spiral	Radiologist 1	207			mRECIST	207	Pleural	PL001	PLEURA	Present Measurable	29
											PL002	PLEURA	Present Measurable	26
											PL003	PLEURA	Present Measurable	32
											PL004	PLEURA	Present Measurable	37
											PL005	PLEURA	Present Measurable	38
											PL006	PLEURA	Present Measurable	45
Cycle 2, Day 15	Yes	03NOV2018 (47)	Spiral	Radiologist 1	202	-2.4	-2.4	mRECIST	202	Pleural	PL001	PLEURA	Present Measurable	29
											PL002	PLEURA	Present Measurable	27
											PL003	PLEURA	Present Measurable	26

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0509-0002 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	03NOV2018 (47)	Spiral	Radiologist 1	202	-2.4	-2.4	mRECIST	202	Pleural	PL004	PLEURA	Present Measurable	42
											PL005	PLEURA	Present Measurable	37
											PL006	PLEURA	Present Measurable	41
Cycle 4, Day 15	Yes	15DEC2018 (89)	Spiral	Radiologist 1	276	36.6	33.3	mRECIST	276	Pleural	PL001	PLEURA	Present Measurable	43
											PL002	PLEURA	Present Measurable	39
											PL003	PLEURA	Present Measurable	50
											PL004	PLEURA	Present Measurable	47
											PL005	PLEURA	Present Measurable	43
											PL006	PLEURA	Present Measurable	54
Subject ID: 0511-0001 Treatment Group: ADIPemPlatinum														
Screening	Yes	22MAR2019 (-18)	CT Scan	Radiologist 2	38			RECIST 1.1	38	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	18
											TN002	LYMPH NODE HILUM	Present Measurable	20
Cycle 2, Day 15	Yes	21MAY2019 (43)	CT Scan	Radiologist 2	26	-31.6	-31.6	RECIST 1.1	26	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	14
											TN002	LYMPH NODE HILUM	Present Measurable	12
Cycle 4, Day 15	Yes	04JUL2019 (87)	CT Scan	Radiologist 2	25	-3.8	-34.2	RECIST 1.1	25	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	12
											TN002	LYMPH NODE HILUM	Present Measurable	13

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0511-0001 Treatment Group: ADIPemPlatinum														
Cycle 6, Day 15	Yes	19AUG2019 (133)	CT Scan	Radiologist 2	22	-12.0	-42.1	RECIST 1.1	22	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	11
											TN002	LYMPH NODE HILUM	Present Measurable	11
Unscheduled	Yes	27SEP2019 (172)	CT Scan	Radiologist 2	25	13.6	-34.2	RECIST 1.1	25	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	12
											TN002	LYMPH NODE HILUM	Present Measurable	13
Week 32	Yes	22NOV2019 (228)	CT Scan	Radiologist 2	23	4.5	-39.5	RECIST 1.1	23	Nodal	TN001	LYMPH NODE HILUM	Present Measurable	11
											TN002	LYMPH NODE HILUM	Present Measurable	12
Subject ID: 0511-0002 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	02MAY2019 (-12)	CT Scan	Radiologist 1	104			mRECIST	104	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	17
											PL003	PLEURA	Present Measurable	18
											PL004	PLEURA	Present Measurable	14
											PL005	PLEURA	Present Measurable	25
											PL006	PLEURA	Present Measurable	15
Cycle 2, Day 15	Yes	20JUN2019 (38)	CT Scan	Radiologist 1	102	-1.9	-1.9	mRECIST	102	Pleural	PL001	PLEURA	Present Measurable	21
											PL002	PLEURA	Present Measurable	10
											PL003	PLEURA	Present Measurable	22

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0511-0002 Treatment Group: PlaceboPemPlatinum														
Cycle 2, Day 15	Yes	20JUN2019 (38)	CT Scan	Radiologist 1	102	-1.9	-1.9	mRECIST	102	Pleural	PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	28
											PL006	PLEURA	Present Measurable	12
Cycle 4, Day 15	Yes	02AUG2019 (81)	CT Scan	Radiologist 1	115	12.7	10.6	mRECIST	115	Pleural	PL001	PLEURA	Present Measurable	18
											PL002	PLEURA	Present Measurable	20
											PL003	PLEURA	Present Measurable	30
											PL004	PLEURA	Present Measurable	10
											PL005	PLEURA	Present Measurable	23
											PL006	PLEURA	Present Measurable	14
Subject ID: 0511-0003 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	05AUG2019 (-1)	CT Scan	Radiologist 1	87			mRECIST	87	Pleural	PL001	PLEURA	Present Measurable	15
											PL002	PLEURA	Present Measurable	11
											PL003	PLEURA	Present Measurable	17
											PL004	PLEURA	Present Measurable	11
											PL005	PLEURA	Present Measurable	22
											PL006	PLEURA	Present Measurable	11
Cycle 2, Day 15	Yes	17SEP2019 (43)	CT Scan	Radiologist 1	79	-9.2	-9.2	mRECIST	79	Pleural	PL001	PLEURA	Present Measurable	14
											PL002	PLEURA	Present Measurable	9
											PL003	PLEURA	Present Measurable	19
											PL004	PLEURA	Present Measurable	8
											PL005	PLEURA	Present Measurable	16
											PL006	PLEURA	Present Measurable	13

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 0511-0003 Treatment Group: PlaceboPemPlatinum														
Cycle 4, Day 15	Yes	24OCT2019 (80)	CT Scan	Radiologist 1	77	-2.5	-11.5	mRECIST	77	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	7
											PL003	PLEURA	Present Measurable	25
											PL004	PLEURA	Present Measurable	9
											PL005	PLEURA	Present Measurable	10
											PL006	PLEURA	Present Measurable	14
Subject ID: 1201-0001 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	18OCT2018 (-13)	CT Scan	Radiologist 1	24			mRECIST	24	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	14
Cycle 2, Day 15	Yes	07DEC2018 (38)	CT Scan	Radiologist 1	26	8.3	8.3	mRECIST	26	Pleural	PL001	PLEURA	Present Measurable	12
											PL002	PLEURA	Present Measurable	14
Cycle 4, Day 15	Yes	18JAN2019 (80)	CT Scan	Radiologist 1	24	0.0	0.0	mRECIST	24	Pleural	PL001	PLEURA	Present Measurable	10
											PL002	PLEURA	Present Measurable	14
Subject ID: 1206-0001 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	28JAN2018 (-9)	CT Scan	Radiologist 1	63			RECIST 1.1	34	Nodal	TN001	PARATRACHE AL LYMPH NODE	Present Measurable	18
											TN002	PERICARDIAL LYMPH NODE	Present Measurable	16
								mRECIST	29	Pleural	PL001	PLEURA	Present Measurable	16

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 1206-0001 Treatment Group: PlaceboPemPlatinum														
Screening	Yes	28JAN2018 (-9)	CT Scan	Radiologist 1	63			mRECIST	29	Pleural	PL002	PLEURA	Present Measurable	13
Cycle 2, Day 15	Yes	15MAR2018 (38)	CT Scan	Radiologist 1	47	-25.4	-25.4	RECIST 1.1	27	Nodal	TN001	PARATRACHE AL LYMPH NODE	Present Measurable	16
								mRECIST	20	Pleural	PL001	PERICARDIAL LYMPH NODE	Present Measurable	11
								mRECIST	16	Pleural	PL001	PERICARDIAL LYMPH NODE	Present Measurable	11
Cycle 4, Day 15	Yes	25APR2018 (79)	CT Scan	Radiologist 1	39	-17.0	-38.1	RECIST 1.1	23	Nodal	PL002	PLEURA	Present Measurable	9
								mRECIST	16	Pleural	TN001	PARATRACHE AL LYMPH NODE	Present Measurable	12
								mRECIST	16	Pleural	TN002	PERICARDIAL LYMPH NODE	Present Measurable	11
								mRECIST	16	Pleural	PL001	PERICARDIAL LYMPH NODE	Present Measurable	8
								mRECIST	16	Pleural	PL002	PERICARDIAL LYMPH NODE	Present Measurable	8
Cycle 6, Day 15	No													
Unscheduled	Yes	20MAY2018 (104)	CT Scan	Radiologist 1	39	0.0	-38.1	RECIST 1.1	21	Nodal	TN001	PARATRACHE AL LYMPH NODE	Present Measurable	12
								mRECIST	18	Pleural	TN002	PERICARDIAL LYMPH NODE	Present Measurable	9
								mRECIST	18	Pleural	PL001	PERICARDIAL LYMPH NODE	Present Measurable	11
								mRECIST	18	Pleural	PL002	PERICARDIAL LYMPH NODE	Present Measurable	7

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.3
Target Lesions - Phase 2 Subjects

Visit	Scan Done?	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Total Sum of Diameters (mm)	% Change from Nadir	% Change from Baseline	Assessment	Sum of Diameter (mm)	Lesion Type	Lesion ID	Location	Tumor State	Diameter ^[2] (mm)
Subject ID: 1206-0001 Treatment Group: PlaceboPemPlatinum														
Unscheduled	Yes	09JUL2018 (154)	CT Scan	Radiologist 1	54	38.5	-14.3	RECIST 1.1	32	Nodal	TN001	PARATRACHE AL LYMPH NODE	Present Measurable	23
											TN002	PERICARDIAL LYMPH NODE	Present Measurable	9
								mRECIST	22	Pleural	PL001	PLEURA	Present Measurable	13
											PL002	PLEURA	Present Measurable	9

Abbreviations: CT = computed tomography; mRECIST = modified Response Evaluation Criteria in Solid Tumors; MRI = magnetic resonance imaging;
RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Percent change from nadir and baseline are calculated after the first assessment.

^[1] Time (days) relative to date of first dose of study drug

^[2] Diameter is based on the longest diameter for non-nodal lesions and on the short axis for nodal and pleural lesions.

Listing 16.2.6.4
Non Target Lesions - Phase 2 Subjects

Subject ID	Treatment Group	Visit	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Lesion Type	Lesion ID	Location	Tumor State
0101-0004	ADIPemPlatinum	Screening	03MAY2018 (-11)	CT Scan	Radiologist 2	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	20JUN2018 (38)	CT Scan	Radiologist 2	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	01AUG2018 (80)	CT Scan	Radiologist 2	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 6, Day 15	14SEP2018 (124)	CT Scan	Radiologist 2	Non-Nodal	NT001	PLEURA	Present Stable
		Week 26	07NOV2018 (178)	CT Scan	Radiologist 2	Non-Nodal	NT001	PLEURA	Present Stable
0101-0011	ADIPemPlatinum	Screening	12AUG2019 (-23)	CT Scan	Radiologist 2	Non-Nodal	NT001	LUNG, LEFT	Present Not Measured
							NT002	PLEURAL CAVITY	Present Not Measured
		Cycle 2, Day 15	12OCT2019 (39)	CT Scan	Radiologist 2	Non-Nodal	NT001	LUNG, LEFT	Present Stable
							NT002	PLEURAL CAVITY	Present Stable
		Cycle 4, Day 15	20NOV2019 (78)	CT Scan	Radiologist 2	Non-Nodal	NT001	LUNG, LEFT	Present Stable
							NT002	PLEURAL CAVITY	Present Stable
		Cycle 6, Day 15	04JAN2020 (123)	CT Scan	Radiologist 2	Non-Nodal	NT001	LUNG, LEFT	Present Stable
							NT002	PLEURAL CAVITY	Present Stable
0102-0003	PlaceboPemPlatinum	Screening	24JAN2018 (-7)	CT Scan	Radiologist 2	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	08MAR2018 (37)	CT Scan	Radiologist 2	Non-Nodal	NT001	PLEURA	Present Stable
0102-0004	PlaceboPemPlatinum	Screening	05FEB2018 (-8)	CT Scan	Radiologist 1	Non-Nodal	NT001	LUNG, RIGHT LOWER LOBE	Present Not Measured
							NT002	PLEURA	Present Not Measured
		Cycle 2, Day 15	21MAR2018 (37)	CT Scan	Radiologist 1	Non-Nodal	NT001	LUNG, RIGHT LOWER LOBE	Present Stable
							NT002	PLEURA	Present Stable
		Cycle 4, Day 15	02MAY2018 (79)	CT Scan	Radiologist 1	Non-Nodal	NT001	LUNG, RIGHT LOWER LOBE	Present unequivocal progression
							NT002	PLEURA	Present unequivocal progression
0110-0002	ADIPemPlatinum	Screening	25JAN2019 (-18)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Not Measured

Abbreviations: CT = computed tomography; MRI = magnetic resonance imaging; RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Non-target lesions are assessed with RECIST 1.1.

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.4
Non Target Lesions - Phase 2 Subjects

Subject ID	Treatment Group	Visit	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Lesion Type	Lesion ID	Location	Tumor State
0110-0002	ADIPemPlatinum	Cycle 2, Day 15	25MAR2019 (42)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	06MAY2019 (84)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
0201-0011	PlaceboPemPlatinum	Screening	22NOV2017 (-21)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	17JAN2018 (36)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	28FEB2018 (78)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 6, Day 15	04APR2018 (113)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Week 24	06JUN2018 (176)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present unequivocal progression
0201-0017	PlaceboPemPlatinum	Screening	24APR2018 (-1)	CT Scan	Radiologist 2	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	29MAY2018 (35)	CT Scan	Radiologist 2	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	10JUL2018 (77)	CT Scan	Radiologist 2	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 6, Day 15	07AUG2018 (105)	CT Scan	Radiologist 2	Non-Nodal	NT001	PLEURA	Present Stable
0201-0018	ADIPemPlatinum	Screening	09APR2018 (-22)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	05JUN2018 (36)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	17JUL2018 (78)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 6, Day 15	28AUG2018 (120)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Week 26	23OCT2018 (176)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Week 34	18DEC2018 (232)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Week 40	12FEB2019 (288)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Week 50	09APR2019 (344)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
0201-0025	PlaceboPemPlatinum	Screening	17OCT2018 (-28)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	19DEC2018 (36)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	30JAN2019 (78)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 6, Day 15	13MAR2019 (120)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Week 26	07MAY2019 (175)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable

Abbreviations: CT = computed tomography; MRI = magnetic resonance imaging; RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Non-target lesions are assessed with RECIST 1.1.

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.4
Non Target Lesions - Phase 2 Subjects

Subject ID	Treatment Group	Visit	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Lesion Type	Lesion ID	Location	Tumor State
0201-0025	PlaceboPemPlatinum	Week 34	02JUL2019 (231)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Week 42	27AUG2019 (287)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
0201-0027	PlaceboPemPlatinum	Screening	12SEP2018 (-20)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	06NOV2018 (36)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	11DEC2018 (71)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Unscheduled	24DEC2018 (84)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
0201-0039	ADIPemPlatinum	Screening	23JAN2019 (-7)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	07MAR2019 (37)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	18APR2019 (79)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 6, Day 15	30MAY2019 (121)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Week 22	26JUN2019 (148)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Week 30	20AUG2019 (203)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
0201-0050	PlaceboPemPlatinum	Screening	26JUN2019 (-27)	CT Scan	Radiologist 1	Non-Nodal	NT001	CHEST WALL	Present Not Measured
		Cycle 2, Day 15	29AUG2019 (38)	CT Scan	Radiologist 1	Non-Nodal	NT001	CHEST WALL	Present Stable
		Cycle 4, Day 15	10OCT2019 (80)	CT Scan	Radiologist 1	Non-Nodal	NT001	CHEST WALL	Present Stable
		Cycle 6, Day 15	20NOV2019 (121)	CT Scan	Radiologist 1	Non-Nodal	NT001	CHEST WALL	Present Stable
0202-0002	ADIPemPlatinum	Screening	29AUG2018 (-14)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	31OCT2018 (50)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	03DEC2018 (83)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 6, Day 15	16JAN2019 (127)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
0203-0004	ADIPemPlatinum	Screening	09FEB2018 (-12)	CT Scan	Radiologist 2	Non-Nodal	NT001	CHEST WALL	Present Not Measured
		Cycle 2, Day 15	06APR2018 (45)	CT Scan	Radiologist 2	Non-Nodal	NT002 NT001	PLEURA CHEST WALL	Present Not Measured Present unequivocal progression

Abbreviations: CT = computed tomography; MRI = magnetic resonance imaging; RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Non-target lesions are assessed with RECIST 1.1.

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.4
Non Target Lesions - Phase 2 Subjects

Subject ID	Treatment Group	Visit	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Lesion Type	Lesion ID	Location	Tumor State
0203-0004	ADIPemPlatinum	Cycle 2, Day 15	06APR2018 (45)	CT Scan	Radiologist 2	Non-Nodal	NT002	PLEURA	Present Stable
0203-0014	ADIPemPlatinum	Screening	18JUL2019 (-6)	CT Scan	Radiologist 1	Nodal	NTN001	RETROPERITONEAL LYMPH NODE	Present Not Measured
						Non-Nodal	NT001 NT002	PERITONEUM KIDNEY	Present Not Measured Present Not Measured
		Cycle 2, Day 15	03SEP2019 (42)	CT Scan	Radiologist 1	Nodal	NTN001	RETROPERITONEAL LYMPH NODE	Present Stable
						Non-Nodal	NT001 NT002	PERITONEUM KIDNEY	Present Stable Present Stable
		Cycle 4, Day 15	15OCT2019 (84)	CT Scan	Radiologist 1	Nodal	NTN001	RETROPERITONEAL LYMPH NODE	Present Stable
						Non-Nodal	NT001 NT002	PERITONEUM KIDNEY	Present Stable Present Stable
		Cycle 6, Day 15	13NOV2019 (113)	CT Scan	Radiologist 1	Nodal	NTN001	RETROPERITONEAL LYMPH NODE	Present Stable
						Non-Nodal	NT001 NT002	PERITONEUM KIDNEY	Present Stable Present Stable
		Week 24	08JAN2020 (169)	CT Scan	Radiologist 1	Nodal	NTN001	RETROPERITONEAL LYMPH NODE	Present Stable
						Non-Nodal	NT001 NT002	PERITONEUM KIDNEY	Present Stable Present Stable
		Week 34	04MAR2020 (225)	CT Scan	Radiologist 1	Nodal	NTN001	RETROPERITONEAL LYMPH NODE	Present Stable
						Non-Nodal	NT001 NT002	PERITONEUM KIDNEY	Present Stable Present Stable
0204-0002	ADIPemPlatinum	Screening	04JUL2018 (-7)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Not Measured

Abbreviations: CT = computed tomography; MRI = magnetic resonance imaging; RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Non-target lesions are assessed with RECIST 1.1.

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.4
Non Target Lesions - Phase 2 Subjects

Subject ID	Treatment Group	Visit	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Lesion Type	Lesion ID	Location	Tumor State
0204-0002	ADIPemPlatinum	Cycle 2, Day 15	22AUG2018 (43)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
0204-0003	PlaceboPemPlatinum	Screening	18JUL2018 (-14)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	03SEP2018 (34)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present unequivocal progression
0301-0005	PlaceboPemPlatinum	Screening	17JUN2019 (-15)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	07AUG2019 (37)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	18SEP2019 (79)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 6, Day 15	29OCT2019 (120)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Week 26	17DEC2019 (169)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
0301-0007	PlaceboPemPlatinum	Screening	01OCT2019 (-14)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	20NOV2019 (37)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	30DEC2019 (77)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present unequivocal progression
		Cycle 6, Day 15	12FEB2020 (121)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
0502-0001	ADIPemPlatinum	Screening	13SEP2019 (-19)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	13NOV2019 (43)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	23DEC2019 (83)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 6, Day 15	03FEB2020 (125)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
		Week 26	30MAR2020 (181)	CT Scan	Radiologist 1	Non-Nodal	NT001	PLEURA	Present Stable
1206-0001	PlaceboPemPlatinum	Screening	28JAN2018 (-9)	CT Scan	Radiologist 1	Nodal	NTN001	AXILLARY LYMPH NODE	Present Not Measured
						Non-Nodal	NT001	PLEURA	Present Not Measured
		Cycle 2, Day 15	15MAR2018 (38)	CT Scan	Radiologist 1	Nodal	NTN001	AXILLARY LYMPH NODE	Present Stable
						Non-Nodal	NT001	PLEURA	Present Stable
		Cycle 4, Day 15	25APR2018 (79)	CT Scan	Radiologist 1	Nodal	NTN001	AXILLARY LYMPH NODE	Present Reduced to Normal
						Non-Nodal	NT001	PLEURA	Present Stable

Abbreviations: CT = computed tomography; MRI = magnetic resonance imaging; RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Non-target lesions are assessed with RECIST 1.1.

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.4
Non Target Lesions - Phase 2 Subjects

Subject ID	Treatment Group	Visit	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Lesion Type	Lesion ID	Location	Tumor State
1206-0001	PlaceboPemPlatinum	Unscheduled	20MAY2018 (104)	CT Scan	Radiologist 1	Nodal	NTN001	AXILLARY LYMPH NODE	Present Reduced to Normal
						Non-Nodal	NT001	PLEURA	Present Stable
		Unscheduled	09JUL2018 (154)	CT Scan	Radiologist 1	Nodal	NTN001	AXILLARY LYMPH NODE	Present Reduced to Normal
						Non-Nodal	NT001	PLEURA	Present Stable

Abbreviations: CT = computed tomography; MRI = magnetic resonance imaging; RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- Non-target lesions are assessed with RECIST 1.1.

^[1] Time (days) relative to date of first dose of study drug

P:\Polaris\POLARIS2015-003\Biostats\Programs\TLFs\l-ntl.sas 25OCT2022 10:14

Listing 16.2.6.5
New Lesions - Phase 2 Subjects

Subject ID	Treatment Group	Visit	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Lesion ID	Location	Tumor State
0102-0003	PlaceboPemPlatinum	Cycle 2, Day 15	08MAR2018 (37)	CT Scan	Radiologist 2	NEW001	LYMPH NODE	Present Not Measured
0102-0008	PlaceboPemPlatinum	Cycle 4, Day 1	20NOV2019 (64)	CT Scan	Radiologist 2	NEW001	LIVER	Present Not Measured
0103-0009	ADIPemPlatinum	Cycle 2, Day 15	26SEP2019 (44)	CT Scan	Radiologist 2	NEW001	LIVER, RIGHT LOBE	Present Not Measured
		Cycle 4, Day 15	07NOV2019 (86)	CT Scan	Radiologist 2	NEW001	LIVER, RIGHT LOBE	Present Stable
0108-0006	PlaceboPemPlatinum	Cycle 2, Day 15	10DEC2019 (42)	CT Scan	Radiologist 2	NEW001	PERICARDIAL LYMPH NODE	Present Not Measured
0110-0001	ADIPemPlatinum	Cycle 4, Day 15	23OCT2018 (85)	CT Scan	Radiologist 1	NEW001	LYMPH NODE	Present Not Measured
0201-0026	PlaceboPemPlatinum	Cycle 2, Day 15	11OCT2018 (37)	CT Scan	Radiologist 1	NEW001	LIVER	Present Not Measured
0201-0033	ADIPemPlatinum	Week 26	10JUL2019 (176)	CT Scan	Radiologist 1	NEW001	LYMPH NODE	Present Not Measured
						NEW002	PLEURA	Present Not Measured
0201-0035	PlaceboPemPlatinum	Week 26	29MAY2019 (176)	CT Scan	Radiologist 2	NEW001	PLEURA	Present Not Measured
						NEW002	CHEST WALL	Present Not Measured
0201-0043	ADIPemPlatinum	Week 26	30OCT2019 (176)	CT Scan	Radiologist 1	NEW001	LUNG	Present Not Measured
0201-0051	PlaceboPemPlatinum	Week 24	10DEC2019 (162)	CT Scan	Radiologist 1	NEW001	MEDIASTINAL LYMPH NODE	Present Not Measured
0203-0008	PlaceboPemPlatinum	Week 26	06FEB2019 (183)	CT Scan	Radiologist 1	NEW001	PLEURA	Present Not Measured
0203-0014	ADIPemPlatinum	Week 34	04MAR2020 (225)	CT Scan	Radiologist 1	NEW001	LYMPH NODE	Present Not Measured
0204-0003	PlaceboPemPlatinum	Cycle 2, Day 15	03SEP2018 (34)	CT Scan	Radiologist 1	NEW001	LUNG, LEFT	Present Not Measured

Abbreviations: CT = computed tomography; MRI = magnetic resonance imaging; RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- New lesions are assessed with RECIST 1.1.

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.5
New Lesions - Phase 2 Subjects

Subject ID	Treatment Group	Visit	Date of Response Assessment (Study Day ^[1])	Modality	Evaluator	Lesion ID	Location	Tumor State
0204-0005	ADIPemPlatinum	Week 42	28JUN2019 (283)	CT Scan	Radiologist 1	NEW001	LUNG, RIGHT	Present Not Measured
0204-0007	ADIPemPlatinum	Cycle 6, Day 15	29MAY2019 (120)	CT Scan	Radiologist 2	NEW001 NEW002	PERICARDIAL LYMPH NODE PERITONEUM	Present Not Measured Present Not Measured
0204-0008	PlaceboPemPlatinum	Week 34 Week 42	23SEP2019 (230) 03DEC2019 (301)	CT Scan CT Scan	Radiologist 1 Radiologist 1	NEW001 NEW001	PLEURA PLEURA	Present Not Measured Present unequivocal progression
0205-0002	PlaceboPemPlatinum	Cycle 6, Day 15	14AUG2019 (122)	CT Scan	Radiologist 2	NEW001	LIVER, RIGHT LOBE	Present Not Measured
0207-0003	ADIPemPlatinum	Cycle 4, Day 15	03OCT2019 (88)	CT Scan	Radiologist 1	NEW001	LUNG	Present Not Measured
0208-0001	ADIPemPlatinum	Week 26	19NOV2018 (190)	CT Scan	Radiologist 1	NEW001	MEDIASTINAL LYMPH NODE	Present Not Measured
0208-0007	ADIPemPlatinum	Cycle 2, Day 15	22AUG2019 (44)	CT Scan	Radiologist 2	NEW001	LIVER	Present Not Measured
0211-0004	PlaceboPemPlatinum	Cycle 6, Day 15	14FEB2020 (122)	CT Scan	Radiologist 1	NEW001 NEW002	PLEURA PLEURA	Present Not Measured Present Not Measured
0301-0003	PlaceboPemPlatinum	Cycle 2, Day 15	06MAR2019 (37)	CT Scan	Radiologist 1	NEW001	MEDIASTINAL LYMPH NODE	Present Not Measured
0511-0001	ADIPemPlatinum	Week 32	22NOV2019 (228)	CT Scan	Radiologist 2	NEW001	PLEURA	Present Not Measured

Abbreviations: CT = computed tomography; MRI = magnetic resonance imaging; RECIST = Response Evaluation Criteria in Solid Tumors

Notes:

- Only assessments from one of the two independent reviewers are displayed. For visits where the two reviewers disagreed, the assessments selected by the adjudicator are presented.
- New lesions are assessed with RECIST 1.1.

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0101-0006	PlaceboPemPlatinum	27APR2020 (386)	Clinic Visit	Alive
		29JUL2020 (479)	Telephone	Alive
0101-0008	ADIPemPlatinum	24OCT2019 (165)	Telephone	Alive
		20JAN2020 (253)	Telephone	Alive
		21APR2020 (345)	Telephone	Alive
		20JUL2020 (435)	Clinic Visit	Alive
		20OCT2020 (527)	Other: NO CONTACT	Alive
		03JAN2022 (967)	Telephone	Alive
		07APR2022 (1061)	Telephone	Alive
0101-0009	ADIPemPlatinum	11OCT2019 (115)	Other: DEATH NOTIFICATION PER EMR SOURCE DATED 10/6/19	Dead
0101-0010	PlaceboPemPlatinum	13FEB2020 (200)	Clinic Visit	Alive
		14MAY2020 (291)	Clinic Visit	Alive
		20AUG2020 (389)	Clinic Visit	Alive
		12NOV2020 (473)	Clinic Visit	Alive
		11FEB2021 (564)	Clinic Visit	Alive
		06MAY2021 (648)	Clinic Visit	Alive
		17AUG2021 (751)	Clinic Visit	Alive
		09NOV2021 (835)	Clinic Visit	Alive
		14FEB2022 (932)	Clinic Visit	Alive
		05MAY2022 (1012)	Clinic Visit	Alive
		04AUG2022 (1103)	Clinic Visit	Alive
0102-0001	ADIPemPlatinum	09APR2018 (216)	Telephone	Alive
		06JUL2018 (304)	Clinic Visit	Alive
		26SEP2018 (386)	Clinic Visit	Alive
		08OCT2018 (398)	Telephone	Alive
		07JAN2019 (489)	Telephone	Alive
		01APR2019 (573)	Clinic Visit	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0102-0001	ADIPemPlatinum	08JUL2019 (671)	Telephone	Alive
0102-0002	ADIPemPlatinum	28FEB2019 (429)	Clinic Visit	Alive
		23MAY2019 (513)	Clinic Visit	Alive
		30AUG2019 (612)	Clinic Visit	Alive
		11SEP2019 (624)	Clinic Visit	Alive
		26FEB2020 (792)	Clinic Visit	Alive
		20MAY2020 (876)	Telephone	Alive
		26AUG2020 (974)	Clinic Visit	Alive
		02DEC2020 (1072)	Clinic Visit	Alive
		16FEB2021 (1148)	Clinic Visit	Alive
		01JUN2021 (1253)	Clinic Visit	Alive
		25AUG2021 (1338)	Clinic Visit	Alive
		17NOV2021 (1422)	Clinic Visit	Alive
		09FEB2022 (1506)	Clinic Visit	Alive
		04MAY2022 (1590)	Clinic Visit	Alive
		17AUG2022 (1695)	Clinic Visit	Alive
0102-0006	PlaceboPemPlatinum	22MAY2019 (134)	Clinic Visit	Alive
		14AUG2019 (218)	Clinic Visit	Alive
		15NOV2019 (311)	Telephone	Alive
		04MAR2020 (421)	Telephone	Dead
0102-0007	ADIPemPlatinum	11DEC2019 (148)	Clinic Visit	Alive
		13MAR2020 (241)	Clinic Visit	Alive
		12JUN2020 (332)	Clinic Visit	Alive
		14SEP2020 (426)	Clinic Visit	Alive
		18DEC2020 (521)	Clinic Visit	Alive
		01FEB2021 (566)	Telephone	Alive
		18MAR2021 (611)	Clinic Visit	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0102-0009	PlaceboPemPlatinum	25MAR2020 (178)	Clinic Visit	Alive
0102-0012	ADIPemPlatinum	21JAN2021 (324)	Clinic Visit	Alive
		26APR2021 (419)	Telephone	Alive
		27JUL2021 (511)	Telephone	Alive
0102-0015	ADIPemPlatinum	09DEC2020 (142)	Other: CORRESPONDING MAIL	Alive
0103-0003	ADIPemPlatinum	07JAN2019 (307)	Telephone	Alive
0103-0006	PlaceboPemPlatinum	02JAN2019 (203)	Email	Alive
0103-0009	ADIPemPlatinum	14JAN2020 (154)	Clinic Visit	Alive
0104-0001	PlaceboPemPlatinum	11JUL2018 (92)	Clinic Visit	Alive
		11APR2019 (366)	Telephone	Alive
		25JUL2019 (471)	Telephone	Alive
		16OCT2019 (554)	Clinic Visit	Alive
0104-0004	ADIPemPlatinum	05MAR2020 (263)	Clinic Visit	Alive
		29MAY2020 (348)	Clinic Visit	Alive
		21AUG2020 (432)	Clinic Visit	Alive
		13NOV2020 (516)	Clinic Visit	Alive
		18JAN2021 (582)	Clinic Visit	Alive
		12APR2021 (666)	Clinic Visit	Alive
		06JUL2021 (751)	Clinic Visit	Alive
		01OCT2021 (838)	Other: EMR PORTAL MESSAGE	Alive
		09JAN2022 (938)	Other: EMR PORTAL MESSAGE	Alive
		18MAR2022 (1006)	Telephone	Alive
		07JUN2022 (1087)	Clinic Visit	Alive
		22JUL2022 (1132)	Clinic Visit	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0104-0004	ADIPemPlatinum	08AUG2022 (1149)	Other: WRITTEN COMMUNICATION VIA EMR PORTAL	Alive
0104-0006	ADIPemPlatinum	01MAY2020 (180)	Telephone	Dead
0107-0001	ADIPemPlatinum	04JAN2019 (270)	Other: EMERGENCY DEPARTMENT	Alive
		01APR2019 (357)	Telephone	Alive
		02JUL2019 (449)	Clinic Visit	Alive
0107-0002	PlaceboPemPlatinum	23JAN2020 (520)	Clinic Visit	Alive
		23APR2020 (611)	Clinic Visit	Alive
		30JUL2020 (709)	Clinic Visit	Alive
		26OCT2020 (797)	Clinic Visit	Alive
		15JAN2021 (878)	Telephone	Alive
		23APR2021 (976)	Clinic Visit	Alive
		09JUN2021 (1023)	Telephone	Dead
0107-0004	ADIPemPlatinum	04JUN2019 (169)	Clinic Visit	Alive
		10SEP2019 (267)	Clinic Visit	Alive
		06DEC2019 (354)	Clinic Visit	Alive
		01JAN2020 (380)	Other: DEATH CERTIFICATE - PUBLIC RECORD	Dead
0107-0005	ADIPemPlatinum	22OCT2019 (246)	Clinic Visit	Alive
0107-0007	ADIPemPlatinum	09DEC2019 (50)	Telephone	Alive
0107-0010	PlaceboPemPlatinum	01JUL2020 (220)	Clinic Visit	Alive
		08OCT2020 (319)	Clinic Visit	Alive
		17DEC2020 (389)	Clinic Visit	Alive
		25MAR2021 (487)	Clinic Visit	Alive
0108-0006	PlaceboPemPlatinum	29JAN2020 (92)	Clinic Visit	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0108-0006	PlaceboPemPlatinum	19FEB2020 (113)	Clinic Visit	Alive
		01APR2020 (155)	Telephone	Alive
		23JUN2020 (238)	Clinic Visit	Alive
		17AUG2020 (293)	Clinic Visit	Alive
		10NOV2020 (378)	Other: CT SCAN AT OUTSIDE INSTITUTION (PER CARE EVERYWHERE)	Alive
		03FEB2021 (463)	Other: TELEMEDICINE VISIT	Alive
		28APR2021 (547)	Clinic Visit	Alive
		21JUL2021 (631)	Clinic Visit	Alive
		15SEP2021 (687)	Telephone	Alive
		05DEC2021 (768)	Other: ONLINE OBITUARY	Dead
0108-0007	ADIPemPlatinum	05MAY2021 (456)	Clinic Visit	Alive
		28JUL2021 (540)	Clinic Visit	Alive
		20OCT2021 (624)	Clinic Visit	Alive
		12JAN2022 (708)	Clinic Visit	Alive
		23MAR2022 (778)	Clinic Visit	Alive
		15JUN2022 (862)	Clinic Visit	Alive
		10AUG2022 (918)	Clinic Visit	Alive
0108-0009	PlaceboPemPlatinum	03FEB2021 (337)	Email	Alive
		07APR2021 (400)	Email	Dead
0110-0001	ADIPemPlatinum	28FEB2019 (213)	Clinic Visit	Alive
		02MAY2019 (276)	Clinic Visit	Alive
		14AUG2019 (380)	Clinic Visit	Alive
		06NOV2019 (464)	Clinic Visit	Alive
		05FEB2020 (555)	Clinic Visit	Alive
		24JUN2020 (695)	Other: VIDEO VISIT	Alive
		18AUG2020 (750)	Other: VIDEO VISIT	Alive
		20OCT2020 (813)	Clinic Visit	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0110-0001	ADIPemPlatinum	05JAN2021 (890)	Clinic Visit	Alive
		08FEB2021 (924)	Other: SOURCE IN PATIENT CHART	Dead
0110-0002	ADIPemPlatinum	13JUN2019 (122)	Clinic Visit	Alive
		08OCT2019 (239)	Other: PATIENT HOSPITAL CHART	Dead
0201-0001	PlaceboPemPlatinum	22MAR2018 (233)	Other: PUBLIC RECORD (NHS SPINE)	Alive
0201-0005	ADIPemPlatinum	06AUG2018 (328)	Telephone	Alive
0201-0007	ADIPemPlatinum	22MAR2018 (163)	Other: PUBLIC RECORD (NHS SPINE)	Alive
		07JUN2018 (240)	Other: PUBLIC RECORD (NHS SPINE)+CLINIC LETTER	Alive
		24SEP2018 (349)	Other: NHS SPINE - PUBLIC RECORD	Alive
0201-0008	ADIPemPlatinum	07AUG2019 (379)	Other: NHS SUMMARY CARE RECORD	Alive
		26FEB2020 (582)	Other: NATIONAL SUMMARY CARE RECORD	Dead
0201-0009	PlaceboPemPlatinum	10APR2019 (533)	Other: NHS SUMMARY CARE RECORD	Alive
		03JUL2019 (617)	Other: NHS SUMMARY CARE RECORD	Alive
0201-0011	PlaceboPemPlatinum	24SEP2018 (286)	Telephone	Alive
		20DEC2018 (373)	Other: NHS SUMMARY CARE RECORD	Alive
		20MAR2019 (463)	Other: NHS SUMMARY CARE RECORD	Alive
		20JUN2019 (555)	Other: NHS SUMMARY CARE RECORD	Alive
0201-0013	ADIPemPlatinum	09AUG2018 (191)	Other: NHS SPINE - PUBLIC RECORDS	Alive
0201-0015	ADIPemPlatinum	20AUG2018 (160)	Other: NHS SPINE	Alive
		21NOV2018 (253)	Other: NHS SUMMARY CARE RECORD	Alive
		21FEB2019 (345)	Other: NHS SUMMARY CARE RECORD	Alive
		16MAY2019 (429)	Other: NHS SUMMARY CARE RECORD	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0201-0015	ADIPemPlatinum	08AUG2019 (513)	Other: NHS SUMMARY CARE RECORD	Alive
		27FEB2020 (716)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		15MAY2020 (794)	Other: NATIONAL SUMMARY CARE RECORD	Dead
0201-0017	PlaceboPemPlatinum	30SEP2018 (159)	Clinic Visit	Alive
0201-0018	ADIPemPlatinum	24JUL2019 (450)	Other: NHS SUMMARY CARE RECORD	Alive
		27FEB2020 (668)	Other: NATIONAL SUMMARY CARE RECORD	Dead
0201-0019	ADIPemPlatinum	24JAN2019 (261)	Other: NHS SUMMARY CARE RECORD	Alive
		24APR2019 (351)	Other: NHS SUMMARY CARE RECORD	Alive
		24JUL2019 (442)	Other: NHS CARE SUMMARY RECORD	Dead
0201-0022	PlaceboPemPlatinum	15OCT2018 (104)	Other: NHS SPINE - PUBLIC RECORD	Alive
		31MAR2020 (637)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		22JUN2020 (720)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		14SEP2020 (804)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		07DEC2020 (888)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		25JAN2021 (937)	Other: NATIONAL CARE SUMMARY RECORD	Alive
		23APR2021 (1025)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		16JUL2021 (1109)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		08OCT2021 (1193)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		04JAN2022 (1281)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		21MAR2022 (1357)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		23JUN2022 (1451)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		08AUG2022 (1497)	Other: NATIONAL SUMMARY CARE RECORD	Alive
0201-0023	ADIPemPlatinum	12SEP2019 (422)	Other: NHS SUMMARY CARE RECORD	Alive
		27FEB2020 (590)	Other: NATIONAL SUMMARY CARE RECORD	Dead
0201-0025	PlaceboPemPlatinum	27FEB2020 (471)	Other: NATIONAL SUMMARY CARE RECORD	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0201-0025	PlaceboPemPlatinum	26MAY2020 (560)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		17AUG2020 (643)	Other: NATIONAL SUMMARY CARE RECORD	Alive
0201-0027	PlaceboPemPlatinum	28MAR2019 (178)	Other: NHS SUMMARY CARE RECORD	Alive
		20JUN2019 (262)	Other: NHS SUMMARY CARE RECORD	Alive
0201-0028	PlaceboPemPlatinum	01DEC2018 (46)	Clinic Visit	Alive
0201-0031	ADIPemPlatinum	11DEC2020 (773)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		20JAN2021 (813)	Clinic Visit	Alive
		07APR2021 (890)	Clinic Visit	Alive
		30JUN2021 (974)	Other: MILLENNIUM AND NATIONAL SUMMARY CARE RECORD	Alive
		22SEP2021 (1058)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		20DEC2021 (1147)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		14MAR2022 (1231)	Other: NATIONAL SUMMARY CARE RECORD	Alive
0201-0033	ADIPemPlatinum	09SEP2019 (237)	Other: NHS SUMMARY CARE RECORD	Alive
		10DEC2019 (329)	Other: NHS SUMMARY CARE RECORD	Alive
0201-0034	ADIPemPlatinum	06JAN2021 (764)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		13JAN2021 (771)	Telephone	Alive
		12APR2021 (860)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		05JUL2021 (944)	Other: MILLENNIUM AND NATIONAL SUMMARY CARE RECORD	Alive
		27SEP2021 (1028)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		20DEC2021 (1112)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		14MAR2022 (1196)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		15JUN2022 (1289)	Clinic Visit	Alive
0201-0038	ADIPemPlatinum	03AUG2022 (1338)	Other: NATIONAL SUMMARY CARE RECORDS	Alive
		27FEB2020 (408)	Other: NATIONAL SUMMARY CARE RECORD	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0201-0038	ADIPemPlatinum	26MAY2020 (497)	Other: NATIONAL SUMMARY CARE RECORD	Dead
0201-0039	ADIPemPlatinum	27FEB2020 (394)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		26MAY2020 (483)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		17AUG2020 (566)	Other: NATIONAL SUMMARY CARE RECORD	Alive
0201-0041	ADIPemPlatinum	27FEB2020 (331)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		26MAY2020 (420)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		17AUG2020 (503)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		11NOV2020 (589)	Other: NATIONAL SUMMARY CARE RECORD	Dead
0201-0043	ADIPemPlatinum	27FEB2020 (296)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		26MAY2020 (385)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		17AUG2020 (468)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		11NOV2020 (554)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		13JAN2021 (617)	Telephone	Alive
		21APR2021 (715)	Clinic Visit	Alive
		14JUL2021 (799)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		06OCT2021 (883)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		04JAN2022 (973)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		21MAR2022 (1049)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		23JUN2022 (1143)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		03AUG2022 (1184)	Other: NATIONAL SUMMARY CARE RECORDS	Alive
0201-0044	PlaceboPemPlatinum	16JUN2020 (399)	Email	Dead
0201-0045	PlaceboPemPlatinum	25SEP2020 (521)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		06JAN2021 (624)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		01APR2021 (709)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		24JUN2021 (793)	Other: MILLENNIUM AND NATIONAL SUMMARY CARE RECORD	Alive
		22SEP2021 (883)	Other: NATIONAL SUMMARY CARE RECORD	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0201-0046	ADIPemPlatinum	27FEB2020 (289)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		31MAR2020 (322)	Other: NATIONAL SUMMARY CARE RECORD	Alive
0201-0048	PlaceboPemPlatinum	27FEB2020 (269)	Other: NATIONAL SUMMARY CARE RECORD	Dead
0201-0049	ADIPemPlatinum	27FEB2020 (248)	Other: NATIONAL SUMMARY CARE RECORD	Dead
0201-0050	PlaceboPemPlatinum	27FEB2020 (220)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		26MAY2020 (309)	Other: NATIONAL SUMMARY CARE RECORD	Alive
0201-0051	PlaceboPemPlatinum	27FEB2020 (241)	Other: NATIONAL SUMMARY CARE RECORD	Dead
0201-0052	PlaceboPemPlatinum	27FEB2020 (226)	Other: NATIONAL SUMMARY CARE RECORD	Dead
0201-0053	ADIPemPlatinum	07AUG2020 (388)	Telephone	Alive
		30SEP2020 (442)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		06JAN2021 (540)	Other: NATIONAL SUMMARY CARE RECORD	Alive
		01APR2021 (625)	Other: NATIONAL SUMMARY CARE RECORD	Alive
0201-0054	PlaceboPemPlatinum	22JUL2020 (337)	Clinic Visit	Alive
		17SEP2020 (394)	Other: NATIONAL SUMMARY CARE RECORD	Alive
0201-0056	ADIPemPlatinum	27FEB2020 (163)	Other: NATIONAL SUMMARY CARE RECORD	Dead
0201-0057	PlaceboPemPlatinum	31MAR2020 (51)	Other: NATIONAL SUMMARY CARE RECORD	Alive
0202-0001	PlaceboPemPlatinum	24SEP2018 (174)	Email	Alive
		21DEC2018 (262)	Telephone	Alive
		22MAR2019 (353)	Other: TELEPHONE CALL FOLLOWED BY AN EMAIL.	Dead
0202-0002	ADIPemPlatinum	22APR2019 (223)	Other: REVIEW OF ELECTRONIC MEDICAL RECORD NOTES.	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0202-0002	ADIPemPlatinum	13JUN2019 (275)	Other: REVIEW OF ELECTRONIC MEDICAL RECORDS.	Alive
		19JUN2019 (281)	Telephone	Dead
0202-0003	ADIPemPlatinum	20JAN2020 (245)	Clinic Visit	Alive
		20APR2020 (336)	Clinic Visit	Alive
		27JUL2020 (434)	Telephone	Alive
		27OCT2020 (526)	Clinic Visit	Alive
		26JAN2021 (617)	Telephone	Alive
		19APR2021 (700)	Telephone	Alive
		13JUL2021 (785)	Other: REVIEW OF NOTES.	Alive
0202-0004	ADIPemPlatinum	21JUN2021 (776)	Telephone	Alive
		23SEP2021 (870)	Clinic Visit	Alive
		16DEC2021 (954)	Clinic Visit	Alive
		14MAR2022 (1042)	Telephone	Alive
		02JUN2022 (1122)	Clinic Visit	Alive
0203-0002	PlaceboPemPlatinum	17AUG2022 (1198)	Telephone	Alive
		05SEP2018 (247)	Clinic Visit	Alive
		19DEC2018 (352)	Clinic Visit	Alive
		20MAR2019 (443)	Telephone	Alive
		04SEP2019 (611)	Clinic Visit	Alive
		27NOV2019 (695)	Clinic Visit	Alive
		26FEB2020 (786)	Clinic Visit	Alive
		10JUN2020 (891)	Telephone	Alive
		08SEP2020 (981)	Telephone	Alive
		31DEC2020 (1095)	Telephone	Alive
		31DEC2020 (1095)	Telephone	Alive
		02FEB2021 (1128)	Telephone	Alive
		17AUG2021 (1324)	Other: PATIENT CENTRE	Dead

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0203-0005	ADIPemPlatinum	14MAR2019 (345)	Clinic Visit	Alive
0203-0013	ADIPemPlatinum	20JAN2021 (680)	Telephone	Alive
		17APR2021 (767)	Other: PATIENT HAD CT SCAN	Alive
		20AUG2021 (892)	Other: PATIENT CENTER	Alive
		27OCT2021 (960)	Telephone	Alive
		31JAN2022 (1056)	Telephone	Alive
		28APR2022 (1143)	Telephone	Alive
0203-0014	ADIPemPlatinum	25JUL2022 (1231)	Telephone	Alive
		09JUN2020 (322)	Telephone	Alive
0203-0019	ADIPemPlatinum	04AUG2020 (378)	Other: CHECKED HOSPITAL SYSTEM.	Dead
		01FEB2021 (48)	Clinic Visit	Alive
0204-0004	PlaceboPemPlatinum	04OCT2018 (45)	Clinic Visit	Alive
0205-0001	ADIPemPlatinum	03APR2019 (275)	Telephone	Alive
0205-0005	PlaceboPemPlatinum	27JAN2020 (154)	Clinic Visit	Alive
0207-0002	PlaceboPemPlatinum	14JAN2019 (49)	Clinic Visit	Alive
		24MAY2019 (179)	Other: SITE PORTAL	Dead
0207-0004	PlaceboPemPlatinum	27JUN2020 (174)	Other: GP	Dead
0208-0004	PlaceboPemPlatinum	03AUG2019 (130)	Other: UNABLE TO CONTACT AS PT DECEASED	Dead
0208-0006	ADIPemPlatinum	13NOV2019 (178)	Clinic Visit	Alive
		13FEB2020 (270)	Clinic Visit	Alive
		28MAY2020 (375)	Telephone	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0208-0006	ADIPemPlatinum	28AUG2020 (467)	Telephone	Alive
		28AUG2020 (467)	Other: HOSPITAL PATIENTS SYSTEM	Dead
0208-0008	ADIPemPlatinum	24AUG2020 (314)	Telephone	Alive
		23NOV2020 (405)	Telephone	Alive
		23NOV2020 (405)	Telephone	Alive
		01FEB2021 (475)	Telephone	Alive
		14APR2021 (547)	Telephone	Dead
0209-0001	ADIPemPlatinum	05JUN2019 (408)	Other: LETTER FROM LEICESTER ROYAL INFIRMARY	Alive
		19SEP2019 (514)	Telephone	Alive
0209-0003	ADIPemPlatinum	10JUN2019 (84)	Other: WARD VISIT WHILST AN IN-PATIENT.	Alive
		18SEP2019 (184)	Other: INPATIENT ON WARD	Dead
0209-0004	ADIPemPlatinum	29JUL2020 (302)	Email	Alive
		03NOV2020 (399)	Telephone	Alive
		02FEB2021 (490)	Telephone	Alive
		07MAY2021 (584)	Other: VIDEO CONSULTATION	Alive
		23AUG2021 (692)	Other: VIDEO CONSULTATION	Alive
		04OCT2021 (734)	Telephone	Alive
		12JAN2022 (834)	Telephone	Alive
		19APR2022 (931)	Telephone	Alive
		20JUL2022 (1023)	Other: CONTACTED GP	Alive
0210-0001	ADIPemPlatinum	20SEP2021 (260)	Clinic Visit	Alive
		03DEC2021 (334)	Clinic Visit	Alive
		25MAR2022 (446)	Clinic Visit	Alive
		29MAR2022 (450)	Other: FAMILY CONTACTED VELINDRE	Dead
0211-0001	PlaceboPemPlatinum	14MAY2020 (303)	Telephone	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0211-0003	ADIPemPlatinum	30JUL2020 (303)	Telephone	Alive
		22OCT2020 (387)	Clinic Visit	Alive
		14JAN2021 (471)	Telephone	Alive
		16APR2021 (563)	Clinic Visit	Alive
		15JUL2021 (653)	Clinic Visit	Alive
		22OCT2021 (752)	Clinic Visit	Alive
		20JAN2022 (842)	Clinic Visit	Alive
		21APR2022 (933)	Clinic Visit	Alive
		14JUL2022 (1017)	Clinic Visit	Alive
0212-0001	ADIPemPlatinum	30MAR2019 (229)	Email	Alive
0212-0004	PlaceboPemPlatinum	23OCT2019 (281)	Telephone	Alive
		25OCT2019 (283)	Clinic Visit	Alive
		28JAN2020 (378)	Telephone	Alive
0212-0005	PlaceboPemPlatinum	17JUL2019 (113)	Other: ELECTRONIC PATIENT RECORD	Dead
0212-0006	ADIPemPlatinum	13OCT2021 (820)	Clinic Visit	Alive
		26JAN2022 (925)	Telephone	Alive
		05APR2022 (994)	Telephone	Alive
		26JUL2022 (1106)	Clinic Visit	Alive
0212-0010	ADIPemPlatinum	04JUN2020 (81)	Telephone	Alive
0212-0011	ADIPemPlatinum	08OCT2020 (115)	Telephone	Alive
		13JAN2021 (212)	Telephone	Alive
		18FEB2021 (248)	Telephone	Dead
0214-0002	ADIPemPlatinum	02SEP2021 (65)	Telephone	Alive
		19OCT2021 (112)	Clinic Visit	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0214-0002	ADIPemPlatinum	18JAN2022 (203)	Telephone	Alive
		19APR2022 (294)	Telephone	Alive
		12JUL2022 (378)	Telephone	Dead
0217-0001	ADIPemPlatinum	14JUN2022 (686)	Other: TELEPHONE CALL FROM RESEARCH NURSES FROM SCUNTHORPE	Dead
0217-0002	PlaceboPemPlatinum	14JAN2022 (255)	Telephone	Alive
		20MAY2022 (381)	Other: ATTENDED CT SCAN	Alive
		28JUL2022 (450)	Clinic Visit	Alive
0218-0001	PlaceboPemPlatinum	26NOV2020 (179)	Telephone	Alive
		26JAN2021 (240)	Telephone	Alive
0218-0003	ADIPemPlatinum	22JUN2021 (371)	Telephone	Alive
0218-0005	ADIPemPlatinum	11DEC2020 (166)	Telephone	Alive
		26JAN2021 (212)	Telephone	Alive
		22APR2021 (298)	Email	Dead
0218-0006	PlaceboPemPlatinum	09DEC2020 (149)	Telephone	Alive
		26JAN2021 (197)	Telephone	Alive
0218-0008	PlaceboPemPlatinum	29APR2021 (269)	Telephone	Alive
0218-0013	ADIPemPlatinum	24JUN2021 (269)	Telephone	Alive
		08SEP2021 (345)	Telephone	Alive
		01DEC2021 (429)	Other: FROM GP RECORDS	Alive
		28FEB2022 (518)	Other: GP RECORD	Alive
		24JUN2022 (634)	Other: ON ELECTRONIC SCR GP RECORD.	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0218-0016	ADIPemPlatinum	18NOV2021 (262)	Telephone	Dead
0218-0019	PlaceboPemPlatinum	17DEC2021 (242) 02MAR2022 (317)	Other: HAD NIVOLUMAB IN CHEMO UNIT ON THIS DAY Clinic Visit	Alive Alive
0219-0001	ADIPemPlatinum	25JAN2021 (76)	Clinic Visit	Alive
0219-0003	PlaceboPemPlatinum	20JUL2021 (182) 27OCT2021 (281)	Clinic Visit Clinic Visit	Alive Alive
0219-0004	PlaceboPemPlatinum	20JUL2021 (182) 06OCT2021 (260) 18JAN2022 (364) 05APR2022 (441)	Clinic Visit Other: CLINIC LETTER Other: CLINIC LETTER Other: CLINIC LETTERS	Alive Alive Alive Alive
0219-0005	ADIPemPlatinum	20SEP2021 (181) 18OCT2021 (209) 10JAN2022 (293) 07APR2022 (380) 14APR2022 (387)	Clinic Visit Clinic Visit Other: ADMITTED TO ED AT UCLH Telephone Other: MEDICAL RECORDS	Alive Alive Alive Alive Dead
0219-0006	ADIPemPlatinum	24DEC2021 (248)	Telephone	Alive
0301-0002	PlaceboPemPlatinum	24SEP2019 (282) 17DEC2019 (366) 24MAR2020 (464) 24JUN2020 (556) 25SEP2020 (649) 24DEC2020 (739) 03FEB2021 (780) 03MAY2021 (869)	Clinic Visit Clinic Visit Clinic Visit Telephone Telephone Telephone Telephone Telephone	Alive Alive Alive Alive Alive Alive Alive Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0301-0002	PlaceboPemPlatinum	19AUG2021 (977)	Telephone	Alive
		10NOV2021 (1060)	Clinic Visit	Alive
0301-0004	PlaceboPemPlatinum	25JUL2019 (136)	Telephone	Alive
		25OCT2019 (228)	Clinic Visit	Alive
		29JAN2020 (324)	Clinic Visit	Alive
		28APR2020 (414)	Telephone	Alive
		08JUL2020 (485)	Telephone	Dead
0301-0005	PlaceboPemPlatinum	28JAN2020 (211)	Clinic Visit	Alive
		28APR2020 (302)	Telephone	Alive
		12JUL2020 (377)	Telephone	Dead
0301-0006	PlaceboPemPlatinum	14APR2020 (267)	Clinic Visit	Alive
		14JUL2020 (358)	Telephone	Alive
		15OCT2020 (451)	Telephone	Alive
		20DEC2020 (517)	Telephone	Dead
0301-0007	PlaceboPemPlatinum	09APR2020 (178)	Telephone	Alive
0302-0001	PlaceboPemPlatinum	04SEP2020 (227)	Telephone	Alive
		08DEC2020 (322)	Telephone	Alive
		27JAN2021 (372)	Telephone	Alive
		01MAR2021 (405)	Telephone	Alive
		10JUN2021 (506)	Telephone	Alive
		06SEP2021 (594)	Telephone	Alive
		06DEC2021 (685)	Telephone	Alive
		17MAR2022 (786)	Telephone	Dead
0303-0002	ADIPemPlatinum	18NOV2020 (113)	Other: DOCUMENTED BLOOD COLLECTION + DISCUSSION WITH DR ABBAS ON SUBJECTS STATUS	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0303-0002	ADIPemPlatinum	08JAN2021 (164)	Other: EMAIL FROM FAMILY MEMBER TO CLINIC STAFF	Dead
0304-0003	PlaceboPemPlatinum	14APR2021 (324)	Telephone	Alive
		08JUL2021 (409)	Telephone	Alive
0304-0004	PlaceboPemPlatinum	19OCT2020 (112)	Telephone	Alive
0305-0001	ADIPemPlatinum	19JUN2019 (325)	Telephone	Alive
		19SEP2019 (417)	Clinic Visit	Alive
		02JAN2020 (522)	Clinic Visit	Alive
		25MAR2020 (605)	Other: INPATIENT	Alive
0305-0004	ADIPemPlatinum	15AUG2020 (146)	Other: NOT CONTACTED IN ERROR. FOLLOW UP NOT DONE	Alive Alive Alive Dead
		16NOV2020 (239)	Other: STATUS CONFIRMED THROUGH TREATING CLINICIAN	
		21JAN2021 (305)	Clinic Visit	
		21APR2021 (395)	Clinic Visit	
		12JUL2021 (477)	Other: IEMR NOTES	
0305-0005	ADIPemPlatinum	15APR2021 (151)	Telephone	Alive
		22JUL2021 (249)	Clinic Visit	Alive
		07OCT2021 (326)	Other: NON-TRIAL CLINIC VISIT	Alive
0502-0001	ADIPemPlatinum	13AUG2020 (317)	Clinic Visit	Alive
		12NOV2020 (408)	Clinic Visit	Alive
		04FEB2021 (492)	Clinic Visit	Alive
		07MAY2021 (584)	Clinic Visit	Alive
		26AUG2021 (695)	Clinic Visit	Alive
		07DEC2021 (798)	Clinic Visit	Alive
		01MAR2022 (882)	Clinic Visit	Alive
		07JUN2022 (980)	Clinic Visit	Alive
		01AUG2022 (1035)	Telephone	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0502-0003	ADIPemPlatinum	19AUG2020 (155)	Clinic Visit	Alive
		19NOV2020 (247)	Clinic Visit	Alive
		08JAN2021 (297)	Clinic Visit	Alive
0502-0004	ADIPemPlatinum	24MAR2022 (422)	Clinic Visit	Alive
		23JUN2022 (513)	Clinic Visit	Alive
		01AUG2022 (552)	Telephone	Alive
0502-0005	ADIPemPlatinum	04NOV2021 (226)	Clinic Visit	Alive
		07FEB2022 (321)	Clinic Visit	Alive
		09MAY2022 (412)	Clinic Visit	Alive
		01AUG2022 (496)	Telephone	Alive
0502-0006	PlaceboPemPlatinum	25NOV2021 (240)	Clinic Visit	Alive
		17FEB2022 (324)	Clinic Visit	Alive
		11MAY2022 (407)	Clinic Visit	Alive
		01AUG2022 (489)	Telephone	Alive
0502-0008	ADIPemPlatinum	20JAN2022 (219)	Clinic Visit	Alive
		06APR2022 (295)	Clinic Visit	Alive
		05JUL2022 (385)	Clinic Visit	Alive
		21JUL2022 (401)	Clinic Visit	Alive
0502-0010	ADIPemPlatinum	13DEC2021 (120)	Clinic Visit	Alive
		14MAR2022 (211)	Other: CT SCAN	Alive
0502-0011	PlaceboPemPlatinum	18JUL2022 (337)	Clinic Visit	Alive
		01AUG2022 (351)	Telephone	Alive
0503-0001	PlaceboPemPlatinum	29OCT2019 (156)	Clinic Visit	Alive
		31JAN2020 (250)	Clinic Visit	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0505-0001	PlaceboPemPlatinum	18SEP2020 (145)	Telephone	Alive
		21DEC2020 (239)	Telephone	Alive
		26JAN2021 (275)	Telephone	Alive
0505-0002	PlaceboPemPlatinum	12OCT2021 (275)	Telephone	Alive
0506-0002	PlaceboPemPlatinum	26MAY2020 (345)	Clinic Visit	Alive
		06AUG2020 (417)	Clinic Visit	Alive
0506-0006	ADIPemPlatinum	18MAY2021 (266)	Telephone	Alive
0506-0008	PlaceboPemPlatinum	18NOV2021 (226)	Clinic Visit	Alive
		18FEB2022 (318)	Clinic Visit	Alive
		12MAY2022 (401)	Clinic Visit	Alive
		18AUG2022 (499)	Telephone	Alive
0506-0009	ADIPemPlatinum	22NOV2021 (167)	Clinic Visit	Alive
0509-0002	PlaceboPemPlatinum	22MAR2019 (186)	Other: CONTACT WITH NEW PATIENT'S PHYSICIAN	Alive
		02MAY2019 (227)	Other: CONTACT WITH NEW PATIENT'S PHYSICIAN	Alive
		23JUL2019 (309)	Other: REGISTRY OFFICE	Dead
0510-0001	PlaceboPemPlatinum	14MAY2020 (79)	Telephone	Alive
		28JUL2020 (154)	Telephone	Alive
		19OCT2020 (237)	Telephone	Alive
		28JAN2021 (338)	Telephone	Alive
		03MAY2021 (433)	Telephone	Alive
		30JUL2021 (521)	Telephone	Alive
		21OCT2021 (604)	Telephone	Alive
		12JAN2022 (687)	Telephone	Alive
		02MAY2022 (797)	Telephone	Alive

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug

Listing 16.2.6.6
Long Term Follow-Up

Subject ID	Treatment Group	Date of Contact (Study Day ^[1])	Method of Contact	Subject Status
0510-0001	PlaceboPemPlatinum	05AUG2022 (892)	Other: SUBJECT STATUS CHECK USING ATS SERVICE OF REGIONE LOMBARDIA	Alive
0511-0001	ADIPemPlatinum	20FEB2020 (318)	Clinic Visit	Alive
		06MAR2020 (333)	Email	Dead
0511-0002	PlaceboPemPlatinum	24SEP2019 (134)	Clinic Visit	Alive
		22NOV2019 (193)	Clinic Visit	Alive
		24JAN2020 (256)	Email	Dead
0511-0003	PlaceboPemPlatinum	19DEC2019 (136)	Clinic Visit	Alive
		07MAR2020 (215)	Telephone	Dead
0511-0004	PlaceboPemPlatinum	06MAY2021 (227)	Clinic Visit	Alive
		31AUG2021 (344)	Other: REGISTRY OFFICE	Alive
		30NOV2021 (435)	Other: REGISTRY OFFICE	Alive
		28FEB2022 (525)	Other: REGISTRY OFFICE	Alive
		07JUN2022 (624)	Other: REGISTRY OFFICE	Alive
0511-0005	PlaceboPemPlatinum	29APR2021 (192)	Clinic Visit	Alive
		31AUG2021 (316)	Other: REGISTRY OFFICE	Alive
		30NOV2021 (407)	Other: REGISTRY OFFICE	Alive
		28FEB2022 (497)	Other: REGISTRY OFFICE	Alive
		18JUL2022 (637)	Other: REGISTRY OFFICE	Alive
0511-0006	PlaceboPemPlatinum	11MAY2021 (141)	Clinic Visit	Alive
1206-0001	PlaceboPemPlatinum	08AUG2018 (184)	Clinic Visit	Alive
1206-0002	PlaceboPemPlatinum	09JUL2018 (57)	Clinic Visit	Dead

Abbreviation: CRF = case report form

Note: Listing includes data captured on the Survival Status CRF page and does not include deaths that are captured only on the End of Study CRF page

^[1] Time (days) relative to date of first dose of study drug